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Summary 
China has attracted increasing amounts of foreign investment since it opened its doors to 
the world and whilst many researchers have focused on foreign investment in popular 
areas, little has been written about medical device market. The medical device market is 
one of the most profitable areas in the global economy. With the development of China’s 
economy, the Chinese medical device market is experiencing significant growth, and has 
become the second largest market in the world.  
The research in this thesis extracted foreign direct investment theory and summarized the 
current situation of the global medical device market and the Chinese medical device 
market. Analysis of the status of the Chinese medical device market from the perspective 
of the healthcare industry and its important market drivers, reveals that the medical device 
market has significant growth potential. 
The research methods such as: regression analysis; location quotient, which revealed the 
Chinese medical device market status, provides suggestions for investors who are 
interested in entering the Chinese market. Investors or companies who want to enter the 
Chinese market need to understand the regulatory environment, comparison of the 
medical device regulations with the US and EU regulations provide investors with a clear 
understanding of the Chinese medical device regulatory regime. 
The research in this thesis contributes to medical device market investment and regional 
economy in medical device industry, and make a clear statement of the changing medical 
device regulations in China, which came into force on 2014. The contribution of this 
thesis, bridges the research gap between investment theory and medical device market 
development.  
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Chapter 1 Introduction 
1.1 Research background 
The economy in China has experienced 30-years of rapid growth and obtained remarkable 
success ever since the great reforms and opening-up policy. This reform in China 
represents a fundamental change and overhaul of China’s value system; policy making; 
institutional infrastructure and socio-economic structure, which constitutes a necessary 
step for mobilizing foreign investment. As an emerging market, China offers long-term 
growth opportunities that no longer exists in relatively saturated and highly competitive 
developed markets [1]. China has substantial size and a high growth rate of its consumer 
market, this is the reason why China is attractive to foreign investors [2]. 
As a high-tech intensive industry, the medical device market is one of the fastest growing 
industries in the world. The medical device industry indicates the level of a country’s 
manufacturing and technology sector. The Chinese government is encouraging the 
development of the medical device industry. The size of the medical device market 
continues to exhibit a rapid growth trend in China, the growth rate recently reaching 23%, 
the total output value reached approximately 688,420 million yuan (RMB) in 2011 [3].  
1.2 Aims and objectives 
The diagnostics market is segmented broadly into the in vivo diagnostics market (in vivo
means within a living organism) and in vitro diagnostics (IVD) market (in vitro means in 
the laboratory or outside the organism). In vivo diagnostics is a specialty market, with the 
key players being large instrument manufacturers of imaging or instrumentation 
technology (GE, Siemens and Philips, etc.). Examples of these devices are CT, MRI 
ultrasound and X-ray. There are two types of IVD products: devices (analysers for 
samples like blood, serum, tissue, bodily fluids, etc.) and reagents (chemicals used to 
mark or recognize specific components in the samples) [4]. 
This thesis will focus mainly on the in vivo diagnostics market. The demand for the new 
technology diagnostic devices has been growing in both developed and developing 
countries in recent years. As a developing country, it is important to know whether the 
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Chinese medical device market offers an attractive investment opportunity, when 
compared with other industries. One powerful development supporting a positive 
hypothesis is that people are paying more attention to their health due to the improved 
quality of life. Another is that treatment of some serious diseases requires high quality 
medical devices. Moreover, the aging population is a big challenge for the Chinese market. 
This thesis aims to explore the potential of the investment opportunities in the Chinese 
medical device market. The purpose of this thesis is: (1) extracted foreign investment 
theory in healthcare or high-tech areas; (2) evaluate the global medical device market 
status and illustrate the Chinese medical device market from the perspective of time lines, 
comparison analysis of the market’s past and present, to show that the market has 
improved greatly; (3) understand the main rapidly growing Chinese medical device 
market drivers; (4) understand medical device regulations in the United States (US), 
European Union (EU) and China, summarize the difference between these regulations; 
(5) identify which are the best investment regions in China.  
The objectives of the research is to provide a background on the Chinese healthcare 
system, reforms and changing regulatory environment to describe the current situation of 
the Chinese medical device market and to define opportunities for foreign investment 
potential therein. 
1.3 Contributions 
Although there is growing interest in investment in China, analysis of the medical device 
area has been slow to develop, but the sector is growing in importance with the improved 
realization that investment in the medical technology area, especially medical device, 
produces exceptional value. Some reports provide valuable information on the Chinese 
medical device market and investment environment, but they are limited in comparison 
with a literature review. Literature on investment in medical device technology and 
market is scarce, this research contributes to the literature on both investment and the 
medical device market. It extracts technology investment theories from foreign 
investment theories. The research demonstrates that the medical device market has 
become a promising global market, especially since the Chinese government pays more 
attention to healthcare than before, relevant policies on medical device investment will 
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be helpful to investors doing business in this area. More and more business research will 
focus on the medical device investment area in the future. Moreover, few papers focus on 
investment in the medical device market, with little attention focused on the medical 
device regulations, especially the new Chinese medical device regulations, which came 
into force on 2014.  
To bridge the gap, this thesis reveals the main drivers of the Chinese medical device 
market, to determine the viability of investment and provides some insights into the future 
investment opportunities in the Chinese medical device market. Comparison of the old 
and new medical device regulations, provides important updated information of the 
changing regulatory environment for the investors who are interested in entering the 
Chinese medical device market. For the first time the location quotient is introduced into 
the analysis of the medical device industry, the results indicate that the best investment 
regions in China are: Bohai Economic Rim, Yangtze River Delta and Pearl River Delta 
Economic Zones. This thesis contains extensive data relevant to the medical device 
industry, illustrating that the Chinese medical device market is one of the most promising 
markets globally.  
1.4 Thesis outline 
The thesis consists of 8 chapters, which are organized as follows:  
Chapter 1 briefly outlines the research background, research aims and objectives and 
research contributions made to the knowledge of the medical device market. 
Chapter 2 introduces foreign direct investment in healthcare or high-tech development 
areas for both developed countries and developing countries. It extracts foreign direct 
investment theory in medical device industry.  
Chapter 3 presents the global medical device market size and main medical device 
companies, especially medical imaging companies and their market share of medical 
imaging devices. It shows the key players in the medical imaging market.   
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Chapter 4 reviews China’s current economic situation and the Chinese medical device 
market from an economic perspective; identifies important parameters controlling this 
market. Regression analysis shows that the main drivers of the Chinese medical device 
market are the number of hospital visits, aging population and the number of hospitals. 
Analysis of the main market drivers, illustrates that the Chinese medical device market 
offers significant investment opportunities.  
Chapter 5 summarizes the US and EU medical device regulations, because they have 
established relatively mature regulations, which have a key influence in the world. 
Compared with the relatively mature regulations, the Chinese medical device regulations 
is evolving. The new regulations, which came into force on 2014, was a milestone in the 
Chinese medical device regulations history. The thesis outlines the changing regulatory 
regime, which provides guidance for the investors who are interested in entering the 
Chinese market.   
Chapter 6 introduces location quotient method to assess which area is the best region for 
medical device investment in China. The location quotient and market share matrix 
reveals that the best investment regions are the: Bohai Economic Rim, Yangtze River 
Delta and Pearl River Delta Economic Zones. It was the first time that the location 
quotient method has been introduced into the medical device market study, which 
provides guidance for the study of medical device market in other countries or regions.   
Chapter 7 is an extension of Chapter 6, it provides SWOT analysis of the Chinese medical 
device market and analysis of the Chinese regional market competitiveness. According 
to Chapter 6’s results, the best investment regions in medical device industry are: Bohai 
Economic Rim, Yangtze River Delta and Pearl River Delta Economic Zones. However, 
each region has its own characteristics and advantages. The detailed analysis provides 
useful information for the investors.  
Chapter 8 is the conclusion of this thesis and gives some suggestions for the future work. 
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Chapter 2 Literature Review 
2.1 Foreign investment theories for the developed countries 
From 1960s, with the rapid development of foreign direct investment (FDI) from 
advanced developed countries, researchers began to study multinational companies’ 
(MNCs) investments from different angles and at different levels in order to illustrate the 
motivations and determinants of FDI. Some of the famous theories for FDI have come 
into being from that time.  
The medical device market has been relatively unaffected by globalization directly before, 
but it plays more and more important role in the global market. Therefore, it is important 
to summarise the literature in the area of health products or the health products industry.    
2.1.1 Monopolistic advantages theory 
Hymer [5] developed a microeconomic explanation of direct investment and tests it 
against miscellaneous facts. The main motivation of a company with international 
production is to fully use its various advantages, such as: advanced technology, perfect 
marketing system and strong management capabilities. Hymer proposes two basic lines 
of explanation as to why a company in one country should assume control over a company 
located in another. Firstly, foreign investment can comprise a strategic move in an 
oligopolistic market, with horizontal FDI1 serving to extinguish competition among rivals 
and vertical FDI2 to avoid the reefs of bilateral monopoly. Secondly, FDI can allow the 
company to make profitable use of some strategic advantage in factor costs, production 
efficiency, distribution system, or product differentiation.  
Kindleberger has promulgated Hymer’s opinions later. They developed the monopolistic 
advantages theory to explain the motivation for control in FDI. They assume that a foreign 
subsidiary has certain disadvantages compared to a domestic company, which are called 
the “liabilities of foreignness”. These disadvantages are: (1) less local knowledge of law, 
1 Horizontal FDI means a company establish factories or value chain in several countries to duplicate its home country-
based activities. 
2 Vertical FDI means a company establish factories to produce raw materials in order to supply the parent company 
itself or its subsidiaries.
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economy, society, culture and language leading to higher information costs and risk; (2) 
foreign companies often face discriminating regulations from government regarding 
taxation or employment; (3) the transfer of earnings are exposed to exchange rate risk; (4) 
the geographical distance between parent company and subsidiary leads to 
communication and coordination costs. In Hymer’s opinion, a company needs to realize 
monopolistic advantages, which are based on defective markets if a company wants to 
overcome these “liabilities of foreignness”. These advantages are: (1) financial 
advantages: in general, MNCs have strong financial strength and a high degree of 
credibility, which makes it easy to obtain loans from the international financial 
institutions; (2) technical advantages: MNCs have strong research teams and have the 
ability to invest in research and development (R&D) of new technologies and new 
products; (3) information and management advantages: MNCs’ subsidiaries located in 
different countries, unify management and global integration strategic principles, which 
brought them together, to exchange ideas so that makes their action unified; (4) credibility 
and trademark advantages: MNCs’ important intangible assets are also an important 
aspect of their monopolistic advantages. MNCs can use their reputation to consolidate the 
existing markets and develop the new markets; (5) economies of scale advantage: MNCs 
always expand their scale to reduce product cost and increase profits; use the international 
distribution channels to sell products in large quantities at low costs globally.  
Michael Klug [6] said, a criticism of this monopoly theory is that it only partially explains 
FDI. A firm’s motivations when investing overseas are to exploit existing advantages 
abroad and aim for additional advantages such as the access to know-how or resources. 
Another aspect of criticism is that the monopolistic theory explains why companies exist 
in foreign markets but does not explain why a subsidiary is more profitable than exporting. 
In summary, Hymer argued that a foreign investor possesses some kind of proprietary or 
monopolistic advantages, which are not available to local firms. These advantages must 
be economies of scale, superior technology, or superior knowledge in marketing, 
management, or finance. FDI took place because of the product and factor market 
imperfections. Hymer’s opinion gave us the theoretical analysis of foreign investment as 
optimization by the company, of the association between investment and the elements of 
market structure have made great strides. However, monopolistic advantages theory also 
has some shortcomings. For instance, the subject of his research is only the powerful 
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American MNCs, which have monopolistic advantages in particular business areas. 
According to Hymer’s theory, the companies cannot do FDI if they do not have 
monopolistic advantages in the business areas. Since the 1980s, with the development of 
FDI from developing countries’ MNCs, this theory has been challenged. 
2.1.2 Product life cycle 
Vernon [7] presented the theory of product life cycle and suggested that a company has 
to use FDI in order to occupy the foreign market in 1966. In Vernon’s opinion, the 
entrepreneur’s consciousness of and responsiveness to opportunity are a function of ease 
of communication; and further, that ease of communication is a function of geographical 
proximity. Producers in any market are more likely to be aware of the possibility of 
introducing new products in that market than producers located elsewhere would be. 
A product life cycle (PLC) refers to the time period between the launch of a new product 
into the market till it is finally outdated. This cycle is split into four different stages which 
encompass the product’s journey from its entry to exit from the market. The four different 
stages are: introduction stage; growth stage; maturity stage and decline stage. Vernon 
defined PLC as location of new products; the maturing product and the standardized 
product. 
Location of new products 
In this stage of introduction of a new product, producers were usually confronted with a 
number of critical conditions. The product itself may be unstandardized for a time. The 
unstandardized nature of the design at this stage carries with it a number of locational 
implications. (1) Producers at this stage are concerned with the degree of freedom they 
have in changing their inputs and the costs of the inputs as well. (2) The price elasticity 
of demand for the output of individual companies is comparatively low; the companies 
can get the monopoly advantages in this stage. (3) The need for swift and effective 
communication on the part of the producer with customers, suppliers, and even 
competitors is particularly high at this stage. In summary, at the introduction stage, the 
producers who find a market for some new product in their own countries may be led to 
select a location for production in their own countries on the basis of national locational 
considerations, which extend well beyond simple factor cost analysis plus transport costs. 
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When products pass through the introduction stage, the sales of products succeed, we can 
say the products enter into the growth stage. Consumers accepted the products. So the 
company has managed to get consumers attention and now works on increasing their 
product’s market share. The cost of production declines, rapid sales and profits are 
characteristic of this stage.  
The maturing product 
This stage is the most competitive as different companies struggle to maintain their 
respective market share. In this stage, (1) the need for flexibility declines; (2) concern 
about production cost begins to take the place of concern about product characteristics. 
In this stage, the producers will consider whether setting up a new production facility in 
other countries. With American producers for example, if the marginal production cost 
plus the transport cost of the goods exported from US is lower than the average cost of 
prospective production in the market of import, the US producers will prefer to avoid an 
investment. However, the locational force, which determined some particular overseas 
investment is so easy and so powerful that one has little difficulty in identifying it. From 
Vernon’s opinion, the US producers have established production units in the advanced 
countries. To compare with a US producing facility and an advanced country producing 
facility, the obvious production-cost differences between the rival producing areas are 
usually differences due to scale and differences due to labour costs. If the market is being 
fully exploited, the principal differences between any two locations are likely to be labour 
costs. According, the company will begin servicing developing countries markets from a 
new location. 
The standardized product 
In this stage, the standardization of some products, the less-developed countries may offer 
competitive advantages as a production location due to the relatively low labour costs, 
which impact labour-intensive products. The producers are looking for a low-cost captive 
source of supply. The competition between companies will be mainly the competition for 
the price of products. At this time, companies may prefer FDI to transfer the production 
to the less-developed countries, which have low-cost labour. 
When developed countries want to increase export business, they transfer technology and 
investment abroad. It reveals that the FDI motivation and foundations; not only depends 
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on the special advantages companies have, but also depends on the companies’ location 
advantages in the host country. PLC shows that the world economic integration to some 
extent and explains the motivation for companies doing business abroad. And it also 
demonstrates the necessity for companies to invest abroad, both for internal and external 
reasons. It is considered defensive because competitors are investing to avoid losing the 
markets served by exports when their initial investor begins local production. They may 
also fear that the initiator will achieve some advantage of risk diversification that they 
will have unless they also enter the market. However, the theory of PLC mainly focuses 
on the production markets, the explanation of resources and technology exploitation in 
other countries is not enough. 
Michael Porter [8] expanded the concepts of PLC in the industry evolution in 1980. Porter 
illustrated that an industry goes through its life cycle with four stages: introduction, 
growth, maturity and decline. Moreover, Porter summarized the common predictions 
about how an industry will change over the life cycle and how this should affect strategy, 
which is shown in Table 2-1. 
Table 2-1 Predictions of PLC. Theories about strategy, competition and performance. 
Introduction Growth Maturity Decline 
Buyers and 
Buyer 
Behaviour 
1, High income 
buyer 
2, Buyers must be 
persuaded to try 
the product 
1, Buyer group 
expansion 
2, Buyer will 
accept uneven 
quality 
1, Mass market 
2, Saturation 
3, Repeat buying 
4, Choosing among 
brands 
Buyers are the 
mastered buyers of 
the product 
Products and 
Product 
Change 
1, Poor quality 
2, Product design 
and development 
key 
3, Many different 
product variations
4, Frequent 
design changes 
5, Basic product 
design  
1, Products have 
technical and 
performance 
differentiation 
2, Reliability is 
important for the 
complex products 
3, Good quality 
1, superior quality 
2, Less product 
differentiation 
3, Standardization 
4, Less rapid 
product changes 
1, Little product 
differentiation 
2, Spotty product 
quality 
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Marketing 1, Very high 
advertising 
2, High market 
costs 
1, High 
advertising 
2, Advertising and 
distribution key 
for nontechnical 
products 
1, Market 
segmentation 
2, Efforts to extend 
life cycle 
3, Service and deals 
more prevalent 
4, Advertising 
competition 
Low advertising and 
other marketing 
Manufacturing 
and 
Distribution 
1, Overcapacity 
2, Short 
production runs 
3, High skill-
labour content 
4, High 
production costs 
5, Specialized 
distribution 
channels 
1, Undercapacity 
2, Shift toward 
mass production 
3, Scramble for 
distribution 
4, Mass 
distribution 
channels 
1, Optimum 
capacity 
2, Increasing 
stability of 
manufacturing 
process 
3, Lower labour 
skills 
4, Long production 
runs with stable 
techniques 
5, Distribution 
channels pare down 
their lines to 
improve their 
margins  
6, Mass distribution 
channels 
1, Substantial 
overcapacity 
2, Mass production 
3, Specialty 
distribution 
channels 
 R&D Changing 
production 
techniques 
--- --- --- 
Foreign Trade Some exports 1, Significant 
exports 
2, Few imports 
1, Decreasing 
exports 
2, Significant 
imports 
1, No exports 
2, Significant 
imports 
Overall 
Strategy 
1, Best period to 
rise market share 
2, R&D, 
engineering are 
key functions 
1, Practical to 
change price or 
quality image 
2, Key function is 
marketing 
1, Bad time to rise 
market share 
2, Bad time to 
change price image 
or quality image 
Cost control is the 
key 
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3, Marketing 
effectiveness is the 
key 
Competition Few Companies 1, Many 
competitors 
2, Many mergers 
and acquisitions 
(M&A) 
1, Price competition
2, Shakeout 
3, Increase in 
private brands 
1, Exits 
2, Fewer 
competitors 
Risk High risk Risk can be taken 
here because 
growth covers 
them up 
Risk cyclicity --- 
Margins and 
Profits 
1, High margins 
and prices 
2, Low profits 
1, Highest profits 
2, Fairly high 
prices 
3, Good 
acquisition 
climate 
1, Lower margins 
and profits 
2, Decreasing prices
3, Increased 
stability of market 
shares and price 
structure 
4, Poor acquisition 
climate 
1, Low margins and 
prices 
2, Falling prices 
Hill and Jones [9] introduced industry life cycle model for analysing the effect of 
industrial evolution. The model has five industry environments, each linked to a distinct 
stage of an industrys evolution: (1) an embryonic industry environment, (2) a growth 
industry environment, (3) a shakeout environment, (4) a mature industry environment, 
and (5) a declining industry environment. Table 2-2 summarized the characteristics of 
each stage. Industry life cycle model is a generalization. In some cases, industries do not 
always follow the pattern. 
Table 2-2 Stages of the industry life cycle. 
Stage Industrial Characteristics 
Product Prices Distribution 
Channels 
Barriers to 
Entry 
Competition 
Methods 
Competition 
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Embryonic 
Industries 
High Poor Access to key 
technological 
know-how  
Educating 
customers; 
Opening up 
distribution 
channels; 
Perfecting 
product 
design 
Lack of rivalry, 
suggests build 
up a strong 
hold on the 
market 
Growth 
Industries 
Fall Develop Technological 
knowledge as 
a barrier to 
entry has 
diminished 
Expand 
revenues and 
profits due to 
rapid growth 
in demand 
Rivalry tends 
to be relatively 
low 
Industry 
Shakeout 
Price war (Cut 
prices) 
Saturation --- Continue to 
add capacity 
at rates 
consistent 
with past 
growth 
Rivalry 
between 
companies 
becomes 
intense 
Mature 
Industries 
Price-
leadership 
agreements; 
most 
industries 
have 
consolidated 
and become 
oligopolies. 
Totally 
saturated 
Barriers to 
entry increase 
(because 
brand loyalty 
and low-cost 
operations 
constitute a 
barrier to 
entry) and the 
threat of entry 
from potential 
competitors 
decreases 
Cost 
minimization 
and building 
brand loyalty 
Reduce the 
threat of 
intense rivalry, 
allowing 
greater 
profitability 
Declining 
Industries 
Price war (Cut 
prices) 
--- --- Companies 
begin to cut 
prices, thus 
sparking a 
price war 
Companies 
gradually exit; 
the degree of 
rivalry usually 
increases 
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2.1.3 Eclectic theory of international production 
Eclectic Theory of International Production was presented by John Dunning in 1977 [10] 
and refined by him several times since then (1988, 1993). Dunnings proposed model was 
preceded by Hymers [5] application of industrial organization economics to the study of 
international trade and investment, and Vernons [7] definition of an international product 
life cycle, both critical steps for international business studies away from macro-
economic trade theory. Dunnings Eclectic Model, is a key contribution to the separation 
of international business studies from international economics and trade theory and to the 
development of global strategy [11]. Dunning expanding the internalization theory, states 
that the incentives to internalize activities are to avoid the disadvantages, of imperfections 
on external (markets and public) mechanisms of resource allocation. The eclectic theory 
has been further elaborated by Dunning in 1981 [12]. The eclectic theory pulled together 
the ownership advantages, location advantages and internalization advantages, which is 
also known as the OLI Paradigm. The OLI Paradigm [10, 13] is an attempt to create a 
framework to explain why MNCs choose FDI to serve foreign markets, MNCs decisions 
on FDI strategy is based on three essential factors:  
(1) O Ownership (or owner-specific) advantages are necessary so that a foreign 
company has some competitive advantage in the host market [6]. As Dunning [14] 
describes, ownership factors are unique competitive or monopolistic advantages, 
typically developed in the home market, that permit the company to complete 
successfully in overseas markets. These factors are of two types: asset advantages arise 
from proprietary ownership of unique assets protected by structural market distortions; 
transactional advantages provide a unique capacity to capture value from the transactional 
benefits of owning a network of assets located in different countries. 
(2) L Location (or location-specific) advantages. These factors are comparative 
advantages that attract FDI to particular locations. These factors might include a low-cost 
but productive labour force, local image, unique sources of raw materials or trade barriers, 
which can be combined with transferable intermediate ownership assets to generate 
superior products.  
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(3) I Internalization advantages. The key ingredient for maintaining a firm-
specific competitive advantage is possession of proprietary information and control of the 
human capital that can generate new information through expertise in research [15]. A 
company needs to realize advantages by internalizing the transaction. Internalization 
factors, typically related to the industry, produce transactional market failure in 
transferring ownership advantages to foreign markets [11]. 
The eclectic theory proposes that only when all three factors (ownership advantages, 
location advantages and internalization advantages) are favourable will international 
production take place. These factors can be transferred into Figure 2-1. The eclectic 
theory discussed the influence of these three factors for the MNCs international 
production. Different combinations of these three factors determine the different ways 
that MNCs participate in international economic activities, which creates a different form 
of market entry: 
Ownership advantages = Licensing 
Ownership advantages + Internalization advantages = Export 
Ownership advantages + Internalization advantages + Location advantages = FDI 
Figure 2-1 The eclectic paradigm and a company’s entry choice. 
Source: adapted from Hoeck (2008) in reference to Welge and holtbrügge (2003) [16] 
Eclectic theory of international production combines a comprehensive theory of MNCs 
in order to research the motivations and determinants of FDI; it had been regarded as a 
perfect FDI theory. This theory indicated that MNCs have entered a relatively mature and 
stable investment stage. However, the research target of this theory is still advanced 
developed countries MNCs. Some of the ideas of FDI are absolute. According to this 
theory, only when all three factors are favourable will international production take place, 
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but for some developing countries MNCs, which still do not have all the three factors 
conditions, this theory cannot explain the international business which is made by some 
developing countries MNCs.  
2.2 Foreign investment theories for the developing countries 
The traditional FDI theory emphasizes that MNCs need to have monopolistic advantages 
if MNCs want to do business abroad. However, with the development of the global 
economy, more and more companies from developing countries invest abroad, traditional 
FDI theory is thus being challenged. Compared with advanced developed countries 
MNCs, MNCs from developing countries have no monopolistic advantages, but they still 
do business abroad even in some advanced developed countries. Therefore, FDI theories 
for developing countries improved traditional FDI theory and made the theory of FDI 
more comprehensive. 
2.2.1 Theory of small-scale technology 
Louis Wells [17] proposed the theory of small-scale technology in his book-- <Third 
World Multinationals: the rise of foreign investment from developing countries> in 1983. 
In Wells opinion, MNCs from the developing countries have three main competitive 
advantages:  
(1) Small-scale technology from developing countries has the feature that it is labour-
intensive and flexible, especially suitable for small batch production and can meet the 
other developing countries relatively narrow market needs. Low-income countries have a 
common characteristic that the commodity market demand is limited. It is hard for mass 
production technology to get profits from this small market demand, so, many developing 
countries are developing the production technology to meet the needs of a small demand 
market. In other words, they have competitive advantages.  
(2) Produce national product in overseas countries. Developing countries foreign 
investment always served their own customers needs in a foreign country. According to 
Wells (1983), some countries such as India, Thailand, Singapore, Malaysia and China 
always produce their national products to meet their customers needs in a foreign country.  
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(3) The marketing strategy of low-price products. Compared with the advanced developed 
countries, MNCs products from developing countries have some competitive advantages: 
low production costs, cheap labour costs, low advertising costs. All of these competitive 
advantages will deliver a good position in market share.  
The main motivations of MNCs from developing countries investing abroad are: to 
protect the export markets. Due to the trade barriers, export is not a long-term 
international business mode, capital exports enable protection of most of their markets. 
Other motivations for FDI are: looking for low cost, spread their assets.  
The feature of the theory of small-scale technology is that it abandoned the traditional 
ideas of MNCs have to rely on monopolistic advantages succeed with their international 
economic activities, it combines the developing countries MNCs competitive advantages 
with these developing countries own market features together. It is useful to analyse how 
the developing countries MNCs got a good position in the world market in the early 
stages of internationalization. According to the small-scale technology theory, MNCs can 
take part in the world business even the developing countries MNCs which have less 
technology, small scope of business and the small scale of production through FDI. It is 
quite meaningful for the developing countries MNCs to invest abroad. However, Wells 
inherited Vernons [7] product life cycle theory; he considered that products produced by 
developing countries are mainly from advanced developed countries mature products. 
Furthermore, this theory cannot explain some foreign investment from developing 
countries high technology companies and it cannot explain the growing phenomenon of 
FDI from developing countries into developed countries.  
The theory of small-scale technology is useful, the spread of foreign investors from 
developing countries is, in net, beneficial to the development process and to international 
relations. [17] 
2.2.2 State of localized technological capacities (Technical localization theory) 
Lall [18] studied how developing countries could gain competitive advantages in the 
global market. The technical localization theory suggests that the formation of technology 
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in developing countries contains internal company innovation activities that become its 
competitive advantages. [19] The developing countries MNCs have their own specific 
advantages due to: (1) developing countries technologies and products linked to their 
price elements and quality; (2) the products applicable to their own economic conditions 
and needs, which means companies transform technologies and products they imported, 
making the products meet the market demand, this kind of innovative activity creates 
competitive advantages; (3) in the small-scale production conditions, technologies arising 
from innovation activities have a higher economic efficiency; (4) in a large domestic 
market, when consumers purchasing power is very different, the products from 
developing countries have some competitive advantages.  
The technical localization theory is emphasis on imported technology regeneration, which 
means developing countries MNCs transformation of imported technology and products 
is not a passive imitation and replication, but is the process of technology digestion and 
innovation so that their products can better meet the needs of their local markets. These 
innovation activities bring competitive advantages to their MNCs. 
2.2.3 Technological innovation and industrial upgrading theory 
Since the middle of 1980s, the accelerated growth trend appears in the FDI of developing 
countries, especially some newly industrialized countries and regions, who invest in 
developed countries, and become the local companies strong rivals. The challenge for 
traditional foreign investment theory is how to explain the new investment trend from 
developing countries. 
John Cantwell and Tolentino [20-22] brought technology innovation & industry upgrade 
to the FDI theory. They highlight that (1) the upgrading of the industrial infrastructure of 
developing countries tells us that developing countries MNCs technological capabilities 
as to improved and expanded, the stable technical ability enhancement is a result of 
continuous accumulation. (2) there is a positive relationship between developing 
countries MNCs technological capabilities and their FDI, which means technological 
capabilities enhancement will bring FDI growth.  
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Technology innovation is the fundamental driving force of the industry and company 
development, which promotes national economic development. Compared with the 
developed countries, which have a large number of R&D investments, developing 
countries do not have strong R&D capabilities in technology innovation, they use their 
unique learning experiences and organizational skills to develop the existing technologies.  
This theory is based on technology accumulation for inner motivation and on the basis of 
geographical extension. With the development of technology accumulation, developing 
countries MNCs FDI transfer gradually from resource-dependent to technology 
dependent. Moreover, as FDI industries have escalated, their structure and regional 
distribution is closely related. Developing countries MNCs geographic expansion was 
largely affected by the psychological distance, which followed the development 
trajectory of neighbouring countries® developing countries® developed countries.
This theory explained the structure of FDI from developing countries especially newly 
industrialized countries; this structural change is from developing countries to advanced 
developed countries, and this change is from the traditional industries to the high 
technology industry. Therefore, this theory is meaningful because it highlights that the 
developing countries strengthen their technological innovation and technology 
accumulation through the FDI in order to upgrade their industrial infrastructure and 
increase international competitiveness.  
2.2.4 The theory of investment development cycle 
In the 1970s, Dunning tried to use the eclectic theory of international production to seek 
a generally applicable FDI theory framework. However, this theory is mainly based on 
the behaviour of FDI of developed countries, the explanatory power of developing 
countries FDI is poor. Therefore, Dunning [23] introduced the theory of the investment 
development cycle in order to further explain the eclectic theory of international 
production in the 1980s.  
The investment development path (IDP) theory hypotheses, illustrated from Dunning, that 
there is a relationship between the countries FDI and their level of economic 
development. Dunning and Narula [24] have used gross domestic product (GDP) as an 
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indicator of the countries economic development level. According to the eclectic theory 
of international production, the dynamic relationship between economic development and 
net outward investment (NOI) position is attributed to the changes of ownership, location 
and internalization (OLI) advantages [14]. According to IDP theory, the OLI dynamic 
interaction can be categorized in five stages, which may be observed in most countries 
(see Figure 2-2). Stage 1: characterizes pre-industrial societies where weak local demand 
and inadequate infrastructure limit the attractiveness of the country to foreign investors, 
while domestic companies lack the requisite O or L advantages. Stage 2: Inward FDI 
increases significantly in this stage due to the development of some L advantages that 
raise the countries attractiveness to MNCs. The O advantages of domestic companies are 
poor and this limits their outward FDI. To the extent that firms do invest abroad, it is in 
response to the local governments support, for example in response to subsidies granted 
for export supporting investment and or capital allocation for resource acquisition [14]. 
During this stage, the NOI position of the country is negative and has a declining trend. 
Stage 3: A gradual decline in the rate of inward FDI due to the growing competitiveness 
of local companies, leads to the increase of the outward FDI. The rate of outward FDI 
may surpass inward FDI flows. Local companies increase their outward FDI due to the 
improvement of O advantages. A countrys NOI is still negative but is on an upward trend. 
Stage 4: The rate of outward FDI increases faster than the rate of inward FDI and a 
countrys NOI is positive due to the development of indigenous companies O advantages, 
which allows them to not only to complete locally with foreign companies but also to 
expand their activities abroad. Stage 5: A countrys NOI is still positive but fluctuates 
around zero at this stage. According to Dunning [25], most advanced countries such as 
the United States, United Kingdom and Japan, their NOI position tends to about zero. 
There are two key features of this stage [26]: <1> A tendency for companies to internalize 
cross-boarder transactions through MNCs activity; <2> As economies become more 
similar in the structures of their location bound assets, their FDI positions are likely to 
become more evenly balanced.  
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Figure 2-2 The Pattern of the Investment Development Path (IDP). 
Source: Dunning and Narula (1996)  
Dunning [23] tested the IDP theory by using data of 67 countries for the period 1967-
1975. The theory of the IDP shows that the countries which have good economic strength 
and advanced productive forces are always the countries with abundant capital output and 
the most active with FDI. However, nowadays not only the scales of advanced countries’ 
FDI expands unceasingly, but also many developing countries’ FDI are very active. 
2.3 Foreign investment theories for the medical device industry 
Whilst there is some literature on the medical device industry and technology investment, 
it is narrowly focused and more general investment data is scarce. While economic cycles 
and uncertainties have affected several global industries in the last few years, the medical 
device industry has gained from the benefits of earlier investments and delivered 
incomparable improvements in the quality of people’s lives in the developed countries 
[27]. It is on the measure of profitability that the medical device industry truly stands out, 
as it has a more consistent rate of growth than nearly every other industry [28]. The 
medical device industry is increasingly significant in the contribution it makes to 
countries’ economic productivity [29]. If the market is being fully exploited, the principal 
difference between any two production locations is likely to be labour costs. When 
product standardization and market saturation give rise to cost pressures and price 
competition in developed countries, those companies that want to increase their export 
business, transfer technology and investment abroad, which means the developed 
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countries shift production to the developing countries [30]. Foreign investment took place 
because of the product and factor market imperfections [5]. Researchers proposed the 
relationship between market imperfections and sustainable opportunities, by recognizing 
and combining known supply and demand elements of the market [31]. The developing 
countries technological capabilities are often improved and expanded, this results in a 
stable technical ability enhancement via continuous accumulation. Technological 
capability enhancement is strongly correlated with foreign investment growth and vice 
versa [26, 32]. 
Investment clearly implies strong consumption now, with the expectation of more 
consumption at a later time [33]. Despite the low rates of return on investment, China has 
attracted a great deal of foreign investment in many industries, while other selected 
countries were not attracting investment, or are even losing foreign capital [34]. China is 
an immense, constantly changing market with huge opportunities for expansion in the 
field of medical devices [35]. With adopted foreign capital, management know-how and 
trained labour, China possesses the capacity to absorb high technology industry, 
especially in the medical device industry [36]. China has been the fastest growing 
economy, expanding at 10.0 percent annually, driven by exports and investment. High 
priority is given to transform the economic structure from an export driven to a 
consumption driven economy during the period of the “National 12th Five-Year Plan”3
[37].  
3 Five-Year Plan (FYP) is a series of social and economic development initiatives, which renews every five years. The 
Five-Year Plan was shaped by the Communist Party of China, who plays a leading role in mapping strategies for China’s 
economic development, setting growth targets and launching reforms. First FYP: 1953-1957, the rest can be done in 
the same manner. So 11th FYP is from 2006-2010 and 12th FYP is from 2011-2015.
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Chapter 3 Global Medical Device Market 
3.1 Global healthcare expenditure 
According to the World Health Organization (WHO) report, the total global healthcare 
expenditure reached US$ 7,593 billion in 2014 [38]. Figure 3-1 shows the global 
healthcare expenditure. In addition, Table 3-1 describes the total expenditure on health as 
a % of GDP by different income groups4. Obviously, the United States spent a lot of 
money on their healthcare, more than other countries. This expenditure is the sum of both 
public and private spending on health goods and services. 
Figure 3-1 Global Healthcare Expenditure. 
Source: WHO, 2015 
Table 3-1 Total Expenditure on Health as % of GDP by Different Income Groups. 
Year Low Income Lower-middle 
income 
Upper-middle 
Income 
High Income Global 
2000 4.6 4.4 5.9 10.0 8.3 
2008 5.4 4.3 6.3 11.1 8.5 
4 The groups are: low income, US$975 or less; lower-middle income, US$976-3855; upper-middle income, US$3856-
11,905; and high income, US$11,906 or more. Countries are divided among these income groups according to 2010 
gross national income (GNI) per capita, calculated using the World Bank Atlas method (WHO).
United 
States, 39%
China, 
8%
Rest of the 
world, 15% Japan, 6% Brazil, 3%
United Kingdom, 
3%
Germany, 6%
France, 4%
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Europe, 
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Europe, 
29%
Global Healthcare Expenditure
United States
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Rest of the world
Japan
Brazil
United Kingdom
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Other Europe
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Source: World Health Statistics 2011 [39] 
Table 3-1 shows the expenditure on health as a % of GDP in high-income countries 
changed significantly between 2000 and 2008 from 10.0% to 11.1%. The reason why 
high-income countries changed much more than other income groups is that the trend of 
their total health expenditure as a % of GDP increased obviously from 2005 to 2010 
according to Table 3-2 which is shown below.  
Table 3-2 illustrates the total expenditure on health as % of GDP of some main high 
income countries such as United Kingdom, United States, Japan, China and Netherlands. 
Table 3-2 Health Expenditure, Total (% of GDP) from the year 2005 to 2010. 
2005 2006 2007 2008 2009 2010 Income level 
China 4.7 4.6 4.4 4.6 5.1 5.1 Upper middle 
income 
Germany 10.7 10.6 10.5 10.7 11.7 11.6 High income 
Japan 8.2 8.2 8.2 8.5 9.5 9.5 High income 
Netherlands 9.8 9.7 9.7 9.9 12.0 11.9 High income 
United 
Kingdom 
8.3 8.5 8.4 8.9 9.8 9.6 High income 
United States 14.7 15.9 16.1 16.5 17.6 17.9 High income 
Source: The World Bank data, 2011 [40] 
3.2 Global medical device market 
According to the Espicom Business Intelligence report [41], the global medical device 
market value is estimated at US$ 250 billion in 2011, with a 5% growth over year 2010’s 
US$ 235 billion. The United States is the world’s largest medical device market, its sales 
accounted for around 42.4% of the global medical device market, which achieved nearly 
US$ 106 billion in 2011. Figure 3-2 describes the global medical device market size in 
2011. Moreover, per capita expenditure of the US achieved US$ 339, which is the third 
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highest in the world, after Denmark and Switzerland. The main driving forces for the US 
market growth are: a huge demand for medical devices, high level of medical expenses, 
scale of 300 million population and an aging population. The US is home to some of the 
largest medical device manufacturers in the world. Table 3-3 shows the Top Ten medical 
device manufacturers in the world and seven of them are from the US, obviously, the US 
is the most significant medical device market in the world. The US, Japan, Germany, 
France and Italy account for 13.1% of global population and 76% of global medical 
device use, conversely, the five most populous countries such as China, India, Brazil, 
Indonesia and Pakistan account for about half of the global population but only 4.4% of 
medical device use in the world [42].  
Figure 3-2 Global Medical Device Market Size in 2011. 
Source: Espicom Business Intelligence, 2012 [41] 
Table 3-3 Top Ten Medical Device Manufacturers in 2011. 
Rank Company Revenue/Sales (Billion US 
Dollars) 
Country 
1 Johnson & Johnson 23.6 United States 
2 Siemens Healthcare 17.4 Germany 
3 GE Healthcare 16 United States 
4 Medtronic 14.6 United States 
5 Baxter International 12.6 United States 
United States, 
42.40%
Europe, 33%
Japan, 11%
China, 3%
Other countries, 
10.60%
Global medical device market size in 2011
United States
Europe
Japan
China
Other countries
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6 Philips Healthcare 11.2 Netherlands 
7 Abbott Laboratories 8.4 United States 
8 Boston Scientific 8.2 United States 
9 Covidien 7.8 Bermuda 
10 Becton Dickinson 7.2 United States 
Source: MPO Medical Product Outsourcing [43] 
As Figure 3-2 shows, China holds just 3% of the global medical device market size, China 
is still one of the fastest growing medical device markets in the world. According to the 
Frost & Sullivan forecast, the growth rate of global medical devices will increase 4% to 
6% annually in the next few years and China’s entire medical device market is expected 
to double, reaching US$ 53.7 billion by 2015 [37]. A detailed analysis of the Chinese 
medical device market will be shown in the following sections. 
3.2.1 Global in vivo diagnostics market 
With increasing emphasis on chronic disease prevention, the global diagnostic imaging 
device (in vivo diagnostics) market is expanding. The annual growth rate of the imaging 
device market share is 4.8% from year 2000 to 2008; global imaging device market share 
reached US$ 14.7 billion according to WHO [44].  
Tomography, as one of the imaging technologies, has a huge market potential in some 
emerging economies such as China, India and Brazil. Moreover, the global market of 
ultrasound equipment continues to expand due to technology development. According to 
Global Data research [45] report forecasts, the market share of ultrasound equipment will 
increase by 7.3% annually and rise to US$ 5.2 billion by 2015 because of breast cancer 
and cervical cancer detection and cardiovascular imaging applications.  
From the year 2001 to 2008, as the technology matures, the growth rate of the ultrasound 
market share increased 5.1% annually. The main reason for the growth is that high 
demand of medical institutions. Moreover, compared to other imaging devices, 
ultrasound equipment has its own advantages: lower cost, portable, lightweight and safe. 
So a lot of medical institutions have the ability to buy ultrasound equipment even some 
small health care centres.  
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From the year 2001 to 2008, the average annual growth rate of X-ray systems and 
computed tomography (CT) increased slowly because of the market size, which is also 
relatively mature and stable. CT will be at a low level in technological innovation 
compared with other types of diagnostic imaging equipment. So the investments in CT 
will not increase dramatically in the future. 
From the year 2001 to 2008, breast screening and diagnosis equipment has a lower speed 
of growth compared to ultrasound. X-ray systems have a global market share of (4.1%) 
according to Global Data research [45] report. However, with the increased incidence of 
breast cancer and the development of nuclear imaging technology, the global market share 
of breast screening and diagnosis equipment will reach 6.9% per year [45]. Therefore, the 
market prospects of breast screening and diagnosis equipment is very optimistic.  
From the year 2001 to 2008, the growth rate of the global market share of magnetic 
resonance imaging (MRI) was higher than 6.6% annually because of the rapid 
development of the MRI area and diseases diagnosis applications. For example, 3Tesla 
(3T) MRI, the new MRI, brings with it important tools to help physicians improve the 
accuracy of diagnoses and treatments of broad categories of diseases including stroke, 
heart disease, musculoskeletal, epilepsy and brain tumours [46]. However, the use cost of 
MRI is relatively expensive. Under the circumstances of a global financial crisis, Global 
Data research [45] report forecasts the global market share growth rate of MRI will be 
slightly decreased (6.1%). Table 3-4 shows the global diagnostic imaging device market 
trends from 2000 to 2008. 
Table 3-4 Global Diagnostic Imaging Device Market Trends from 2000 to 2008. 
Category Market share (2008) 
(Million US Dollars) 
Average annual growth rate % 
(2000-2008) 
X-ray systems 3743.77 3.8% 
Ultrasound 3326.97 5.2% 
 MRI 2563.66 6.6% 
Nuclear imaging equipment 2294.83 4.6% 
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 CT 2060.45 3.6% 
Breast X-ray equipment 728.24 4.1% 
Total 14717.92 4.7% 
Source: Medical Economic News, 2010 [47] 
3.2.2 Global medical imaging for cancer and breast cancer detection/treatment 
According to WHO’s report [48], cancers of the breast, lung and colon are among the top 
ten causes of death of older women globally. The incidence (new cases) of breast cancer 
is much higher in high-income countries compared to low-and middle-income countries, 
but mortality is similar. This is due to the availability of better treatment in the high-
income countries. Worldwide, breast cancer accounts for 22.9% of all cancers in 
women. In 2008, breast cancer caused 458,503 deaths worldwide and 13.7% of cancer 
deaths in women according to World Cancer Report, [49]. Figure 3-3 shows the estimated 
annual number of new cases and deaths for breast cancer in different income groups in 
2008 (World Bank method, mentioned before).  
In recent years, clinical treatment found that, an average 10-year survival rate of breast 
cancer achieved 60%. The survival rate of breast cancer after early treatment achieved 
80%. And after earliest treatment, the survival rate closer to 100%. Therefore, early 
detection and treatment for breast cancer is quite significant. 
In the diagnostic imaging equipment, all of the imaging devices can diagnose breast 
cancer to some degree, but they are often inaccurate. Specialized diagnostic imaging of 
breast cancer is still scarce in the medical device market because the breast imaging 
workflow is still immature. So the breast cancer diagnostic equipment market has great 
commercial potential. In recent years, the market for cancer diagnostic equipment is 
expanding because the number of cancer deaths is increasing worldwide and the incidence 
of cancer tends to occur at a lower age. The developed countries are scrambling to develop 
cancer-related diagnostic scanning equipment in order to get a good position in this huge 
potential market. Table 3-5 illustrates the market size for the breast cancer detection 
medical devices from 2004 to 2007. According to the Frost & Sullivan forecast, by 2014, 
the market size for X-ray mammography, breast ultrasound, MRI and nuclear breast 
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imaging will be 925.2, 532.3, 12.7 and 27.5 million US dollars respectively. The market 
has the great potential. 
Figure 3-3 Estimated Annual Number of Deaths for Breast Cancer in Different Income 
Groups in 2008. 
Source: Global status report, [50] 
Table 3-5 The Market Size of the Breast Cancer Detection Medical Devices from 2004 to 
2007.                                                                                                        (Million US Dollars) 
Year X-ray 
Mammography 
Breast 
Ultrasound 
MRI Breast 
Coil 
Nuclear 
Breast 
Imaging 
Total Market 
2004 256.0 150.5 11.3 5.6 423.4 
2005 245.8 184.8 12.2 7.0 449.8 
2006 406.7 218.9 12.9 7.0 645.5 
2007 630.0 258.6 13.1 8.6 910.3 
Source: Frost & Sullivan, [51] 
3.3 Introduction of main medical device companies 
GE Healthcare, Siemens Healthcare and Philips Healthcare are the leaders of the global 
in vivo diagnostics market. In the year 2009, they accounted for 69% of global market 
share in diagnostic imaging equipment. GE Healthcare accounted for 26.1% of global 
market share in diagnostic imaging equipment, ranking it first. Followed by Siemens 
Healthcare and Philips Healthcare, they accounted for 21.7% and 21.2% of market share, 
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respectively. Therefore, to study and analyse the main large medical device companies’ 
market performance is helpful to understand the global in vivo diagnostics market.
3.3.1 GE Healthcare 
The history of General Electric Company (GE) can be traced back to the late 1870s. By 
1890, famous scientist, inventor, Thomas Edison, established the Edison General Electric 
Company. By aligning multiple businesses to bring innovation to the marketplace, Edison 
laid the path for today’s GE [52]. In 1892, Edison General Electric Company and the 
Thomson-Houston Company combined. They are called the General Electric Company. 
GE is the only one company who has more than 60,000 patents and two Nobel Prize-
winners in the world. GE is a well-known globally diversified multinational company 
which has a set of technical, manufacturing and service industries as a whole, and is 
committed to be a global leader in each industry to obtain their business.  
GE Healthcare is an affiliated enterprise of GE. GE healthcare is headquartered in London. 
The revenue achieved US$ 16 billion in 2011 and ranked in the third place among the 
medical device manufacturers in the world according to Table 3-3. Moreover, GE 
healthcare is the leader of global in vivo diagnostics market. The predecessor of GE 
Healthcare is the Victor Electric Company, acquired by GE in 1926. The Victor Electric 
Company operated an X-ray business and were making X-ray machines in 1896 (one year 
after Roentgen’s discovery) [53]. Victor Electric depends on its innovative products 
became the main supplier in the X-ray machine area. Based on these advantages, GE 
healthcare developed a series of CT scanning, ultrasound, MRI as the representative in 
vivo diagnostics equipment, and gradually became the industry leader.  
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3.3.2 Siemens Healthcare 
The company “Telegraphen-Bauanstalt von Siemens & Halske” founded by Siemens. 
Werner von Siemens laid the foundations in 1847 for today’s Siemens AG in Germany. 
His invention is based on the telegraph. [54]. Headquartered in Berlin and Munich, 
Siemens is now one of the world’s largest electrical engineering and electronics 
companies. 
Siemens Healthcare (Med) formerly was known as Siemens Medical Solutions, and, 
Siemens Medical Systems. Med is one of the Germany’s Siemens’ business groups, and 
it is also one of the famous medical device manufacturers and suppliers in the world. Med 
focused on the research and development of CT and MRI systems. Med has the new 
medical technology; quality service and complete solution that can help their customers 
achieve tangible, sustainable clinical results and economic benefits. 
According to Table 3-3, the sales of Med reached US$ 17.4 billion in 2011, it is higher 
than its main competitors such as GE Healthcare (US$ 16 billion) and Philips Healthcare 
(US$ 11.2 billion), ranked in the second place among the global top ten medical device 
manufacturers.  
3.3.3 Philips Healthcare 
Royal Dutch Philips Electronics was founded by Gerard Philips in 1891 in Eindhoven in 
Netherlands. The company begun manufacturing carbon-filament lamps and had become 
one of the largest producers in Europe. Philips’ introduced its first innovation in X-ray 
and radio technology during the industrial revolution in Europe [55]. Philips ranked first 
in the global lighting market, top three in the medical patient monitoring systems and is 
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in the Top Ten in the diagnostic imaging systems in the world. Moreover, Philips has 
more than 80,000 patents. 
Philips Healthcare provides one of the world’s most outstanding medical system products 
to the customers and their ultrasound equipment and X-ray equipment are world leaders. 
As Table 3-3 shows, the total sales of Philips Healthcare reached US$ 11.2 billion in 2011. 
Figure 3-4 illustrates Philips ultrasound equipment revenue and service revenue from 
2006 to 2010. The market value from 2008 to 2010 is estimated by Philips.  
Figure 3-4 Philips Ultrasound Market Value (Million Euros). 
Source: Philips Internal Report, [56] 
3.4 Market share of in vivo diagnostics device manufacturer by market segment 
GE, Siemens and Philips are the largest players in the in vivo diagnostics market. Besides 
them there are some other companies such as Toshiba, Hitachi, Aloka, etc. who have 
specialized exclusively on medical diagnostic imaging devices. The medical imaging 
market positions of the largest players are close. There is of course a difference in medical 
imaging market position. GE leads in the CT and MRI market, Philips leads in the X-ray 
(Mammography) and ultrasound market. Moreover, Siemens leads in global Customer 
Relationship Management (CRM) and Healthcare Information Technology (IT)/Health 
Services according to the Siemens Healthcare report [57]. The following will show how 
the largest players engage with the medical device market, together they represent nearly 
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70% of the global medical imaging device market, their performance in the different 
market segments, for example CT, ultrasound etc. is valuable to understand. 
3.4.1 CT market share 
Figure 3-5 shows the market share for CT of the three main large medical imaging 
manufacturers. Obviously, the three imaging leaders have a strong position in the CT 
market, GE, Siemens and Philips account for 35%, 20.1% and 14.7% respectively. They 
account for about 70% of the CT global market.
Figure 3-5 Market Share of CT in 2008.
Source: Frost & Sullivan, [58] 
3.4.2 Ultrasound market share 
Figure 3-6 describes the market share of ultrasound by the main large medical imaging 
manufacturers. Obviously, GE, Siemens and Philips account for 64% of the global total 
ultrasound market share. Moreover, GE gained one point share to 26% global (25%, in 
2005). Other companies such as Aloka, Hitachi and Medison etc. account for 22% of the 
market share and Toshiba accounted for 14% of the ultrasound market share in 2006 
(same as 2005). Both GE and Philips appear to be coming on strong in ultrasound. The 
market share of Siemens and Toshiba are close, at 16% and 14% respectively. 
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Figure 3-6 Market Share of Ultrasound in 2006.
Source: Philips Internal Report, [59] 
3.4.3 MRI market share 
Figure 3-7 shows the market share of MRI by the main three large medical imaging 
manufacturers in 2008. For MRI market, three medical imaging device market leaders- 
GE, Siemens and Philips represent 70% of the market share. The latter two together 
comprise 35% of the market share, the same as GE’s market share. 
Figure 3-7 Market Share of MRI in 2008.
Source: Frost & Sullivan, [58] 
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3.4.4 X-ray (Mammography) market share 
Breast cancer is the most common type of cancer in women. Every woman has a 1/8 life 
time chance of developing it. Mammography is the most valuable method for detecting 
potentially cancerous anomalies in the breast [60]. Mammography can reduce breast 
cancer mortality by 20% to 30% in women over 50 years old in high-income countries 
[49]. Figure 3-8 shows the market share of X-ray (Mammography) taken by the main 
three large medical imaging manufacturers in 2008. Philips is the leader in the X-ray 
market. Philips is the X-ray market leader accounting for 24% of market share. 
Figure 3-8 Market Share of X-ray in 2005.
Source: Philips Internal Report, [61] 
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Chapter 4 The Chinese Medical Device Market 
4.1 China’s healthcare industry 
With the rapid growth of its economy, China has expanded its healthcare expenditure. 
According to Figure 3-1 and Table 3-2, China accounts for only 4% of global healthcare 
expenditure and its healthcare expenditure, as a percentage of GDP5, accounted for just 
5.1% of the economy in 2009. During the years from 2001 to 2011, China’s total annual 
healthcare expenditure gradually increased. Figure 4-1 shows total healthcare expenditure 
as a percentage of GDP from 2001 to 2011. 
Figure 4-1 China’s total healthcare expenditures and percentage of GDP (2001-2011). 
By comparison, in 2009, total healthcare expenditure, as a percentage of GDP for the: US 
accounts for 17.7%; Germany-11.7%; UK-9.7%; Japan-9.5%, even Brazil is 8.8%, which 
is higher than China [62]. The above data suggest that China has the capacity to 
substantially improve its healthcare service. A significant factor is that China has the 
largest population in the world (1,331 million in 2009), which is nearly 4 times that of the 
US (307 million) and about 21 times that of the UK (62 million) in 2009 [63]. More 
specifically, in 2009, total health expenditure per capita6 for the US was US$ 7,990 and 
UK was US$ 3,445 while China was only US$ 191 [64]. The medical fee-for-service 
5 Gross domestic product (GDP) is the market value of all officially recognized final goods and services produced 
within a country in a given period of time.  
6 Total health expenditure per capita is the sum of public and private health expenditures as a ratio of total population.
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system in China leads to many Chinese people needing to pay for the services from their 
own pocket. The medical fee-for-service system creates barriers to seeking adequate 
quantity and quality of care for poor families and individuals [65]. The Chinese 
government is trying to make medical services for people affordable, especially for the 
low-income people. The government has determined to carry out healthcare reform, and 
invested 850 billion yuan (about US$ 140 billion) in healthcare systems covering 
infrastructures and equipment from 2009 to 2011 [66]. Figure 4-2 shows the detailed 
allocation of the investment funds. According to the government report, the reform has 
five aspects: (1) establish a basic medical security system and medical insurance system; 
(2) establish a national drug system; (3) improve the basic medical and health service 
system; (4) improve the equality of basic public health services; and (5) promote the 
reform of public hospitals. All this will inevitably lead to spending on capital goods, most 
notably medical devices [67]. Despite these reforms, the Chinese government still needs 
to be vigilant both technically and politically due to the challenges of: affordability and 
accessibility to medical devices [68]. 
Figure 4-2 Breakdown of China’s healthcare reform.
Source: Author’s compilation 
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4.2 China’s medical device market 
“Medical Device” — covers a very broad area, from simple but essential products (such 
as a wheelchair) to complex high-tech products (such as a pacemaker), which involves 
many areas such as mechanical, electronic… Therefore, medical devices have many 
different types of products. Medical dressings and disposable products such as cotton 
wool, gauze, bandage and some surgical instruments do not have high-tech skill 
requirements, so the product differentiation is small, many manufacturers can produce 
these products, and the competition is very fierce. However, as the high-end medical 
imaging devices, CT, Ultrasound, MRI and X-ray are produced by few companies, the 
Chinese high-end medical device market is dominated by these companies.   
4.2.1 Background 
The global medical device market is highly centralized [69]. The market share of the 
developed countries accounted for more than 80% of the global medical device market 
share (US: 42.4%, Europe: 33%, Japan: 11%) in 2011 [41]. With superior know-how in 
technology and/or management, international companies are typically larger than 
domestic companies and have a competitive advantage due to the economies of scale [5]. 
According to Charles Hill and Vernon’s product life cycle theory, the developed countries 
will export their production and technology from their relatively saturated market to the 
developing countries due to the market pressures and other competition in their 
established markets [7, 30, 70]. Despite China only accounting for 3% of the global 
medical device market share [41], this study shows that the developing countries’ medical 
device markets are experiencing rapid growth, especially in China. Increasing medical 
expenditure, rising healthcare consumption and health awareness improvements are all 
possible factors in promoting the development of the Chinese medical device market. The 
Chinese government’s healthcare reform has injected additional “power” into the 
development of the medical device market. In fact, by the end of 2011, the Chinese 
medical device industry output value was 688.42 billion yuan, total percentage of GDP is 
1.40%. Figure 4-3 shows the Chinese medical device industry output value and its total 
percentage of GDP, its value continues to climb from 2001 to 2011. In 2011, the 
percentage of medical device industry output value accounted for 1.40% of Chinese GDP. 
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Although the output value of the medical device industry is currently a limited proportion 
of the national economy, Figure 4-3 shows a rising trend year by year except 2008.  
The Chinese high-end medical device market is dominated by the US, Germany and Japan, 
it is dependent upon imports from these countries. The US is the most significant medical 
device market in the world. Close to 60% of all medical devices consumed around the 
world are produced by American companies [28]. According to the APCO Worldwide 
market analysis report, 90% of value-added high-tech medical devices are foreign made, 
which accounts for 70% of the Chinese medical device market [69]. These high-tech 
medical devices include CT, MRI, Ultrasound, X-ray, implants and assistive devices. 
Figure 4-3 China’s medical device industrial output value and its total (% of GDP). 
Source: National Bureau of Statistics of China [3, 71] 
China’s high-end medical device market is dependent upon imports and dominated by 
foreign companies’ products, especially for the diagnosis and treatment devices. 
Table 4-1 shows the Chinese medical market trade statistics according to the China 
Chamber of Commerce for Import & Export of Medicines & Health Products 
(CCCMHPIE) in 2010. The overall trend of the Chinese healthcare market shows that 
export value is higher than import value; hence the export value of the pharmaceutical 
and medical device industry is higher than the import value. However, only the import 
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value of medical diagnosis and treatment devices is higher than the export value, which 
took a 29.05% share of total import volume in China. By comparison, medical dressings, 
disposable products, health protection and recovery products, dental equipment and 
materials, total only 6.8% of import volume, which is only one-quarter of the import 
volume of the medical diagnosis and treatment sector. 
Table 4-1 China’s import and export structure of medicines and health products, 2010. 
                                                                                                             (Unit: million US Dollars)  
Trade name Export 
Value 
Export value 
growth rate 
annually (%) 
Share in 
total 
export 
volume 
(%) 
Import 
Value 
Import value 
growth rate 
annually (%) 
Share in 
total 
import 
volume 
(%) 
Total 39,733.10 24.87 100 20,464.36 23.98 100 
1.Traditional Chinese 
Medicine 
1,944.47 22.78 4.89 687.95 22.61 3.36 
2.Pharmaceuticals 23,930.02 28.17 60.23 12,440.84 20.53 60.79 
3.Medical Devices 13,858.61 19.83 34.88 7,335.57 30.45 35.85 
3.1 Medical 
dressings 
4,687.51 11.95 11.8 207.77 25.63 1.02 
3.2 Disposable 
products 
1,922.27 15.42 4.84 880.76 27.73 4.3 
3.3 Medical 
diagnosis and 
treatment 
4,543.60 25.56 11.44 5,944.73 30.34 29.05 
3.4 Health 
protection 
and recovery 
products 
2,416.41 30.87 6.08 149.37 83.83 0.73 
3.5 Dental 
equipment 
and materials 
288.82 16.51 0.73 152.94 21.37 0.75 
Source: CCCMHPIE, 2011 [72] 
More specifically, Table 4-2 illustrates the trade statistics for medical devices in China in 
2010. The total export value of medical devices reached US$ 13.86 billion in 2010, while 
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the total import value reached US$ 7.3 billion. North America and Asia are the main 
export target areas for China, which accounted for 29.23% and 33.7% of the total export 
volume; the US and Japan are the main export target countries, which absorbed 27.91% 
and 10.39% of the total export volume respectively. Europe and North America are the 
main exporters to China, which accounted for 39.01% and 31.41% of the total import 
volume. Germany and the US are the main importing countries, which provide 17.34% 
and 30.71% of the total import volume. 
Table 4-2 China’s import and export markets of medical devices in 2010.    
                                                                                                           (Unit: million US Dollars)  
Country Export Value Export 
value 
growth 
rate 
annually 
(%) 
Share in 
total 
export 
volume 
(%) 
Import Value Import value 
growth rate 
annually (%) 
Share in 
total 
import 
volume 
(%) 
Total (All countries) 13,858.61 19.83 100 7,335.57 30.45 100 
Asia 4,669.96 12.87 33.7 1,938.77 29.28 26.43 
Europe 3,631.06 18.53 26.2 2,861.38 34.38 39.01 
North America 4,051.03 24.48 29.23 2,303.79 25.81 31.41 
1. U.S. 3,867.61 24.72 27.91 2,252.64 26.48 30.71 
2. Germany 778.06 14.72 5.61 1,271.74 35.43 17.34 
3. Japan 1,440.07 -13.5 10.39 1,113.90 26.99 15.18 
Source: CCCMHPIE, 2011 [73] 
For the Chinese medical device market, with growth from many sources of demand
(unmet clinical needs, aging population, disease profiles, etc.), medical diagnosis and 
treatment devices still have a great growth potential. China now has a fee-for-service 
healthcare system financed largely by payments from patients, employers and health 
insurance companies [74]. However, many patients especially high income people are 
willing to pay more money by themselves for the highest quality of care, especially for 
the treatment of cancers, heart disease, cerebrovascular disease, etc., which needs to use 
high-tech medical diagnosis and treatment devices or high-grade drugs, which is not 
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affordable for low income people. For example, the average fees for CT whole body scan 
is nearly 2500 yuan (about US$ 400) in China, this is not a small expenditure for low 
income people; they always choose the most economic ways to treat their diseases. 
However, China’s health institutions especially the Tier-3 hospitals 7  have a strong 
demand for high-end diagnostic devices due to the rising number of visits and inpatients, 
changed disease profiles, etc.. Figure 4-4 illustrates the main information of the Chinese 
medical device market [75].  
Increased aging population and healthcare spending are the main driving forces of the 
medical device industry rapid development. Notably, China relies heavily on foreign 
imports for medical devices, especially for the medical imaging devices, which have high 
technical barriers. Hospitals are the largest distribution channel for medical devices. Tier-
3 hospitals imported nearly 100% of their medical devices such as CT, MRI, etc. 
Moreover, 90% of local manufacturers focus on low value-added low-cost medical 
products. The discrepancy between foreign and Chinese medical device companies is 
commonly attributed to the high entry barriers for the high-end medical imaging market: 
producing more technologically advanced devices is capital-intensive, require lots of 
technical knowledge and generally has a long time to market. Faced with a lack of 
financing, 90% of Chinese companies are unable to invest in R&D for high-end devices 
and it is more difficult for the Chinese companies to reproduce these devices. Foreign 
companies provide the training and maintenance of these devices to increase market 
reliance and to ensure lasting profitability [35].  
7 There are three levels of Chinese hospitals: Tier-3 Hospitals (6%) tend to be the best and highest level (first class) 
hospitals, which may offer the most comprehensive medical treatment; complex clinical diagnosis, advanced scientific 
research and R&D abilities, which are provincial and municipal hospitals in big cities; Tier-2 Hospitals (34%) are 
providing comprehensive medical services, basic teaching and research functions, which are municipal hospitals in 
smaller cities as well as district and county hospitals; Tier-1 Hospitals (25%) are grass-roots healthcare institutions, 
providing basic medical services, which are the primary healthcare facilities in small towns; Other healthcare 
institutions account for 35% of total medical institutions. 
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Figure 4-4 China’s medical device industry at a glance. 
4.2.2 Data  
The improvement of medical and health services has greatly increased the market 
capacity for the Chinese medical device industry. The important medical device industry 
drivers are (1) demographics, the percentage of the global and Chinese population above 
65 years old is growing. (2) unmet clinical needs, the trend of using new medical devices 
or products to address diseases or medical needs that previously were simply not treated 
is increasing. (3) procedure penetration, there is a tendency among doctors to use more 
medical products and procedures. (4) pricing, positive pricing trends have generally been 
favourable in the medical device industry. Medical products are not selected on the basis 
of price. (5) geographic reach, the market potential for the highly-populous less-
developed countries (including China) is very compelling [76]. 
The data sources are mainly collected from government reports. Data for medical device 
industry revenues from 2000 to 2012 was collected from the China Statistics Yearbook 
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on High Technology Industry [77]. Data on the number of hospital visits and number of 
hospitals were extracted from the China Health Statistical Yearbook [78]. Data on 65+ 
population was collected from the China Statistical Yearbook [79], and is presented in 
Table 4-3. Other data are collected from United Nations (UN) and their organizations and 
specialized agencies such as the International Monetary Fund (IMF) and World Bank; 
some non-commercial agents such as the China Association for the Medical Devices 
Industry (CAMDI), China Association of Medical Equipment (CAME) and Chinese 
Hospital Association (CHA). 
Table 4-3 Chinese healthcare related data. 
Year 
Medical device 
industry revenues 
(million yuan) 
Number of 
hospital visits 
(million) 
65+ 
population 
(million) 
Number of 
hospitals (Unit) 
2000 55,813 1,286 88 16,318 
2001 62,797 1,250 91 16,197 
2002 73,404 1,243 94 17,844 
2003 88,048 1,213 97 17,764 
2004 130,300 1,305 99 18,393 
2005 175,218 1,387 101 18,703 
2006 236,382 1,471 104 19,246 
2007 302,975 1,638 106 19,852 
2008 325,563 1,782 110 19,712 
2009 425,937 1,922 113 20,291 
2010 553,090 2,040 119 20,918 
2011 673,860 2,259 123 21,979 
2012 777,200 2,542 127 23,170 
The China Statistical Yearbook datasets contain data from every mainland Chinese 
province and city except: Hong Kong, Macao and Taiwan. It also includes the most 
important Chinese statistical data, which is an annual digest of economic and social 
development. The major data sources are obtained from annual statistical reports and 
sample surveys. This study does not include lower level health institutions in the number 
of hospitals, such as grass-roots health care institutions 8 , specialized public health 
8 Grass-roots Health Care institution include community health centre and station, sub-district health centre, village 
clinic, outpatient department, and, clinic (infirmary).
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institutions9 and other Institutions. This is because, in China, high-end medical diagnosis 
devices are always located in Tier-3 hospitals as other health institutions do not have the 
resources to purchase these expensive medical devices.  
4.2.3 Methods and empirical analysis 
This study analyses the Chinese medical device market using quantitative research 
methodologies (regression analysis). Many data sets are collected from official statistics, 
which are created by government departments or other organizations. Although there is 
some limitation to official statistics, many researchers still use this method to analyse 
markets because it saves cost and time, gives access to high-quality data and provides the 
opportunity for longitudinal and cross-culture analysis, etc. [80]. Some forms of official 
statistics are very precise, such as births and deaths data [80] and population census data 
[81]. Data analysis makes the developing trends more clearly understandable. Trend 
analysis can be used to predict the future value of the market. More and more researchers 
have started to focus on the past and its importance for understanding the present situation 
and for predicting the future more effectively via in-depth historical analysis. In the 
population section, this study uses Neural Network Time Series prediction, to predict the 
total Chinese population and the number of 65 year olds and above from 2011 to 2020. 
Neural Networks are widely used in many areas but few researchers have used it for 
population prediction. Therefore, analyses of the data trends from the past to the present 
shows the importance and changing trends for medical devices demand.  
In the real economic environment, one variable is affected by several factors. Multiple 
regression analysis has been selected as the research method in this study. Assume the 
regression equation is: 
      		  
    4  1
where   is the dependent variable,   are the explanatory variables,   the stochastic 
disturbance term, and  the th observation [82]. Using the data in Table 4-3, we set: 
9 Specialized Public Health Institution include Chinese Centre for Disease Control and Prevention (CDC), specialized 
disease prevention and treatment institution, health education centre, maternal and child health centre, emergency centre, 
centre for blood collection & supply, centre for health supervision and centre for family planning service.  
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 =medical device revenues,  =number of hospital visits, 	 =65+ population, =hospital number. From Microsoft Excel we obtained the following regression result:  
  1026663.83  370.46  6119.01	  3.70  7.6946 6.1616 1.5722 0.2008 4  2	  0.9928 	  0.9904
where =estimator of , 	=adjusted ,  =  value, used for  test. 
Regression (see Table 4-4) shows that the number of hospital visits, 65+ population and 
hospital number together explain 99% of the variation in medical device revenues. The 
estimated value of the coefficients of the: number of hospital visits, 65+population and 
hospital number are 370.46; 6119.01 and 3.70, respectively.  
Table 4-4 Multiple regression analysis results. 
SUMMARY OUTPUT 
Regression Statistics 
Multiple R 0.996392262 
R Square 0.99279754
Adjusted R Square 0.99039672 
Standard Error 23813.59461 
Observations 13 
ANOVA
  df SS MS F Significance F 
Regression 3 7.03513E+11 2.34504E+11 413.524344 5.89061E-10 
Residual 9 5103785595 567087288.3 
Total 12 7.08617E+11       
  Coefficients Standard Error t Stat P-value Lower 95% Upper 95% 
Intercept -1026663.83 133427.07 -7.69 3.02E-05 -1328496.831 
-
724830.822 
number of hospital visit 370.46 60.12 6.16 1.66E-04 234.448567 506.46896 
65+ population 6119.01 3891.99 1.57 0.15 -2685.27294 14923.298
hospital number 3.70 18.44 0.20 0.85 -38.00456748 45.40976 
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Hypothesis testing (the  test) assumes : =0, (=1, 2, 3). Regression results (Table 4-4) 
illustrates that the   of = 6.1616,   of 	= 1.5722,   of = 0.2008. The   test of 
significance decision rules is shown in Table 4-5.  
Table 4-5 The  test of significance: decision rules. 
Type of Hypothesis : The Null Hypothesis  : The Alternative 
Hypothesis 
Decision Rule: 
Reject  if 
Two-tail =* ¹* ||>/	,df 
Right-tail £* >* >,df 
Left-tail ³* <* <,df 
Notes [82]: * is the hypothesized numerical value of . || means the absolute value of . or /	 means the critical  value at the  or /2 level of significance. 
df: degrees of freedom, (  2) for the two-variable model, (  3) for the three-variable model, 
and so on 
The same procedure holds to test hypothesis about .  
If we assume  10 =0.05, degrees of freedom (df) = n-4= 13-4 =9 11 . According to 
percentage points of the  distribution (Appendix 1), /	,=./	(9)=2.262. Therefore, =6.1616>./	(9), which is significant, so reject , which means that the number of 
hospital visits has significant impact on medical device revenues. 	=1.5722<2.262 and =0.2008<2.262, so accept : 	=0 and : =0, which are insignificant. 
The regression model is based on several assumptions, one of the assumptions is that 
There is no exact collinearity between the   (explanatory) variables. Insignificant 
values but a high overall 	  is one of the signals for multicollinearity [82]. After 
correlation using Excel we obtained 	 =0.9644, = 0.9423, 	= 0.9831, which means 
three explanatory variables are highly correlated. Thus, we regress  on  individually.  
10  (0< <1) is known as the level of significance. 
11 n means number of observations
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Table 4-6  and  regression analysis results. 
SUMMARY OUTPUT 
Regression Statistics 
Multiple R 0.992251249
R Square 0.984562541 
Adjusted R Square 0.983159136 
Standard Error 31535.32702 
Observations 13
ANOVA 
df SS MS F Significance F
Regression 1 6.97678E+11 6.97678E+11 701.552517 2.57875E-11 
Residual 11 10939245351 994476850.1 
Total 12 7.08617E+11
  Coefficients 
Standard 
Error t Stat P-value Lower 95% Upper 95% 
Intercept -609743.6033 35388.49349 -17.2299961 2.6283E-09 -687633.1522 -531854.0543 
number of hospital 
visit 553.3439799 20.89128221 26.48683668 2.5788E-11 507.3625777 599.325382 
Therefore, the relationship between  and  could be: 
  609743.60  553.34  17.23 26.49 	  0.98 4  3
The regression (equation 4-3) shows that the number of hospital visits variable is highly 
significant, and /	,=./	(11)=2.201. =26.49>./	(11), therefore reject . The 
same with equation (4-2)s results, which means the number of hospital visits has 
significant impact on medical device revenues.  
56 
Table 4-7  and 	 regression analysis results. 
SUMMARY OUTPUT 
Regression Statistics
Multiple R 0.980909914 
R Square 0.96218426 
Adjusted R Square 0.958746466
Standard Error 49356.65704 
Observations 13 
ANOVA 
  df SS MS F Significance F 
Regression 1 6.8182E+11 6.8182E+11 279.884167 3.59461E-09
Residual 11 26796875539 2436079594 
Total 12 7.08617E+11       
  Coefficients Standard Error t Stat P-value Lower 95% Upper 95% 
Intercept -1748028.048 123092.6949 -14.2009081 2.0251E-08 -2018953.243 -1477102.854
65+ population 19391.36416 1159.095439 16.72973899 3.5946E-09 16840.2123 21942.51602 
Table 4-7 shows the relationship between  and 	 is: 
  1748028.05  19391.36	  14.20 16.73 	  0.96 4  4
The regression (equation 4-4) and  test (	=16.73>./	(11)=2.201) illustrates that the 
65+ population variable was statistically insignificant, whereas now it is highly 
significant.  
Table 4-8  and  regression analysis results. 
SUMMARY OUTPUT 
Regression Statistics
Multiple R 0.96151241 
R Square 0.924506115 
Adjusted R Square 0.917643034
Standard Error 69737.33142 
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Observations 13
ANOVA 
df SS MS F Significance F
Regression 1 6.55121E+11 6.55121E+11 134.707165 1.63777E-07 
Residual 11 53496249335 4863295394 
Total 12 7.08617E+11
  Coefficients Standard Error t Stat P-value Lower 95% Upper 95% 
Intercept -1897611.305 190203.0518 -9.97676581 7.5668E-07 -2316245.399 -1478977.211 
hospital quantity 114.0216304 9.824080196 11.60634157 1.6378E-07 92.39897565 135.6442851 
Table 4-8 shows the relationship between  and  is: 
  1897611.31  114.02  9.98 11.61 	  0.92 4  5
=11.61>./	(11)=2.201, and regression equation (4-5) shows that the number of 
hospitals now has a significant impact on medical device revenues, whereas in equation 
(4-2) it had no effect on medical device revenues. 
Therefore, compared with other variables, hospital quantity is one of the drivers in the 
Chinese medical device market, but the number of hospital visits and 65+ population 
played a more important role than hospital quantity. 
4.3 Analysis 
4.3.1 Number of hospital visits 
According to the previous analysis, the correlation equation (4-3):    609743.60  553.34
which means there is a positive linear correlation between the number of hospital visits 
and medical device industry revenues, which means every one million change in the 
number of hospital visits will cause a positive change of 553.34 million yuan in medical 
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devices revenues. This result shows that the number of hospital visits is a vital contributor 
to the Chinese medical device market.  
Table 4-9 Number of visits and inpatients in health institutions. 
Year Visits (Million) Inpatients (Million) 
 Hospital Township 
Health 
Centre 
Total (Include 
other 
institutions) 
Hospital Township 
Health 
Centre 
Total 
(Include other 
institutions) 
2008 1,782 827 4,901 73.92 33.13 114.83 
2009 1,922 877 5,488 84.88 38.08 132.56 
2010 2,040 874 5,838 95.24 36.30 141.74 
2011 2,259 866 6,271 107.55 34.49 152.98 
Source: China Health Statistical Yearbook, 2012
According to Table 4-9, the general trend in the number of visits and inpatients in health 
institutions increased from 2008 to 2011. In 2011, the total number of visits in health 
institutions achieved 6,271 million. The hospitals have 2,259 million visits, which 
accounts for about 36% of total visits. Grass-roots health care institutions have 3,806 
million visits, which accounts for about 60.7% of the total visits. The number of medical 
and health institutions, and visits and inpatients in health institutions has experienced 
growth every year, consequently there is an increased demand for medical devices, 
especially the good quality, multi-functional medical systems. The frequency of use of 
medical devices will accelerate and the renewal period will be shortened.   
4.3.2 Demographic factors 
The huge population and aging population are one of the factors for the growth of Chinas 
pharmaceutical market [83], as well as the medical device market. According to equation 
(4-4):   1748028.05  19391.36	
the regression shows that every one million change in 65+ population will cause a positive 
change of 19391.36 million yuan in medical devices revenues. It is clear that the 65+ 
population is the most important driver of the medical device market.  
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The UN identifies, populations who have reached the age of 60 years as older population 
[84]. Moreover, the UN considers a country to be aging when 10% of their total 
population is aged over 60 or 7% of their total population is aged over 65 [85]. According 
to the National Bureau of Statistics of Chinas Sixth National Population Census12 in 
2010 [86], the total population of China reached about 1.37 billion, where people aged 60 
and above accounted for about 0.18 billion (13.26% of the total population), people aged 
65 and above accounted for about 0.12 billion (8.87% of the total population). According 
to the IMF and UN statistics, China has 0.11 billion people that are over 65, which is 8.19% 
of the total population (1.34billion). Which means that China has entered the aging 
society category.  
Figure 4-5 shows the changing trend of the Chinese population between 1980 to 2010 
[87]. In addition, it is necessary to understand Chinas profile in respect of the aging 
society. There is no direct data on the percentage of 65 years olds and above from 1980 
to 2010, but we can extrapolate how many 65 years olds and above there are from the UN 
Population Division [88]. After calculation, we can evaluate that the approximate 
percentage of 65 year olds and above in China from 1980 to 2010, see Figure 4-6. All 
data shown in Appendix 2.  
Figure 4-5 Chinese population from 1980 to 2010. 
Source: IMF, 2012 [87] 
12 Peoples Republic of China have six national population census before. The first one was in the year of 1953, second 
one was in 1964, third one was in 1982, then 1990, 2000 and 2010. 
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Figure 4-6 Percentage of 65 year old and above population in China from 1980 to 2010. 
Source: UN, 2011 [88] 
From the year of 1990 to 2010, the Chinese population increased from 1.14 billion to 
1.341 billion. However, the population growth rate declined since 1990 [89]. Figure 4-7  
shows the trend of Chinese total population growth rate from 1980 to 2010; data taken 
from Appendix 2. The total population increased slowly, but the population growth rate 
decreased year by year since 1990 due to the decrease in fertility and mortality [90]. The 
reduction in population growth rate speeds up the growth in the aging population. An 
important need of the aging society is high quality healthcare, because the elderly are 
experiencing increasing rates of chronic diseases [91]. Therefore, the Chinese medical 
device market is set to expand. 
Figure 4-7 China population growth rate from 1980 to 2010. 
Source: The World Bank, 2012 [89] 
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Prediction is used in a number of areas. Recently there has been a growing interest in 
applying neural networks to dynamic systems identification, prediction and control [92]. 
Back Propagation (BP) Neural Networks are widely used with great success. McClelland, 
Rumelhart and Hinton [93] established the Parallel Distributed Processing (PDP) models. 
The PDP research group proposed the BP algorithm, this method solved the problem of 
a lack of suitable training methods for the multilayer perceptron (MLP), and this greatly 
assisted the development of neural networks.  
Neural networks are increasingly used by business and management for prediction and 
systems optimization. This includes financial analysis and forecasting [94], bankruptcy 
prediction [95] and stock market prediction [96]. Luo and Huang [97], Xie and Li [98] 
have discussed the prediction of population based on neural networks. 
We use neural network time series prediction in this research. This is a simple way to 
predict population. In the neural network time series prediction, the method of nonlinear 
autoregression (NAR) [99] has been chosen because there is only one series involved 
(here it is Population). The future value schema of a time series y(t) is shown in Figure 4-8. 
Figure 4-8 Diagram of NAR neural network. 
Using a neural network time series prediction based on the real population from 1980 to 
2010, the predicted total population in China from 2011 to 2020 is extrapolated in 
Figure 4-9.  
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Figure 4-9 Real Chinese population and predicted population. 
After training many times, it was found that the optimum number of delays is 5, and the 
number of hidden neurons is 16 (see Figure 4-10), this minimized the error of the neural 
network13 to 0.029528, which gives the best prediction performance. Detailed data shown 
in Appendix 4. 
Figure 4-10 Diagram of NAR neural network used for Chinese total population prediction. 
The World Bank data show that the Chinese total population in 2011 and 2012 is 1,344.13 
million and 1,350.70 million respectively, while the results of the neural network time 
series prediction shows the population is 1,342.32 million (2011) and 1,347.63 million 
(2012) [100]. The error is relatively small and a reliable prediction has been achieved. 
Therefore, a Neural Network performs well in predicting the population. This method is 
13 Neural network error= 


2010
1980
2)(
i
ii DP , where Pi is year i population, Di is year i predicted population.
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used to predict the 65 year old and above population in China, with results illustrated in 
Figure 4-11.  
Figure 4-11 Real Chinese 65+ population (1980-2010) and predicted 65+ population 
(2010-2020). 
Predicting the population for 65 year olds and above permits prediction of a major 
element of the future value of the medical device market based on past records. 
Figure 4-11 illustrates the real Chinese aged 65 and over population from 1980 to 2010 
and the predicted 65 year olds and above population from 2011 to 2020. The predicted 
Chinese 65 year olds and above population from 2011 to 2020 is reported in Appendix 3.  
4.3.3 The number of hospitals in China 
Equation (4-5):    1897611.31  114.02
illustrates that the number of hospitals has a positive linear correlation with medical 
device revenues. According to the China Health Statistical Yearbook, by the end of 2011, 
the number of Chinese medical and health institutions reached 954,389 (see Table 4-10). 
Grass-roots health care institutions account for more than 90% of the total number of 
medical institutions. With the recent reform of China’s healthcare system, this situation 
is changing. According to the healthcare system reform program, the Chinese government 
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invested 850 billion yuan to promote the development of medical and healthcare service 
from 2009. Due to the technology level of the medical devices in these health care 
institutions was lower than in hospitals, the speed of upgrading medical devices will cause 
substantial growth in the coming years. This indicates that there is huge potential for the 
Chinese medical device market.  
Table 4-10 Number of medical and health institutions. 
Institutions 2008 2009 2010 2011 
Hospital 19,712 20,291 20,918 21,979 
Grass-roots Health 
Care Institution 
858,015 882,153 901,709 918,003 
Specialized Public 
Health Institution 
11,485 11,665 11,835 11,926 
Other Institution 2,268 2,462 2,465 2,481 
Total 891,480 916,571 936,927 954,389 
Source: China Health Statistical Yearbook, 2012 [101] 
In summary, China now has hundreds of thousands of medical and healthcare institutions; 
increasing numbers of hospital visits; unmet medical needs has made these medical and 
health institutions require more and more medical devices. China has a large population, 
who have experienced rapid economic development, which has resulted in continuous 
improvement of people’s living standards; the descending population growth rate, means 
that the aging population has become a vital element in driving the medical device market. 
The Chinese medical device industry is in a period of development and expansion, there 
are very broad market opportunities. The huge demand provides a good market 
opportunity for medical device companies. The improvement of Chinese medical and 
health services provides a good development platform and market capacity for the 
Chinese medical device industry.   
Other driving forces such as ownership rate of medical devices among the main hospitals 
and diseases cannot easily use quantitative methods to assess their impact. 
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4.3.4 The ownership rate of medical devices among the main hospitals 
The China Health Statistical Yearbook summarized the number of medical devices in the 
main hospitals and the percentage of medical devices. Although no official data was 
collected after 2004, we can get some data from other agents such as CAME and CHA in 
order to explore the medical device market investment situation in China. Table 4-11 and 
Table 4-12 illustrate the number and percentage of medical devices in the main hospitals. 
Table 4-11 Number of medical devices in the main hospitals in China (units). 
Device 
                      Year 
1996 1998 2000 2001 2004 
Electrocardiograph 35,295 41,230 46,122 48,073 --- 
B-mode ultrasound 19,077 21,842 23,911 24,893 19,653 
Colour Doppler 
Ultrasound 
2,455 4,596 5,110 5,926 7,613 
CT 2,549 3,543 4,247 4,760 4,752 
MRI 356 512 604 714 1,110 
Cardiac Monitor 19,108 27,580 39,995 47,024 --- 
Source: China Health Statistics, [102, 103] 
Table 4-12 Percentage of medical devices in the main hospitals in China (%). 
Device 
                            Possession rate 
1996 1998 2000 2001 2004 
Electrocardiograph 88.1 90.2 92.8 93.7 --- 
B-mode ultrasound 87.1 89.3 91.8 92.7 83.0 
Colour Doppler Ultrasound 15.4 22.0 29.0 32.8 35.7 
CT 17.8 22.6 27.7 30.6 29.2 
MRI 2.5 3.2 4.0 4.8 7.2 
Cardiac Monitor 39.3 43.4 48.2 49.8 --- 
Source: China Health Statistics [102, 103] 
Nearly 90% of the main hospitals purchased Electrocardiograph and B-mode ultrasound, 
because electrocardiograph and B-mode ultrasound are relatively cheap and are used 
widely, ordinary people can afford the diagnostic fees. In addition, many of 
electrocardiograph and B-mode ultrasound devices are indigenous products, there is 
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massive competition especially price competition in this area, which has reduced the 
profit margins, investment in these devices will not gain more profits. Table 4-11 
illustrates that the units for Cardiac Monitoring were 47,024 in 2001, almost the same as 
Electrocardiograph, but its percentage in the main hospitals accounts for 49.8%, this is a 
large difference between Electrocardiograph’s 93.7% in 2001. It means that with the high 
growth rate of the number of Cardiac Monitors, the market for these devices still has room 
for expansion. From both Table 4-11 and Table 4-12 we can understand that the market 
for Colour Doppler ultrasound, CT and MRI has great investment potential, especially 
MRI. This situation is caused for many reasons including the disease profiles, which are 
described below. 
Today the Chinese hospital’s reputation is said to rely on them possessing the latest and 
most expensive medical devices such as Colour Doppler ultrasound, CT and MRI [104], 
because most hospitals’ revenues are generated by these expensive medical devices. In 
1996, China had 2,549 CT scanners, 2,455 Colour Doppler ultrasound and 356 MRIs. 
The increasing speed of adoption of these medical devices is impressive. Until 2004, 
China had 4,752 CT scanners, 7,613 Colour Doppler ultrasound and 1,110 MRIs (see 
Table 4-11). According to CHA’s report [105], China had 9,109 CT scanners in 2008, 
10,101 CT scanners in 2009 and 11,242 CT scanners in 2010. With the increasing number 
of CT’s, China had 5.5 CT scanners per million people in 2006, which increased to 8.6 
CT scanners per million people in 2010, which shows a rapid growth. However, compared 
with other countries, the ownership rate of CT devices is relatively low. For example, 
Japan had 98 CT scanners per million people in 2006. Therefore, it can be predicted that 
there will be huge future demand for this kind of medical device in China. 
4.3.5 The main diseases 
With the increase in the population of elderly people; the improvement of people's living 
standards; population movements and the accelerated process of urbanization, disease 
profiles have altered significantly in China.  
China now belongs to the upper middle income countries [106]; of the top ten leading 
causes of death in the middle income countries, seven are chronic disease-related deaths, 
which accounted for 91% of total deaths [107]. The higher burden of chronic diseases in 
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low- and middle income countries is manifest in China [108], which means these diseases 
will cost a great deal. Although digestive diseases, respiratory diseases, infectious and 
parasitic diseases are the top ten leading cause of death in low- and middle income 
countries, we need to focus more attention on cancers, cardiovascular diseases and 
cerebrovascular diseases, which account for the top three percent of total deaths in China 
[107]. 
Figure 4-12 and Figure 4-13 show the percentage of total deaths from the top five main 
diseases in Chinese cities and counties from 2003 to 2011. All the data are collected from 
the Ministry of Health of the People’s Republic of China health statistics. Detailed data 
are shown in Appendix 5 (city) and Appendix 6 (county). Due to the scarcity of data; the 
years of 2007 and 2010 are not included.  
Figure 4-12 illustrates the percentage of total deaths from the top five main diseases in 
Chinese cities from 2003 to 2011. By comparison, the top three leading causes of death 
in middle-income countries are cardiovascular diseases, cerebrovascular diseases and 
respiratory diseases [108-110], there were 2.8 million deaths from cardiovascular diseases 
in China in 2003 [109]. China has a different profile when compared with other middle-
income countries. Cancers caused the highest mortality in China and has maintained the 
first position among the five leading causes of death in both the cities and counties, except 
in 2005, according to Figure 4-13. The major risk factors causing cancers are tobacco 
consumption, chronic infections, diet and lack of physical activity, etc. [111]. 
Figure 4-12 Percentage of total deaths from the top five main diseases in Cities. 
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Source: China Health Statistics [101, 112-118] 
Compared with Figure 4-12 and Figure 4-13, cancers, cardiovascular diseases and 
cerebrovascular diseases are the top three causes of death in cities in China, but we cannot 
neglect respiratory diseases, which accounted for 23.45% of deaths in the counties in 
2005 (see Appendix 6). Major risk factors for respiratory diseases include air pollution, 
tobacco consumption, occupational long term exposures, etc. [119]. Cerebrovascular 
diseases have reached second place among the ten leading causes of death in the 
developing countries, as well as in China. Major risk factors for cerebrovascular diseases 
are tobacco consumption, obesity and life stress, etc. Injury, poisoning and external causes 
are ranked in position five of the leading causes of death in both the cities and counties 
in China. From analysis of these diseases, it can be seen that tobacco is the greatest cause 
of health problems. Several diseases and conditions were added to the lists as being 
causally related to smoking [120]. 
Figure 4-13 Percentage of total deaths from the top five main diseases in the County 
regions. 
Source: China Health Statistics [101, 112-118] 
Cancer is a leading cause of death globally, accounting for 7.6 million deaths in 2008 
[121]. Nearly 70% of cancer deaths occurred in low- and middle-income countries. It is 
predicted that deaths from cancer will increase, with an estimated 13.1 million deaths in 
2030 [122]. Cancer is a big problem for the society worldwide as well as for China. 
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According to the Chinese Cancer Registry Annual Report [123], the incidence of the top 
10 most common cancers accounted for 76.39% of all cancers in China in 2012. Lung 
was the leading common cancer incidence with the rate of 18.74%, followed by stomach 
(12.67%), colon (10.30%), liver (10.04%), esophagus (7.74%) and breast (7.42%). In 
males, top incidence of common cancers are lung (22.14%), stomach (15.60%), liver 
(13.21%), colon (10.18), esophagus (9.57%) and prostate (3.12%), while in females, 
breast cancer was the leading common cancer with 16.81% of the incidence rate, followed 
by lung (14.36%), stomach (8.89%), liver (5.97%) and esophagus (5.39%). The mortality 
of the top 10 leading causes of cancer death accounted for 84.27% of all cancer deaths. 
Lung cancer was the leading cause of cancer deaths (25.24%), followed by liver (14.42%), 
stomach (14.33), esophagus (9.29%) and colon (7.88). In males, top mortality of cancers 
are lung (27.21%), liver (16.93%), stomach (15.45%), esophagus (10.39%) and colon 
(7.02%), while in females, top mortality of cancers are lung (21.91%), stomach (12.45%), 
liver (10.19%), colon (9.34%) and breast (7.54%).        
Medical devices can guide optimized medical intervention plans, treat people’s illnesses 
and reduce the discomfort caused by the disease. High quality, well designed medical 
devices provide safe and effective clinical care for patients [124]. With the gradual 
increase in the number of patients and mortality, the demand for diagnosis and treatment 
devices will inevitably increase. Good market prospects indicate that medical devices for 
these diseases have great investment potential. 
4.4 Discussion 
The correlation coefficient informs us about the direction and the relationship strength 
between the dependent variable and independent variables. This study suggests that the 
Chinese medical device market is not only driven by the three variables (number of 
hospital visits, 65+ population and number of hospitals) but is also impacted by the 
ownership rate of medical devices among the main hospitals; the main diseases and the 
government healthcare policy, which is not easily quantified. Regression analysis 
illustrates that people aged 65 and above play an important role in China’s medical device 
market. The Chinese 65+ population are projected to be 236 and 334 million by the years 
2030 and 2050, respectively [125]. Therefore, due to the importance of the aging 
population in China, we used neural network time series prediction to estimate the total 
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population and 65+ population from 2010 to 2020. Prediction results show that there is a 
smooth rising trend of Chinese 65+ population from 2010 to 2020, revealing that aging 
population plays an important role in the Chinese healthcare industry, which indicates 
that the Chinese medical device market has possible investment opportunities in the future.  
The purpose of medical devices is to assist with: patient stratification, diagnosis, 
prognosis, treatment and treatment planning; the macroeconomic variables such as 
population structure; disease profiles and economic level can affect the demand for 
medical device services. Disease profiles affect the development of medicine as well as 
medical device capabilities and the total medical device market. Therefore, diseases 
should be one of the elements driving medical device investment. 
The top five diseases have a significant impact on China’s economy via healthcare costs 
and lost productivity. Popkin et al [126] estimated that diet-related chronic diseases 
(cancer, cardiovascular diseases, cerebrovascular diseases and diabetes, etc.) accounted 
for 22.6% of healthcare costs in China, while the cost of lost productivity due to these 
diseases was about 0.5% of GDP in 1995.  
With the advancement of medical technology, the diseases which threaten human life are 
changing as well. Cancers, cerebrovascular diseases, cardiovascular diseases and 
respiratory diseases will become the major diseases which threaten human health and life 
in the 21st century. Medical devices demand analysis is the basis of industrial investment 
opportunities. 
If the incidence or mortality from the disease is low, the demand and frequency of use of 
the appropriate diagnosis and treatment equipment will be relatively low, the investment 
payback period for such medical devices will be long for hospitals; in such a scenario, it 
is difficult for hospitals to recover the cost of medical devices throughout their entire life 
cycle. So only the large general hospitals will consider purchasing such medical devices. 
Small and medium-sized hospitals do not have the capacity to buy such equipment. Thus, 
the market demand for medical devices with low disease incidence is relatively small; 
investment risk is large and does not have financial investment value. If the incidence or 
mortality of the disease is high, the demand and frequency of use of the appropriate 
diagnosis and treatment equipment will be relatively high, the large general hospitals will 
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be very motivated to purchase such medical devices as well as small and medium-sized 
hospitals because the investment payback period for such devices will be short. 
This study predicts the medical device market demand based on disease profiles and the 
extent of the medical device market saturation. In a perfectly competitive market, the 
prices of all products and services in an industry are determined by equating the demand 
for a good with its supply [31]. In the economics area, there is a principle that as “the 
price of a good or service rise, the quantity demand falls”, this is the price elasticity of 
demand. However, research reports that the demand for medical technology is extremely 
inelastic (it does not rely on price) and is free of this principle “competition will make 
prices fall, narrowing margins and reducing profits” [28]. Other arguments show that the 
demand for most new products tends to be based on non-price factors [30]. The medical 
device market has sustainable growth because of the general demographic trends, 
especially the growth of the aging population and the continued prevalence of diseases 
[28]. For the Chinese medical device market, the growth of medical services institutions, 
medical diagnosis and treatment devices, disease profiles and population - especially the 
aging population, means that the market has great investment potential. 
The main medical devices companies’ investment activities and/or mergers and 
acquisitions in China give good indicators of how the market is developing. All these 
activities contribute to China’s medical device industrial growth. Moreover, the Chinese 
government has developed rural areas healthcare systems in recent years and this 
investment is continuing, this creates more investment potential for investors. Therefore, 
foreign investment can make a positive contribution to a host country by supplying capital, 
management resources and technology that would otherwise not be available and this 
increases the country’s economic growth rate [127, 128]; enhanced technology prowess 
can stimulate further economic development and industrialization [30]. So, China is a 
market with fabulous investment potential for health care providers and medical device 
manufacturers [104]. The strongest fields of foreign investment in the Chinese medical 
device market include medical imaging (CT, MRI and ultrasound, etc.) and advanced 
products for treatment of cancers and chronic diseases [35].  
As with many studies, this study has several limitations. Appropriate explanatory 
variables are hard to find, three explanatory variables made the sample size too small to 
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perform regression analysis. Other market drivers like disease and policy are hard to 
assess through regression analysis. The market drivers not only include these three drivers; 
the ownership rate of medical devices and diseases, but also contains other elements. 
Some of the data from the government report is hard to access, for example: the number 
and percentage of medical devices in the main hospitals in China, for which data was only 
reported for the years of 1996, 1998, 2000, 2001 and 2004. The number of medical 
devices in Chinese hospitals after 2004 is hard to access from the Chinese Ministry of 
Health database. Despite the data limitations, the chapter describes the Chinese medical 
device market current situation and identifies the investment potential of the market. The 
multicollinearity often happens in multiple regression analysis, the adjusted results 
reported herein are more reliable. Moreover, analysis of the prevalence of diseases shows 
that cancers are the big challenge for the whole medical area, and that there is an 
increasing trend in the incidence of death from breast cancer, this indicates that there is a 
requirement for further research and analysis in this area.  
4.5 Conclusion 
This study indicates that the Chinese medical device market has great investment 
potential for identified reasons. China has a rapidly developing economy, there is 
government investment in the healthcare industry to improve the medical environment, 
the government is encouraging foreign medical companies to investment in China. Some 
large foreign companies like GE healthcare, Siemens healthcare and Philips healthcare 
continue to increase investment in China. This indicates that the Chinese medical device 
market has significant investment potential for the future. Foreign investment will bring 
both benefits and risks to the country’s health sector [129]. The Chinese medical device 
market still has room for investment due to the growing aging population and the 
increasing number of hospital visits. Because China continues to develop economically 
and socially, the predominance of infectious diseases is decreasing. Chronic diseases 
(epidemiological transition) are emerging as an increasing problem, hence the healthcare 
system is experiencing huge pressures from both changing and increasing demands [130]. 
This chapter provides the first study of its kind in providing a better understanding of the 
Chinese medical device market. Study suggests that the Chinese medical device market 
has great potential and shows that medical diagnosis and treatment devices will be in 
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tremendous demand in the future. The rising numbers of aging people in China, the 
changed disease profiles and the constant increase in the incidence of chronic diseases 
like cancers, which requires medical diagnosis and treatment devices such as CT, MRI 
and ultrasound are driving this demand. 
It is noteworthy that China’s high-end medical device market relies on imports from the 
developed countries. These foreign made high-tech medical devices account for 70% of 
China’s medical device market. The number of medical and health institutions increased 
year by year as did the number of visits and in-patients in healthcare institutions, this huge 
and increasing demand provides an expanding market for medical devices. Disease 
profiles determine which kind of medical devices have more investment value in China. 
Demand analysis indicates that Colour Doppler ultrasound, CT and MRI have great future 
investment potential. The growth in the aging population is a big test of the health care 
industry in China, peoples’ desire for good health is stronger than before, therefore 
significant opportunities exist in the medical device market.  
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Chapter 5 Medical Device Regulations 
5.1  Introduction 
Unlike ordinary products, medical devices utilise a large number of the latest 
achievements of modern science and technology and play a significant role in promoting 
human health. Due to the potential health risks, and the evaluation of the safety and 
effectiveness of medical devices, many countries have established medical device 
regulations for their supervision and management. Medical devices must be qualified by 
passing the safety and effectiveness procedures before they can be marketed in any 
particular country. 
The US was the first country to legally define a ‘medical device’, and also was the first 
country to establish a medical device management procedure [131]. As the second largest 
medical device manufacturers and consumers in the world, the EU also has a rich history 
of medical device regulations. The US and EU have established relatively mature medical 
device regulations, which have a key influence in the world. For instance, most of the 
guidance documents of the Global Harmonization Task Force (GHTF)14 are based on the 
US and the EU medical device regulations. China established Regulations for the 
Supervision and Administration of Medical Devices in 2000; these regulations aim to 
strengthen the supervision and administration of medical devices, ensuring their safety 
and protecting human health and life. The Chinese State Council released new 
Regulations for the Supervision and Administration of Medical Devices and these came 
into force on June 1st, 2014. The revisions are intended to create a more scientific and 
efficient regulatory regime for medical device supervision.
5.2 The United States medical device regulations 
In the year of 1938, the US Congress passed the Federal Food, Drug, and Cosmetic Act 
(the Act). The Act made provisions for medical devices. The US Congress passed the 
Medical Device Amendments of 1976, which changed the Federal Food, Drug, and 
Cosmetic Act. These amendments strengthened the supervision and management of 
14 The organization GHTF (was born in 1992) has been permanently replaced by the International Medical Device 
Regulators Forum (IMDRF) in 2011. 
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medical devices, and established a classified management regime for medical devices. 
These amendments and the Safe Medical Devices Act (1990) gave the government 
administration—U.S. Food and Drug Administration (FDA) the primary authority to 
oversee and manage medical devices, to make sure that the manufacturers produce safe 
and effective medical equipment. The medical device regulations can be found in the 
Code of Federal Regulations-Title 21-Food and Drugs (21 CFR 800-1299) [132] and are 
enforced by the FDA [133].  
The FDA assigns medical devices into one of three regulatory classes based on their risks 
and the evaluation necessary to describe their safety and effectiveness [134-136]. Class I 
devices are low-risk such as surgical instruments, medical gloves and stethoscopes, etc. 
These Class I devices are subject only to “general controls”, such as manufacturers 
registering their name and products with the FDA (Device Establishments); product 
quality must meet the requirements of the US quality systems (QS) and provide sufficient 
labelling information. Most Class I devices are exempt from 510(k) premarket 
notification but must follow the general controls.  
Medium-risk Class II devices such as: CT; electrocardiogram devices; absorbable suture 
etc., must meet the requirements of “general controls” and are also subject to “special 
controls”, such as acceptance of post-market surveillance and additional labelling 
requirements. These Class II devices usually are required to pass through the 510(k)15
premarket notification and review-process before the devices enter into the market. The 
minority of these devices also need to provide some clinical data, via clinical trials, 
approximately 10% of 510(k) applications include clinical data [137]. In the 510(k) 
premarket notification process, the manufacturer must provide all the relevant documents 
and data to the FDA to demonstrate that the new device they produced is at least as safe 
and effective as a previously cleared (predicate) device (legally U.S. marketed device). 
This is the substantial equivalence (SE)16 determination by the FDA[138]. Clinical data 
15 A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is at least as safe 
and effective, that is, substantially equivalent to a legally marketed device. 
16 Substantial equivalence means that a new device is at least as safe and effective as the predicate device, which  
 has the same intended use; and
 has the same technological characteristics; or
 has the same intended use; and 
 has different technological characteristics and the information submitted to FDA; (1) does not raise new 
questions of safety and effectiveness; and (2) demonstrates that the device is at least as safe and effective as 
the legally marketed device.
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may be necessary to prove that the new device is “substantially equivalent” to a 510(k) 
device [137]. The new device cannot legally enter into the market without SE. If the new 
device was determined as substantially equivalent, additional clinical data is not usually 
required [139], but performance standards, patient registries and post-market surveillance 
may be imposed [134, 137]. If the FDA decides that a device does not qualify for SE, the 
applicant may: resubmit another 510(k) with new data; request a Class I or Class II 
designation through the de novo17 process; file a reclassification request or submit a 
premarket approval application (PMA) [138].   
High-risk Class III devices are used to support and sustain human life; they may be 
implanted into the human body permanently, playing a vital role in human health, such 
as: a prosthetic heart valve; pacemaker or artificial blood vessels, etc. For these devices 
general and special controls are insufficient for the assurance of their safety and 
effectiveness [137], hence they require the most strict controls, therefore the formal 
review process PMA will be imposed. PMA requirements apply to Class III devices, the 
most stringent regulatory category for medical devices [140]. Most Class III devices 
require PMA before they can be legally marketed. The manufacturer must supply the 
scientific report and clinical data to the FDA to illustrate that the device is safe and 
effective for its intended use. If the new device does not have a predicate device, it will 
be classified as Class III automatically, regardless of its risk level. But if the device is 
classified as low- or medium-risk, the manufacturer can apply for reclassification to Class 
I or Class II devices through the de novo process and do not go through the PMA process 
[135]. If the new Class III device has little changes to the former PMA-approved device, 
the manufacturer may not need to provide more clinical studies [141, 142], but some 
selected Class III devices are subject to post-market surveillance [137].  
An investigational device exemption (IDE) allows the investigational device to be used 
in a clinical study in order to collect safety and effectiveness data. Investigational use also 
includes clinical study of certain modifications or new intended use of legally marketed 
devices [143]. All clinical study of investigational devices, unless exempt, must submit 
an IDE and be approved by the FDA before the study is initiated. An approved IDE 
17 The de novo is a risk-based and evidence-based classification process, which provides a pathway to classify a low- 
or medium-risk device for which general controls or special controls provide reasonable assurance of safety and 
effectiveness, but for which there is no legally marketed device. Devices are that classified into Class I or Class II 
through the de novo process may be marketed and used as predicates for future 510(k) submissions. 
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permits a manufacturer to collect sufficient data from the clinical trials to support the 
marketing submission (small percentage of 510(k) and PMA) [144]. FDA allows a 
manufacturer with an approved IDE to conduct clinical trials of investigational devices 
without complying with other requirements that would apply to devices in commercial 
distributions. For example, a manufacturer need not register its product, submit a 510(k) 
or PMA. In addition, an approved IDE is also exempt from the Quality System Regulation 
except for the requirements for design controls. Good Clinical Practices (GCP) refers to 
the regulations and requirements that must be complied with while conducting a clinical 
trial. These regulations apply to the manufacturers, sponsors, clinical investigators, 
institutional review boards, and the medical devices [143].  
Moreover, the humanitarian use device (HUD) 18  is exempt from the effectiveness 
requirements of a PMA, called humanitarian device exemption (HDE) [145]. To obtain 
approval for an HUD, an HDE application is submitted to the FDA. An HDE is similar 
in both form and content to a PMA, but is exempt from the effectiveness requirements of 
a PMA. But the application must contain sufficient information to show that the device 
does not pose a risk. In addition, the applicant must describe that no comparable devices 
are available to treat or diagnose the disease. The cost of these kind of devices’ R&D will 
exceed their market returns for the manufacturers. The HUD provision provides an 
incentive for manufacturers to conduct R&D into these devices. 
The statutory mission of the US FDA is to protect public health and aims to ensure that 
all marketed medical devices are safe and effective [146]. The FDA requires mandatory 
medical device reporting (MDR) for post-market surveillance. Manufacturers, device 
users and importers must report the device-associated deaths, serious injuries and 
malfunctions. The FDA also encourages patients or any other medical device related 
people to report any serious adverse events that may be associated with a medical device, 
and quality issues, use errors, etc. [147]. All these actions are taken by the FDA to protect 
and promote public health. 
18 An humanitarian use device is for very low prevalence patients (no more than 4,000 individuals in the US per year) 
diagnosis and treatment. 
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5.3 The European Union medical device regulations 
Until the 1990s, in the area of medical devices, the EU enacted three directives to replace 
each member state’s regulations. The directives harmonised the EU medical devices 
market, ensuring medical device safety and a high level of protection for human health 
and effective functioning of the “single market”. As a part of the single market program, 
the EU enacted three directives in the medical devices field, namely: Active Implantable 
Medical Devices Directive (AIMDD, 90/385/EEC); Medical Devices Directive (MDD, 
93/42/EEC) and In Vitro Diagnostic Medical Devices Directive (IVDMDD, 98/79/EC) 
[148]. The EU directives set out “Essential Requirements” for the approval process for 
medical devices; any product (including medical device) that conforms to EU 
requirements will be Conformité Européen (CE)-marked [29] (Figure 5-1). Only CE-
marked medical devices can be sold in the market. According to these directives, medical 
devices are categorized into four-classes (Classes I, IIa, IIb, III) based on the risk level 
associated with the technical design and manufacture of the devices [149].
Figure 5-1 The CE mark.
Class I are low-risk devices, these only require self-declaration conformity with the 
essential requirements of a Competent Authority19 governmental body, without any need 
to refer to the Notified Bodies 20  or any involvement with them [134, 135]. The 
intervention of a Notified Body is for approval for medium and high risk medical devices 
(Classes IIa, IIb, and III). The manufacturer is responsible for Class IIa device’s design, 
the Notified Body will verify the device quality and assess the conformity at the 
production stages. Conformity assessment and Notified Body verification of Class IIb 
and Class III are vital procedures at both the design and production stages [137]. In 
19 Competent Authority such as the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; Federal 
Institute for Drugs and Medical Devices (BfArM) and Paul Ehrlich Institute in Germany, etc.
20 A Notified Body is usually a third-party, independent, private commercial company that assess and inspect whether 
a product (including medical device) meets the EU standards, for CE marks.
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addition, the Notified Body will not only verify Class IIb device’s quality but also the 
manufacturer must provide the design documents to the Notified Body. Besides 
conformity assessment, Notified Body verification and design documents submission, the 
Notified Body will examine Class III device’s risk analysis report. The Notified Body 
examination results will be reported to the Competent Authority and the European 
Commission. Although clinical trial evidence is a stringent requirement for Class III 
devices, the evidence requirements are vague, and not available to the public [134, 135, 
150]. Moreover, if the device performs as intended, in which the benefits outweigh the 
expected risks, the standard is met [134, 151]. In the quality systems, the standard adopted 
by the European Committee for Standardization (CEN) is EN ISO 13485 21 is harmonized 
with the EU Medical Device Directives 93/42/EEC. The Notified Bodies will certificate 
the quality of the devices, and also assess the performance of high-risk devices in their 
laboratory. Any device that passes the quality certification will obtain the CE mark and 
can be sold within the EU. Compared with the US medical device regulation, the EU 
regulatory regime is designed to access the device’s safety and performance (that a device 
functions as intended or is ‘fit for purpose’) rather than effectiveness, as in the US [29, 
135]. 
When the devices enter into the European market, the Member States are required to 
establish the vigilance procedure for post-market surveillance [152]. The vigilance 
system requires that the Competent Authorities, Notified Bodies, manufacturers, users 
and other related authorized representatives jointly monitor the system. Manufacturers 
are required by law to report all serious adverse events (involving devices they produce 
or sell or recall a device for technical or medical reasons) to the Competent Authorities 
[153, 154]. Each Competent Authority has rights to access to the European Databank on 
Medical Devices (EUDAMED), which is not publicly accessible. EUDAMED contains 
data on manufacturers, authorized representatives and devices; certificates issued, 
modified, supplemented, suspended, withdrawn or refused; clinical investigations, which 
use is obligatory since May 2011 [155]. The purpose of EUDAMED is to enhance market 
surveillance and transparency in the medical devices area by providing Competent 
Authorities with quick access to information as well as to contribute to a uniform 
21 ISO 13485 is an International Organization for Standardization (ISO), requiring a quality management system for 
the design and manufacture of medical devices. 
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application of the Directive [156]. The Member State shall immediately inform the 
Commission or EUDAMED of any activities, which constitute non-compliance with the 
Directive requirements [157].
5.4 The Chinese medical device regulations 
In recent years, the Chinese government issued many medical device related policies, 
involving the most important things are healthcare reform and medical device regulations. 
The Chinese government healthcare reform will effectively boost the demand for medical 
devices; while more stringent medical device regulations would demand a higher 
requirements of medical device safety and production, to make the Chinese medical 
device market become more standardized. Companies interested in entering the Chinese 
market should realize they must overcome existing barriers and the changing regulatory 
environment.  
5.4.1 The old medical device regulations 
There is little research into the Chinese medical device regulations because compared 
with the relatively mature US and EU regulations, the Chinese regulations are evolving 
with the new regulations just released, hence there is a requirement for more research in 
this area. In this chapter, we describe the differences between the “Old Regulations” and 
the “New Regulations”. Generally speaking, the new regulations moderate the 
supervision on low-risk devices and strengthens the oversight of high-risk devices. 
Relatively speaking, the Chinese medical device regulations were established late. In 
2000, Regulations for the Supervision and Administration of Medical Devices were 
established, the regulations laid down the legal status of medical devices’ supervision and 
management. This was the first edition of the regulations and was a milestone in China’s 
medical device regulation history. The “Regulations” gave the China Food and Drug 
Administration (CFDA) authority to oversee medical devices and ensure their safety and 
effectiveness, and protect human health and life.  
China’s definition of a medical device can be found in the Regulations for the Supervision 
and Administration of Medical Devices, 2000 [158]. Medical devices are defined as: 
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Any instrument, apparatus, material, or other article whether used alone or in combination, including the 
software necessary for its proper application. It does not achieve its principal action in or on the human 
body by means of pharmacology, immunology or metabolism, but which may be assisted in its function by 
such means; the use of which is to achieve the following intended objectives: 
1. Diagnosis, prevention, monitoring, treatment or alleviation of disease; 
2. Diagnosis, monitoring, treatment, alleviation of or compensation for injuries or handicap 
conditions; 
3. Investigation, replacement or modification for anatomy or a physiological process; 
4. Control of conception. 
Similar to the US medical device regulations, the CFDA classify medical devices into 
three classes [158]. Class I devices are those for which safety and effectiveness can be 
ensured subject to routine administration (general controls) and do not need clinical trials; 
Class II devices need further controls (special controls) to ensure their safety and 
effectiveness; Class III devices are subject to strict controls because these kinds of devices 
may be implanted into the human body, or be for life support, they have the potential to 
put the patient’s life at risk. The Chinese medical device registration system is different 
from the US system and EU system. In China, Class I devices are inspected and approved 
by the city’s CFDA (city level). The province’s CFDA (province level) are responsible 
for Class II devices’ inspection and registration certificate. All the Class III devices are 
controlled by the State/central CFDA (national level) [159]. Most Class I devices can be 
registered for production directly but must follow general controls. Class II and III 
devices’ registration are not only subject to special and strict controls, but also requires 
clinical trial evaluation before they are put into production. Furthermore, when importing 
medical devices into the Chinese market for the first time, no matter what the class level 
is, the central CFDA will be responsible for the device’s supervision and administration. 
The importer needs to provide details of the devices’ intended use, quality standards, 
testing methods, product sample and other relevant documents for the central CFDA 
oversight.  
Medical devices in China are covered by China National Standards (GB standards) and 
professional/industry standards (YY standards) [160]. Medical devices must at least meet 
the requirements of the Chinese GB standards or YY standards, or meet other standards 
like ISO or equivalent if the devices want to sell in the Chinese market. Some medical 
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devices still need the China Compulsory Certification (CCC) mark for product safety, 
such as medical diagnostic X-ray equipment, electrocardiograph, pacemaker, etc. [67].  
China established the adverse events monitoring system and information networks, 
medical devices re-evaluation and medical device recalls but these systems are still under 
construction and need more legislative support.  
The mission of the CFDA is: public health protection and to ensure that all the marketed 
medical devices are safe and effective. The CFDA usually carries out random testing for 
medical devices’ manufacturers and users. The CFDA has established the adverse events 
systems to collect all the information on medical devices surveillance, this encourages 
medical devices related people to report any medical devices relevant information, like 
quality issues and serious injuries or deaths of patients [161]. 
5.4.2 The new medical device regulations—major changes 
The Chinese State Council released the new Regulations for the Supervision and 
Administration of Medical Devices in 2014, which was the second edition of the medical 
device regulations. Compared with the old regulations (48 articles), the new ones have 80 
articles and many changes on device registration; clinical trials; adverse events; recalls, 
etc. The new regulations are consistent with the goal of the “National 12th five-Year Plan” 
to foster innovation and encourage domestic companies’ R&D while enhancing the 
protection of public health [162]. The government overhauled the regulations in order to 
catch up with the fast development in the medical device industry and economy.  
According to the new regulations, the revised definition of medical device is [163]: 
Any instrument, apparatus, appliance, in-vitro diagnostic reagent and calibrator, material, or other articles 
alike, including the necessary software, directly or indirectly used on human body, which functions by 
means of physical ways, instead of by means of pharmacology, immunology or metabolism, or the 
participation of pharmacology, immunology or metabolism means only plays an assistive role; the use of 
medical devices is to achieve the following expected purposes: 
1. Diagnosis, prevention, monitoring, treatment or alleviation of disease; 
2. Diagnosis, monitoring, treatment, alleviation of or compensation for injuries or handicap 
conditions; 
3. Investigation, replacement, modification or support of a physiological structure or process; 
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4. Supporting or maintaining of life; 
5. Control of conception; 
6. Providing information for treatment or diagnosis purpose by inspecting the samples from human 
body. 
<1> Classification of medical device
The new regulations classify and administer medical devices based on their risk levels. 
Class I medical devices are those with a low-risk level, which through routine 
administration their safety and effectiveness can be ensured; Class II medical devices are 
those with a middle-risk level, for which strict control and administration is required to 
ensure their safety and effectiveness; Class III medical devices are those with a high-risk 
level, for which special measures and strict control shall be taken to ensure their safety 
and effectiveness. Compared with the old regulations, the new regime introduces risk 
management into the regulations. Risk management not only in the device classification 
sections, but also in other parts. For example, “medical device registration should submit 
a risk analysis report of the product; medical device recalls and adverse events”.  
<2> Medical device regulation
According to the new regulations, Class I devices will no longer require registration, but 
will change to record-filing. The applicant shall submit the required documents to a city 
CFDA (same as the old regime) for the device record-filing procedure. The applicant shall 
submit the following materials to the regulatory authority for Class I devices record-filing; 
Class II and Class III devices registration: (1) Risk analysis report of the product; (2) 
Technical requirements of the product; (3) Testing report of the product; (4) Clinical trial 
materials; (5) Product instructions for use and sample label; (6) Quality management 
system documentation related to R&D and manufacturing of the product; (7) Other 
documents which prove the safety and effectiveness of the product. Moreover, the 
applicant for the medical devices record-filing or registration shall be responsible for the 
authenticity of the submitted documents [164].  
Like the old regulations registration procedure, Class II devices are administered by a 
provincial CFDA and Class III devices are administered by the central CFDA. Class I 
devices do not require clinical trials for the record-filing procedure, Class II and Class III 
devices require clinical trials for registration. However, clinical trials can be exempted in 
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any of the following circumstances: the device is at least as safe and effective as a 
previously cleared (predicate) device (legally Chinese marketed device), which has 
similar intended use and no severe adverse events record; a medical device which proves 
to be safe and effective through non-clinical evaluation assessments; a medical device 
which proves to be safe and effective through the analysis and evaluation of the data 
obtained from clinical trials or clinical application of the substantially equivalent medical 
devices. In addition, the duration of the medical device registration certificate is five years 
(the old regulations suggest the registration certificate must be renewed every four years). 
<3> Medical device production
The new regulations pay more attention to Good Manufacturing Practices (GMPs) for 
medical device production management. GMP is that part of quality assurance, which 
ensures that medical products are consistently produced to the required product 
specification and controlled to the quality standards appropriate to their intended use. 
GMP is concerned with both production and quality control [165].  
The CFDA requires that all the medical devices in the Chinese market should be 
accompanied with product specifications and labels. In addition, the new regulations 
require Class II and Class III devices should also indicate the registration certificate 
number and register’s affiliations with product specifications and labels. Moreover, if the 
medical device can be used by the consumer independently, the product specifications 
and labels should include special instructions for its safe use.  
According to the new regulations, if a medical device is within a manufacturing 
consignment, the consigner shall be responsible for the quality of medical devices. The 
consignee shall be a medical device manufacturer which meets the CFDA’s requirements. 
In addition, the embedded medical devices with a high-risk level shall not be 
manufactured in consignments [166]. 
<4> Distribution/operation and use of medical devices 
The old regulations required companies who distribute/operate Class I medical devices to 
file records with the provincial CFDA. Companies distributing/operating Class II and 
Class III medical devices need to obtain the Medical Device Distributing Enterprise 
License, which is issued by the provincial CFDA. The New Regulations removes record-
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filing for Class I device distributors and requires Class II device distributors to file records
with the provincial CFDA.  
The new regulations also place more obligations on medical device distributors and users. 
Such obligations cover all aspects of using medical devices including device supplier’s 
certificates, quality certificates, records of purchase/sales, transportation and storage, 
operator technical training. Moreover, the medical device user shall inspect, verify and 
maintain the devices periodically to ensure the devices are in good condition, safe and 
effective.  
Imported medical devices shall be accompanied with product specifications or user 
manuals and labels in Chinese, and specify the devices’ place of origin and agent’s 
affiliations. The medical device exporters shall ensure the exported devices comply with 
the requirements of the importing countries. 
<5> Medical device adverse events and recalls
The old regulations were silent about medical device adverse events and recalls. However, 
the central CFDA and the Chinese Ministry of Health (MOH) issued provisional Decree 
425 for tracking adverse events [167] and provisional Decree 82 for managing medical 
device recalls [168] in 2011, respectively.  
The new regulations issued requirements on monitoring medical device adverse events 
and managing recalls. These requirements set clear responsibilities from device 
manufacturer personnel to distributors and patients/consumers. The central CFDA 
established the medical device adverse events monitoring system and information 
networks to: collect information, analyse, evaluate and control adverse events in a timely 
manner. Any medical device manufacturer, distributor and user has rights to report 
adverse events to this monitoring system and information networks, and the CFDA will 
also collect adverse events information proactively.  
The new regulations require the device manufacturer to stop production if the device does 
not meet the compulsory standards or contains other defects, furthermore, they must 
notify relevant distributors or users to stop distributing or using this kind of device and 
recall the devices which are already on the market. According to MOH Decree 82, there 
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are three levels of recalls based on the severity of medical device defects [168]. Level I 
recalls means that if use of the medical device has caused, or may cause, serious health 
hazards that are of a permanent nature; Level II recalls means use of the medical device 
may cause health hazards that are of a temporary or permanent nature; Level III recalls 
mean use of the medical device may not be likely to cause harm but it is still defective 
[67].  
<6> Supervision and inspection
The new regulations require that the CFDA enhance supervision and inspection of 
medical devices’ registration, record-filing, production, distribution and use, sometimes 
using random checks. The provincial CFDA or central CFDA will issue medical device 
quality circulars based on the results of timely random checks.  
The central CFDA has established a shared medical device supervision and inspection 
information network. The CFDA should legally and in a timely manner publish the 
medical devices’ license, record-filing, random check results and illegal behaviour 
through the information network. In addition, the CFDA also established the credit files 
for medical device registrants, record-filing applicants, manufacturers, distributors and 
users, and increased the frequency of inspection upon those who have a poor credibility 
record. Moreover, the CFDA publish their contact information for inquires, complaints 
and reports. Information disclosure is a major breakthrough for the Chinese medical 
device market participants’ supervision and inspection. 
<7> Legal liabilities
The new regulations have increased sanctions and penalties for various violations. For 
example, administrative penalties up to 20 times (5 times in the old regulations) the value 
of the manufactured products may be imposed on medical devices produced without the 
proper permits. In some severe circumstances, relevant personnel and companies will be 
suspended from application for any medical device permits or licences for 5 years, and 
may be subject to criminal sanctions if such violation constitutes a criminal offense. 
Penalties or criminal offenses may be incurred for the following actions: permits (medical 
device registration certificate, production permit, distribution permit, advertisement 
approval certificate) are obtained by providing false information or by using other 
methods of cheating;  relevant medical device permits or certificates are forged, altered, 
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transferred, leased and lent; manufacture, distribute or use of devices which are not 
compliant with the compulsory standards or technical requirements; any clinical trials 
conducted in violation of the Regulations or medical device clinical trial institutes issuing 
false reports, etc.  
5.4.3 New regulations versus old regulations 
Table 5-1 Comparison of the Chinese medical device regulations. 
 Category New regulations (2014) Old regulations (2000) Comparison 
1 Classification 
Classify and management of 
medical devices according to 
their risk levels. 
Classify medical devices and 
administer them based on the 
classification. 
Main changes: the 
classification of 
medical devices, 
which introduced risk 
levels into the rules. 
Class I medical devices are low-
risk and safety and effectiveness 
can be ensured through routine 
administration (general 
controls). 
Class I medical devices are 
those for which safety and 
effectiveness can be ensured 
through routine 
administration (general 
controls). 
Class II medical devices are 
medium risk and further control 
(special controls) is required to 
ensure their safety and 
effectiveness. 
Class II medical devices are 
those for which need further 
controls (special controls) to 
ensure their safety and 
effectiveness. 
Class III medical devices are high 
risk devices subject to strict 
controls to ensure their safety 
and effectiveness. 
Class III medical devices are 
implanted into human body, 
or used for life support, need 
strict controls.  
To evaluate the risk levels of 
medical devices, shall consider 
medical devices expected 
objectives and user instructions, 
etc. 
n/a 
Class I medical devices shall be 
subject to record-filing and do 
not need clinical trials;  
Class II and Class III devices 
require registration, need 
clinical trials. 
Class I, Class II and Class III 
devices all require 
registration. 
Class II and Class III devices 
need clinical trials. 
Simplified the 
application 
procedure of Class I 
medical devices. 
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2 Registration 
Class I devices record filing, Class 
II and Class III devices 
registration need to submit: (1) 
Risk analysis report of the 
product;  
(2) Technical requirements of 
the product;  
(3) Testing report of the product; 
(4) Clinical trial material;  
(5) Product instructions for use 
and sample label;  
(6) Quality management system 
documentation related to R&D 
and manufacturing of the 
product; 
(7) Other documents which 
prove the safety and 
effectiveness of the product. 
No detailed requirements. The new regulations 
proposed the 
detailed submission 
materials for devices 
record filing and 
registration.  
Registration order: apply for 
registration certificate first, then 
apply for manufacturing license. 
Registration order: apply for 
manufacturing license first, 
then apply for registration 
certificate. 
The advantages of the 
changes: 
Companies do not 
need large initial 
investments before 
they get a registration 
certificate. Ensure 
companies focus on 
products R&D. After 
got the registration 
certificate, 
companies can invest 
more into 
production. 
Medical device registration 
certificate shall be valid for 5 
years. 
If the registration certificate 
needs renewal, an application 
shall be filed with the original 
The term of validity for the 
registration certificate is 4 
years.  
The registration certificate 
need to be renewed within 6 
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registration department 6 
months prior to expiration date. 
If the CFDA review is not 
completed by the certificate 
expiry date, automatic renewal 
is granted. However, renewal 
will not be granted if 
applications are not lodged in 
time or devices do not meet the 
compulsory standards. 
months before certificate 
expires. 
When companies continuous 
stop production for more than 
2 years, their registration 
certificate will automatically 
invalidated.  
Applying for medical device 
registration: 
The CFDA shall transfer 
application materials to 
technical review institutions 
within 3 working days after 
acceptance of the application; 
The technical review institutions 
shall submit review opinions to 
the CFDA after technical review; 
The CFDA needs to make 
decisions within 20 working days 
from the date when received the 
review opinions. 
Applying for medical device 
registration: 
Citys CFDA shall make 
decisions within 30 working 
days from the date of 
application; 
Provinces CFDA shall make 
decisions within 60 working 
days from the date of 
application; 
Central/State CFDA shall make 
decisions within 90 working 
days from the date of 
application. 
The new regulations 
shorten the review 
time, improved the 
efficiency. 
Class I devices need 
record-filing with 
citys CFDA; Class II 
and Class III devices 
need to register with 
provinces CFDA and 
central CFDA, 
respectively.  
Uncategorized devices may 
apply using Class III pathways, or 
according to the classification 
rules to determine the products 
categories, to apply for 
classification to the CFDA, then 
record-filing or registration. 
n/a 
Device manufacturers shall 
have: 
Production site, environmental 
conditions and professional 
technical personnel; quality 
testing staff and institutions; 
Device manufacturers shall 
have: 
Professional technical 
personnel; facilities/factories 
and environmental conditions; 
manufacturing equipment; 
The new regime 
require 
manufacturers to 
have a quality 
management system. 
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3 Production 
quality management system; 
after-sales service; R&D and 
production process documents.  
quality testing staff and 
institutions. 
Medical device 
manufacturing/production 
license valid for 5 years; 
If a license needs renewal, the 
CFDA will in accordance with 
relevant laws and rules renew 
the license. 
Manufacturing/Production 
license valid for 5 years.  
Upon expiration, re-inspection 
and license renewal shall be 
conducted.  
Renewal of the 
existing license, the 
new regulations 
require no further 
reviews and re-
inspection. 
The new regulations proposed 
medical device manufacturers 
must follow the requirements of 
device quality management, to 
ensure their products meet the 
Chinese GB standards or YY 
standards or other standards 
such as CCC. Moreover, 
manufacturers must ensure that 
the technical requirements of 
their products consistent with 
the records they submitted to 
the CFDA. 
n/a 
The new regime 
introduce quality 
management system 
into device 
production and 
quality control. 
The new regulations require 
detailed devices instructions 
and labels; 
Class II and Class III devices also 
need to contain registration 
certificate number and registers 
affiliations. 
No detailed requirements.  
Class I device operators are not 
required to file records and 
license; 
Class II device operators need to 
file records with the citys CFDA; 
Class III device operators need to 
apply for an operating license 
with the citys CFDA. 
Class I device operators need 
to file records with the 
provinces CFDA; 
Class II and Class III device 
operators need to apply for an 
operating license with the 
provinces CFDA. 
The new regulations 
improve the 
efficiency of medical 
device operation. 
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4 Operation 
Medical device 
distributing/operating license 
valid for 5 years; 
If license needs renewal, the 
CFDA will in accordance with 
relevant laws and rules renew 
the license. 
Distributing/Operating license 
valid for 5 years; 
Upon expiration, re-inspection 
and license renewal shall be 
conducted. 
Same method with 
manufacturing 
license renewal, the 
new regulations 
require no further 
reviews and re-
inspection for 
operating license 
renewal. 
Require device operators 
establish sales/purchase record 
system, especially Class II and 
Class III devices. Records must 
include: (1) device name, model, 
specification and quantity; (2) 
device serial number, validity 
and sale date; (3) name of device 
manufacturer; (4) device 
supplier or buyers detailed 
contact information; (5) related 
documentation and license; (6) 
Class III devices provide key 
technical parameters 
information. 
n/a 
Imported devices should have 
instructions and labels in 
Chinese, specify the devices 
place of origin and agents 
affiliations. 
n/a 
Companies should ensure that 
their devices exported to other 
countries, should meet the 
requirements of the importing 
countries.  
n/a 
The medical device 
manufacturers, operators and 
users should monitor adverse 
No detailed requirements. The old regulations 
were silent about 
adverse events and 
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5 Adverse 
events and 
recalls 
events, report any adverse event 
to the CFDA timely. 
recalls, but using the 
supplementary 
decrees to oversight 
the medical device 
adverse events and 
recalls. The new 
regime added 
adverse events and 
recalls to the 
regulations. 
The CFDA established the 
medical device adverse events 
monitoring system and 
information networks to collect 
adverse events information and 
control adverse events.    
No detailed requirements. 
Device manufacturers or users 
found that their products do not 
meet the mandatory standards 
or are flawed, need to stop using 
the devices and recall the 
devices or report to the CFDA. 
No detailed requirements. 
6 Supervision 
and 
inspection 
The CFDA must focus 
supervision and inspection on:  
(1) whether the device 
manufacturers production is in 
accordance with the technical 
requirements they submitted to 
the CFDA; 
(2) whether the device 
manufacturers quality 
management system operates 
effectively; 
(3) whether the device 
manufacturers and operators 
production and operation 
conditions still continued 
compliance with the statutory 
requirements.  
No detailed requirements. The new regulations 
clearly defined the 
contents of 
supervision and 
inspection: technical 
indicators and quality 
management system. 
The CFDA  staff have the 
following rights for oversight:  
(1) access to the manufacturing 
site for inspection and take 
samples; 
No detailed requirements. The new regulations 
strengthened the 
CFDAs supervision, 
refined contents of 
oversight. 
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(2) read, copy and confiscate 
contracts, bills or other related 
documents; 
(3) close down, confiscate 
devices or production site which 
have not met the statutory 
requirements. 
The central CFDA established a 
unified information platform for 
the supervision and 
management of medical devices. 
Citys CFDA and provinces CFDA 
should promptly publish 
supervision information through 
the unified information 
platform, but cannot disclose 
commercial secrets.  
No detailed requirements. The new regulations 
advocate information 
disclosure, which 
increased the 
transparency of the 
supervision. 
7 Legal 
liabilities 
Value of the illegally 
manufactured devices not 
exceeding 10,000 yuan, will be 
subject to a fine of 5 to 10 times 
of 10,000 yuan; value of the 
illegally manufactured devices 
exceed 10,000 yuan, will be 
subject to a fine of 10 to 20 times 
of the devices value.    
Illegal gains from the illegally 
manufactured devices not 
exceed 10,000 yuan, will get 
10,000 yuan to 30,000 yuan 
penalties; illegal gains exceed 
10,000 yuan, will get a fine of 
3 to 5 times of illegal gains. 
The new regulations 
increased sanctions 
and penalties for 
various violations. 
Moreover, the new 
regime increased 
penalties for 
dishonesty. 
In some severe circumstances, 
relevant companies will be 
suspended from application for 
any device license or permit for 
5 years, and may be subject to 
criminal sanction:  
(1) manufacturing or distributing 
Class II and Class III devices 
without licenses or permits;  
(2) be licensed through providing 
false information or deception; 
n/a 
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(3) clinical trials illegally. 
Any personnel and company 
advertising false medical devices 
to the public, will get 20,000 
yuan to 50,000 yuan penalties; 
Any personnel and company 
tampering with approved 
advertising content, will be 
suspended from application for 
medical device advertisement 
for 2 years. 
No detailed requirements. 
The CFDA issued the new Measures for the Administration of Medical Device 
Registration; Measures for the Administration of In Vitro Diagnostic (IVD) Reagents 
Registration; Provisions on the Administration of Manuals and Labels of Medical 
Devices; Measures for Supervision and Administration of Medical Device Production 
and Measures for Supervision and Administration of Medical Device Operation that came 
into force on the 1st October, 2014. The new Measures for the Administration of Medical 
Device Registration outlines the timeline from application acceptance to certificate 
delivery for medical devices (Figure 5-2). 
Submission 
acceptance
3 working days
Technical review
60 working days (Class II devices)
90 working days (Class III devices)
Administrative 
review
20 working days
Registration 
certificate 
delivery
10 working days
Figure 5-2 Timeline of medical device registration. 
Note: excludes time spent in responding to review questions or expert committee reviews. 
The timeline of medical device registration shows that Class II devices need at least 93 
working days to get the medical device registration certificate from the province’s CFDA 
and Class III devices need at least 123 working days to get the registration certificate from 
the central/state CFDA. Class I devices only need filing with the city’s CFDA. The 
timeline of medical device registration in the old guidance illustrated that the 
administrative reviews and issue a decision for the registration certificate needed at least 
30 working days (Class I devices); 60 working days (Class II devices) and 90 working 
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days (Class III devices), respectively. The new medical device regulations and new 
registration guidance show that the CFDA is moving towards a simplified registration 
review process for low risk/Class I devices so that resources can be directed to supporting 
the high risk devices regulatory review [169].
The new guidance Measures for Supervision and Administration of Medical Device 
Production outlines the timeline from submission acceptance to certificate delivery for 
the Class II and Class III  medical device manufacturing/production licenses, which need 
at least 40 working days (30 working days for administrative reviews and issue of a 
decision; 10 working days for license delivery) from the province’s CFDA. Class I device 
manufacturers need to complete record-filing with the city’s CFDA to obtain the 
production licenses. The medical device manufacturing/production license is valid for 5 
years. This provision is only for domestic manufacturers. 
The new guidance Measures for Supervision and Administration of Medical Device 
Operation outlines that Class I device operators do not need to file records and license; 
Class II device operators need to file records with the city’s CFDA; Class III device 
operators need to apply for an operating license from the city’s CFDA. The timeline from 
application acceptance to certificate delivery for the Class III  medical device operation 
licenses, which need at least 40 working days (30 working days for administrative reviews 
and issue of a decision; 10 working days for license delivery) from the city’s CFDA. The 
medical device operation license is valid for 5 years. 
The CFDA issued the new Rules for Medical Device Classification in 2015 that came into 
force on the 1st January, 2016. The CFDA uses “classification rules” and “classification 
catalogues” to implement medical devices classification. The new Medical Device 
Classification Catalogues are still under revision. The “classification rules” are the guide 
to make “classification catalogues” and provides the identification of a new device 
registration category. 
The CFDA also issued the new Provisions on the Administration of Manuals and Labels 
of Medical Devices to control medical device labelling. The new provisions have 19 
articles, which mainly specify the requirements of device manuals and labels for medical 
device safety. The new provisions require both domestic devices and imported devices 
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should have manuals and labels for the Chinese version. The manuals and labels of 
imported devices could contain other languages but reviews are based on the Chinese 
version description. 
5.5 Comparison of medical device regulations 
The US, EU and Chinese approaches to medical devices regulation are different. In this 
section we will compare aspects of registration, classification, premarket and post-market 
controls between the US, EU and China.   
<1> Registration 
The US FDA is open to all medical devices related companies for all medical devices 
(Class I, II and III) registration, whereas only manufacturers can register medical devices 
in China; if the devices are imported, their Chinese agents need to register the devices. 
The EU medical device registration system is similar to the US FDA’s. Manufacturers 
and other related medical companies need to register their devices with the Competent 
Authorities.   
Figure 5-3 FDA registration system. 
Centralization of the US FDA registration system (Figure 5-3) provides consistent 
evaluation criteria. Class I devices are low-risk and subject only to general controls, 
manufacturers can register their devices with FDA; Class II devices are medium-risk, 
which require special controls. The majority of these devices usually are required to pass 
through the 510 (k) premarket notification process before enter into the market; high-risk 
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Class III devices require strict controls and have to pass through the formal review 
process—PMA. 
Some experts suggested that the 510 (k) clearance process should stop and be replaced 
with an evaluation of device safety and effectiveness process [170], greater centralization 
leads to a strict, time-consuming and costly regulatory process [171, 172]. Moreover, the 
Institute of Medicine recommended the FDA should eliminate the 510 (k) premarket 
notification process because it was ineffective and unsalvageable [173]. The current FDA 
system has been simultaneously faulted for inadequate assurance of safety and efficacy 
[174]. In addition, both the US FDA and EU authorities require device manufacturers to 
prove the safety of their products, the FDA still need to certificate the new products’ 
effectiveness (perform better than already marketed devices) rather than the ‘performance 
(fit for purpose)’ of the EU regulation, which means the EU system is relatively faster 
than the US. However, a centralized system provides searchable listings for the public 
and has a database of serious adverse events and post-market reports, these resources are 
useful to independent researchers evaluating specific medical devices [134, 175-177].  
Different from the centralized FDA registration system, the EU system relies on 7422
decentralized designated agencies—Notified Bodies. The decentralization of the EU 
system provides the governmental Competent Authorities with the high working 
efficiency and a fast review process compared with the FDA. However, the decentralized 
system also has disadvantages. Different Member States have inconsistent levels of 
technological development, this makes it difficult to guarantee the Notified Bodies’ staff 
or reviewers have consistent knowledge, cognitive level and inspection standards, which 
means there may be inconsistency in the process for approving similar medical devices 
among Notified Bodies [178]. Manufacturers can choose the Notified Body that they put 
their devices through and can select the Notified Body with the least rigorous reviews 
[179], which permits them to identify the easiest route to getting the CE mark [134]. In 
addition, decentralization also inhibits the collection of safety data for patients to detect 
the potential problems and identify the adverse events [180].
22  Number of 74 Notified Bodies, updated until June 2014. Refer to the European Commission website:  
http://ec.europa.eu/enterprise/newapproach/nando/index.cfm?fuseaction=directive.notifiedbody&dir_id=13 
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The Chinese registration system is a hierarchical system (Figure 5-4). This system 
theoretically should have a short processing time and high efficiency. The CFDA has 
local regulatory agencies, which includes 31 provincial, 433 municipality and 1,936 
county-level agencies. Technical organizations include 16 state, 122 provincial, 373 
municipal  and 436 county-level organizations [181]. The regulatory agencies (except 
county-level), which can issue a medical device registration certificates. 
Figure 5-4 CFDA registration system.   
Similar with the US FDA’s pathways to approval, the new pathway of the CFDA requires 
low-risk Class I devices record filing with the city CFDA for premarket approval; 
medium-risk Class II devices should register with the province CFDA and high-risk Class 
III devices register with the central CFDA. Both Class II and Class III devices require a 
more in-depth technical review for approval. Moreover, Class I devices do not require 
clinical trials; Class II and Class III devices require clinical trials, some devices may be 
exempted from clinical trials if included in the List of Exempted Devices. Devices not 
listed may also apply for exemption if the devices are substantially equivalent. In addition, 
medical device registration certificate renewal must be submitted at least 6 months prior 
to the expiration.
<2> Classification 
The US FDA has established classifications for about 1,700 distinct types of medical 
devices and organized them into 16 medical speciality “panels” such as cardiovascular 
devices or ear and nose devices. These panels can be found in 21 CFR Part 862-892 [136, 
182]. These actions ensure that all the devices on the US market have scientific and 
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unique names. If a device cannot find a predicate device on the market, or due to some 
reasons needs reclassification, the FDA staff will review and evaluate the device’s safety 
and effectiveness. The FDA has a rigorous classification review process to ensure the 
medical devices are safe and effective and promotes good public health. The Class I and 
Class II devices accounted for 90% of medical devices in the US market, from which 47% 
of medical devices fall under Class I and 43% fall under Class II. 10% of medical devices 
fall under Class III (Table 5-2). In addition, about 95% of Class I devices and a small 
number of Class II devices (about 8%) are exempt from the premarket notification process 
[183].
Table 5-2 Percentage breakdown of medical devices classification levels.  
Country/Class Class I devices Class II devices Class III devices 
US 47% 43% 10% 
EU 23% 64% 13% 
China 36% 41% 23% 
The EU directives classify medical devices into four categories: non-invasive devices 
(Rule 1-4); invasive devices (Rule 5-8); active devices (Rule 9-12) and the Special Rules 
(Rules 13-18) [184]. Due to the large number of medical products, the EU four levels of 
classification system is considered more reasonable. The GHTF adopted the EU 
classification methods as their guidance documents: ‘Principles of Medical Devices 
Classification’ [185]. Table 5-2 shows the comparisons of different medical devices 
classifications.  
The Chinese medical device classification criteria are similar to the US’s. The CFDA 
classify the devices into three classes. There are no more than 5,000 types of medical 
devices in the Chinese market, but there are more than 60,000 devices that have the 
registration certificate issued by the CFDA regulatory agencies [186]. The reason for this 
is that under the old standard, the naming of devices was inconsistent, this results in the 
same products having different names, or the same names may be different products. In 
contrast, in the US, one device can only have one name and one product code; different 
products have different names and codes. The US FDA device classification system is a 
database system associated with an expert group providing technical support; the EU 
devices classification system is based on the ‘Directives Rules’. The CFDA uses the 
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devices ‘classification rules’ and ‘classification catalogues’ to implement the medical 
devices classification. For instance, when a device needs to be classified, the reviewers 
will first look at classification catalogues, if the product does not appear in the catalogues, 
the reviewers will classify the device according to the classification rules. In addition, 
only about 8%-10% of medical devices are classified as high-risk devices in the US 
whereas more than 20% of devices are classified as high-risk devices in China, see 
Table 5-2. For instance, the CT scanner was classified into Class II devices in the US 
[187, 188], while it is classified into Class III in China [189]. Many products are classified 
as high-risk devices in China. This not only brings a heavy economic burden to the 
manufacturers, but also creates high cost and low efficiency for the government 
management. The US FDA pays more attention to review 10% high-risk Class III devices 
because they are usually the new products using new technology. In China, Class III 
devices accounted for 23% of the total devices, but, high-risk and innovative products do 
not exceed 5% of total applications for registration [190]. 
<3> Premarket controls and post-market surveillance 
The US and EU device authorities are fully aware of the importance of the ‘Standards’, 
so the authorities cooperate with ISO for the latest knowledge and information. The EU 
directives established the legal status for the ‘Standard’, made the ‘Standard’ 
requirements as the key basis for devices safety review. CFDA established its own 
Standards system in China, such as national standards (GB standards) and professional 
standards (YY standards). Moreover, due to the complex and diverse products, devices 
premarket controls need more technical support. The US and EU have relatively mature 
and adequate technical support, for example, the Device Committee in the EU and three 
centres in the US, for the devices oversight (Center for Devices and Radiological Health; 
Center for Biologics Evaluation and Research; Center for Veterinary Medicine) [191]. 
Although CFDA established the state and provincial technology assessment centres and 
testing centres, technical resources are inadequate when compared with the US and EU. 
In addition, for the effectiveness of some products, the FDA requires clinical trials for the 
devices verification; the EU directives encourage manufacturers to use literature reviews 
and laboratory documents to verify the effectiveness of the devices; similar to the FDA’s 
requirements, the CFDA requires clinical trials for some devices verification. Last but not 
least, as described before, the EU system permits the applicants to choose the Notified 
Bodies that put their devices though the least stringent reviews and identify the easiest 
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way to get the CE mark; in this respect the FDA and CFDA are different from the EU 
system.  
The post-market surveillance is an important guarantee for ensuring that the devices 
continue to be safe and effective. The US and EU’s medical devices regulatory legislation 
have strict requirements for the marketed devices. Manufacturers must establish and 
follow quality systems to help ensure that their devices consistently meet applicable 
requirements. The quality system is known as current good manufacturing practices 
(CGMP’s). This quality system, combined with medical device recalls (MDR), medical 
device tracking and Medical Product Safety Network (MedSun), are beneficial to the 
public health protection. The EU has the vigilance system for post-market surveillance, 
such as EUDAMED. China established the adverse event monitoring system, adverse 
event information networks, medical devices re-evaluation and medical device recalls to 
protect public health. 
<4> Summary 
Table 5-3 Summary of key elements of the regulatory systems that control the marketing 
of medical devices in the US, EU and China. 
Region/statutory 
regulator 
Low risk Medium risk High risk 
US Comply with QS 
Regulation GMPs 
excluding design 
controls. 
Comply with full QS 
Regulation GMPs. 
Comply with full QS 
Regulation GMPs. 
FDA Notify FDA of 
establishment and 
device listings. 
Submit 510(k) 
premarket notification; 
About 10% of 510(k) 
submissions require 
clinical data. 
Submit premarket 
approval application—
PMA; 
Market approval on 
review of extensive 
safety and 
effectiveness data. 
EU Manufacturer’s self-
declaration of 
conformity to the 
Declaration of 
conformity to the 
Essential Requirements 
Declaration of 
conformity to the 
Essential Requirements 
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Essential 
Requirements. 
supported by Notified 
Body certifications. 
supported by Notified 
Body certifications. 
Competent Authorities Manufacturer informs 
Competent Authority 
for devices record-
filing; 
CE mark indicates 
compliance. 
Notified Body informs 
Competent Authority 
of certificates issued; 
CE mark with Notified 
Body number indicates 
compliance. 
Notified Body informs 
Competent Authority 
of certificates issued; 
CE mark with Notified 
Body number indicates 
compliance. 
China Comply with GMPs 
requirements; 
GB standards or YY 
standards or CCC mark 
indicate compliance. 
Comply with GMPs 
requirements; 
GB standards or YY 
standards or CCC mark 
indicate compliance. 
Comply with GMPs 
requirements; 
GB standards or YY 
standards or CCC mark 
indicate compliance. 
CFDA Manufacturer submits 
application to the city’s 
CFDA for device 
record-filing; 
No clinical data 
required. 
Manufacturer submits 
application to the 
province’s CFDA for 
device registration; 
Clinical data required, 
except exemption 
devices. 
Manufacturer submits 
application to the 
central CFDA for device 
registration; 
Clinical data required, 
except exemption 
devices. 
Source: author’s compilation and Tobin [192] 
5.6 Discussion 
This review of medical devices regulation in the US, EU and China illustrates that every 
regulatory system has its particular advantages and disadvantages. Although the US and 
EU regulations have shortcomings, they still play a vital role in the global medical devices 
market. Some studies have shown that some high-risk devices gained an EU CE mark but 
when they tried to enter the US market they were withdrawn by the US FDA due to the 
safety risks [134, 135].  
In the US and EU, the legislation clearly prescribes that the device manufacturer or 
applicant will take the main responsibilities for device safety and all the consequences 
resulting from the device performance. However, the old Chinese legislation did not 
clearly define this situation, the CFDA bears some responsibility for the medical devices’ 
use, failures, and even adverse events. The new regime clearly delineates every medical 
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device related participants responsibilities. For example, medical device manufacturers, 
distributors and users shall monitor adverse events. If any adverse events are identified, 
they shall report it to the medical device adverse event monitoring technical institutes 
[193].  
The new regulations are intended to establish a more efficient and scientific regulatory 
regime for supervision and administration of medical devices. Risk management has been 
introduced to the new regulations. In addition, the CFDA pays more attention to the Class 
III devices supervision and moderates the Class I devices oversight. The old regulations 
required that all the Class II and Class III devices need clinical trials, inspection and 
approval by the provincial CFDA and central CFDA, respectively [159]. The exemption 
from clinical trials for some special circumstances has been introduced in the new 
regulations. Moreover, the registration is replaced by record-filing for Class I devices 
application, which make the registration process more efficient.  
As previously described, due to there not being a national unified product naming and 
coding system; too many devices are classified as high-risk devices when they should not 
be categorised at the high-risk level, resulting in an unnecessary waste of effort and low 
efficiency of medical device supervision in China. Nevertheless, the new regulations have 
tried to establish a unique unified national medical device naming and coding system, to 
reduce the incidence of: the same products having different names or the same names 
referring to different products , and the central CFDA will analyse and evaluate medical 
devices risk, to adjust the classification catalogue [194].   
Post-market surveillance is an important guarantee to ensure that the devices continue to 
be safe and effective. The US and EUs medical devices regulatory legislation have strict 
requirements for the marketed devices. For example, the EU has the vigilance system for 
post-market surveillance, such as the EUDAMED. The adverse events and recall of 
medical devices does not appear in the old regulations. The new regulations combined 
the central CFDA Decree 425 and MOH Decree 82 requirements, they clearly describe 
the device participants responsibilities and have established the medical device adverse 
events monitoring system and information networks to control adverse events and recalls; 
they have established a re-evaluation system for registered medical devices to regulate 
supervisory activities.  
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In addition, the US Congress passed medical device regulations (21 CFR 800-1299), 
therefore the US medical device regulations have a high legal status. In contrast, the new 
Regulations for the Supervision and Administration of Medical Devices released by the 
Chinese State Council are administrative regulations, the legal status is not higher than 
the laws or regulations passed by the National Peoples Congress (NPC)23. The first 
edition of the Drug Administration Law of the People’s Republic of China was released 
by NPC in 1984 and that came into force in 1985. Compared with the Drug 
Administration Law, the medical device regulations were established late. In 1996, the 
former State Pharmaceutical Administration issued the Measures for the Administration 
of Medical Device Registration, which adopted the developed countries registration 
system. The new medical device regulations are in line with Chinas national conditions. 
With the development of the economy, the regulations have continued to be modified and 
changed to this day. 
5.7 Conclusions 
This chapter briefly reviews the US, EU and Chinese medical devices regulations and 
makes a comparison of the relatively mature regulations in the US and EU with those of 
China; this is useful as it provides guidance for the development and enhancement of the 
management of the Chinese medical device regulations. Furthermore, it is vital for 
investors to understand the regulatory environment into which they are entering. Some of 
the US and EU medical device regulations philosophy has been adopted by the Chinese 
authorities, and reflected in the Regulations for the Supervision and Administration of 
Medical Devices (2014). For instance, premarket approval and quality system 
management.  
The overview of the medical device regulations in the US, EU and China demonstrates 
that they have similar regulations but the EU devices classification system is considered 
more reasonable. The US and Chinese centralized systems seem to provide some safety 
benefits, while the EU decentralized system has vulnerabilities, which have been outlined. 
Each jurisdiction has its own regulatory framework with different legislation [133].  
23 The National Peoples Congress (NPC) is the national legislature of the Peoples Republic of China. The NPC is 
structured as a unicameral legislature.
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The changes made in the new regulations demonstrate the Chinese governments efforts 
to upgrade and maintain an effective regulatory framework for the medical device market. 
The Chinese government has promulgated the new regulations, which covers various 
perspectives of the regulatory regime of medical devices, such as device classification 
and registration, supervision of production and distribution, etc. Driven by the more 
powerful regulatory requirements under the new regulations, the Chinese medical device 
market will become increasingly dynamic in the future.  
Further in-depth research on this topic will be carried out in the future. Some regulations 
and policies still need modification and the recommendation is for more studies to 
understand the changing market environments, this should result in continuous 
improvement of policies. 
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Chapter 6 The Chinese Medical Device Market Investment Guidance  
6.1  Introduction 
The medical device market is one of the most attractive and profitable areas in the global 
economy. Since China opened its doors to the world, it has attracted increasing amounts 
of foreign investment. The Chinese medical device market is currently one of the most 
promising and fastest growing markets, which is the second largest market in the world 
with 200 billion yuan total sales in 2013. According to Chapter 4 analysis, the global 
medical device market is highly centralized, the market share of the developed countries 
accounted for more than 80% of the global medical device market share (US: 42.4%, 
Europe: 33%, Japan: 11%) in 2011. Medical devices are a growth industry in China due 
to increasing medical expenditure, rising healthcare consumption and health awareness 
improvements. By studying the distribution of the Chinese medical device market and 
regional advantages, investment strategies for investors who are doing business in China 
can be optimised and enhanced. 
6.2 Data 
Data on the medical device industry total output value of each province in China from 
2001 to 2011 were collected from the China Statistics Yearbook on High Technology 
Industry [195], the detailed data are shown in Appendix 7. Other data such as gross 
regional product and gross domestic product of China are collected from the National 
Bureau of Statistics of the Peoples Republic of China [196] (see Appendix 9 and 
Appendix 10). According to Appendix 7, most of these provinces medical device output 
value has grown steadily from 2001 to 2011, which demonstrates an increase in the 
expansion of the Chinese medical device industry. The average of the Chinese medical 
device industry total output value was calculated based on the information in Appendix 
7, detailed data shown in Appendix 8 (listed in declining trend). Data show Jiangsu, 
Zhejiang, Guangdong, Shandong, Shanghai and Beijing are the most productive 
provinces in China24. Each Chinese province was classified into five levels according to 
24 The administrative divisions of China include: 23 provinces (including Taiwan), 5 autonomous regions (Guangxi, 
Ningxia, Xinjiang, Inner Mongolia and Tibet), 4 Municipalities (Beijing, Tianjin, Shanghai and Chongqing) and 2 
special administrative regions (Hong Kong and Macau).  
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its average total output value of the medical device industry, which are £ 1,000, 1,000-
4,000, 4,000-7,000, 7,000-10,000 and ³ 10,000. This information is plotted on the map 
of China (see Figure 6-1). In this study, we select 30 provinces (including 4 autonomous 
regions and 4 municipalities), the data on the medical device industry total output value, 
do not include: Tibet, Taiwan, Hong Kong and Macau.  
Figure 6-1 Geographic distribution of the Chinese medical device industry. 
6.3 Methods 
A location quotient (LQ) has been used as a proxy for the spatial or geographic 
dependency of a given economic sector [197, 198]. LQ is the ratio of an industrys share 
of the economic activity of the regional economy being considered to that industrys share 
of the national economy [199]. The basic formula for the location quotient in regional 
economic sector can be described as: [200]  

i
i
i
ij
iij
ij EE
EE
LQ                          (6-1) 
Where: =Regional i employment in industry j
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=Total regional i employment 

i
ijE =National employment in industry j

i
iE =Total national employment  
The LQ analysis technique is frequently calculated on the basis of employment, but 
employment can be defined in many ways such as service or manufacturing [201]. 
Industry LQ is a way of quantifying how concentrated an industry is in a region 
compared to a larger geographic area, such as the state or nation [202]. Therefore, 
variables in equation (6-1) could be defined as follows: = economic activity in area i
industry j; = total economic activity in area i; 
i
ijE = economic activity of industry j in 
the whole area and 
i
iE = total economic activity in the whole area. In this chapter, the 
locational analysis technique is applied to the following variables: = provincial output 
value of medical device industry j in area i; = provincial gross regional product; 
i
ijE
= China output value of medical device industry j and 
i
iE = China gross domestic 
product.  
If LQ is greater than 1, it is assumed that medical device industry output value exceeds 
the local demand and appears to be exporting much of its goods to non-local markets or 
areas, which means the medical device industry in this region has comparative advantages. 
If LQ is equal to or less than 1, it indicates that the medical device industry does not 
export from the region, and the output value of the medical device industry does not meet 
the local demand. Hence, industry in the region is not strongly competitive [199, 203].  
LQ is an index that measures regional industrial professional level (specialization) and 
concentration (see Table 6-1). The higher the LQ, the higher the industrial concentration 
in the region. LQ is a ratio, which reflects the relative degree of professional level skills 
in one region rather than the actual degree of specialization in this region. For instance, 
if the medical device industry has high LQ in one region, this result may be because this 
region has a high output value in the medical device industry or this region has low 
109 
regional product output value but has high medical device output value. Therefore, we 
introduce market share (MS)25 into this study. Detailed data were shown in Table 6-2. 
If LQ > 1 and MS is higher than the country average level (in the study, average 
level=100%÷30=3.33%), the industry in the region has comparative advantages. The 
matrix illustrates the relationship between LQ and MS (Figure 6-2).  
Figure 6-2 Matrix of each province’s industry professional level. 
Area A has a high LQ and high MS; provinces in this area have a high professional 
industrial level and have comparative advantages throughout the country. Area B shows 
that the regions total industrial scale is too small; industrial output value has a significant 
share of the regional commercial activity, but actually the industrial level does not have 
comparative advantages. Area C illustrates that the industry has comparative advantages 
in the country, but other industries in this region also have a high level and comparative 
advantages, so this industry has a low LQ in the region. Area D means that industry does 
not have any comparative advantages in the region or the whole country.  
25 In this study, market share= /
i
ijE            (6-2) 
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6.4 Results 
Based on the data (shown in Appendix 7, Appendix 9 and Appendix 10), using the 
formula for the LQ (equation (6-1)), the LQ results are evaluated for each province, see 
Table 6-1. 
Table 6-1 LQ of each province in China from 2001 to 2011. 
LQ Beijing Tianjin Hebei Shanxi 
Inner 
Mongolia Liaoning Jilin 
Heilong-
jiang 
2001 3.569 1.730 0.292 0.190 0.024 0.891 0.398 0.397
2002 3.173 1.475 0.246 0.149 0.020 0.930 0.348 0.255
2003 3.136 1.542 0.307 0.217 --- 0.914 0.435 0.158
2004 2.586 1.165 0.251 0.179 0.004 0.809 0.498 0.213
2005 2.477 0.894 0.238 0.251 --- 0.728 0.295 0.192
2006 2.286 0.858 0.230 0.217 --- 0.718 0.255 0.181
2007 1.986 0.659 0.252 0.201 --- 0.832 0.257 0.226
2008 1.792 0.751 0.227 0.136 0.004 0.931 0.390 0.173
2009 1.631 0.645 0.283 0.146 0.022 0.954 0.403 0.176
2010 1.412 0.607 0.288 0.142 0.029 0.857 0.452 0.153
2011 1.247 0.417 0.264 0.138 0.016 0.693 0.415 0.114
Shang-
hai Jiangsu Zhejiang Anhui Fujian Jiangxi Shandong Henan 
2001 3.015 2.099 2.399 0.333 0.506 0.350 0.640 0.275
2002 2.840 1.848 2.044 0.534 0.604 0.635 0.612 0.257
2003 2.304 1.709 2.198 0.573 0.738 0.511 0.633 0.221
2004 2.435 1.572 1.682 0.486 0.560 0.596 0.653 0.439
2005 2.026 1.577 2.023 0.478 0.480 0.497 0.824 0.349
2006 2.032 1.752 2.041 0.454 0.476 0.553 0.952 0.531
2007 1.925 1.935 2.032 0.504 0.465 0.663 0.967 0.595
2008 1.838 2.683 1.598 0.283 0.390 0.747 0.832 0.619
2009 1.526 2.798 1.683 0.611 0.396 0.763 0.897 0.679
2010 1.542 2.948 1.698 0.640 0.383 0.797 0.821 0.607
2011 1.377 3.389 1.427 0.654 0.389 0.788 0.834 0.710
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Hubei Hunan 
Guang-
dong Guangxi Hainan 
Chong-
qing Sichuan Guizhou 
2001 0.869 0.592 0.796 0.131 0.185 2.194 0.310 0.150
2002 0.830 0.616 0.819 0.171 0.133 2.017 0.362 0.184
2003 0.632 0.347 0.878 0.236 0.039 2.152 0.390 0.258
2004 0.430 0.329 1.479 0.193 0.015 1.691 0.327 0.258
2005 0.647 0.390 1.433 0.195 0.003 1.467 0.343 0.210
2006 0.595 0.363 1.212 0.165 --- 1.339 0.411 0.188
2007 0.528 0.381 1.295 0.186 --- 1.118 0.446 0.197
2008 0.423 0.865 1.079 0.206 --- 1.080 0.632 0.117
2009 0.377 0.780 0.842 0.230 --- 0.949 0.693 0.158
2010 0.314 0.911 0.841 0.261 --- 1.126 0.336 0.113
2011 0.252 1.026 0.788 0.213 0.229 0.866 0.353 0.089
Yunnan Shaanxi Gansu Qinghai Ningxia Xinjiang
2001 0.390 1.411 0.241 --- 1.936 0.014
2002 0.405 1.291 0.247 --- 1.980 0.007
2003 0.331 1.087 0.362 0.222 1.472 0.021
2004 0.231 1.278 0.178 0.233 1.256 0.027
2005 0.190 0.855 0.138 0.191 0.938 0.033
2006 0.212 0.978 0.090 0.121 0.214 0.025
2007 0.181 0.796 0.081 0.137 0.572 0.027
2008 0.180 0.427 0.030 0.136 0.487 0.018
2009 0.160 0.749 0.066 0.065 0.496 0.023
2010 0.147 0.595 0.050 0.053 0.406 0.020
2011 0.092 0.631 0.033 0.053 0.327 0.010
LQ is a relative result, which cannot reflect the real industrial professional level, in this 
study, two indicators (LQ and MS) have been selected to measure the industrial 
professional level. The MS (equation (6-2)) for each province was evaluated from 2001 
to 2011, which shown in Table 6-2.
Table 6-2 MS of each province in China from 2001 to 2011. 
Beijing Tianjin Hebei Shanxi 
Inner 
Mongolia Liaoning Jilin 
Heilong-
jiang 
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2001 9.26% 2.90% 1.49% 0.31% 0.03% 4.09% 0.74% 1.29%
2002 11.42% 2.64% 1.23% 0.29% 0.03% 4.22% 0.68% 0.77%
2003 11.60% 2.93% 1.57% 0.46% --- 4.04% 0.85% 0.47%
2004 9.80% 2.27% 1.33% 0.40% 0.01% 3.38% 0.97% 0.63%
2005 9.22% 1.79% 1.30% 0.57% --- 3.10% 0.58% 0.57%
2006 8.32% 1.73% 1.24% 0.48% --- 3.07% 0.50% 0.52%
2007 7.36% 1.30% 1.29% 0.45% --- 3.49% 0.51% 0.60%
2008 6.34% 1.61% 1.16% 0.32% 0.01% 4.05% 0.80% 0.46%
2009 5.82% 1.42% 1.43% 0.32% 0.06% 4.26% 0.86% 0.44%
2010 4.96% 1.39% 1.47% 0.33% 0.09% 3.94% 0.98% 0.40%
2011 4.29% 1.00% 1.37% 0.33% 0.05% 3.26% 0.93% 0.30%
Shanghai Jiangsu Zhejiang Anhui Fujian Jiangxi Shandong Henan
2001 13.61% 18.21% 14.76% 1.00% 1.96% 0.69% 5.51% 1.42%
2002 13.55% 16.29% 13.59% 1.56% 2.24% 1.29% 5.23% 1.29%
2003 11.36% 15.66% 15.71% 1.65% 2.71% 1.06% 5.63% 1.12%
2004 12.29% 14.75% 12.26% 1.45% 2.02% 1.29% 6.14% 2.35%
2005 10.04% 15.61% 14.70% 1.39% 1.70% 1.09% 8.25% 2.00%
2006 9.74% 17.53% 14.85% 1.29% 1.68% 1.19% 9.72% 3.07%
2007 9.05% 18.94% 14.34% 1.40% 1.62% 1.45% 9.38% 3.36%
2008 8.23% 26.47% 10.92% 0.80% 1.34% 1.66% 8.20% 3.55%
2009 6.74% 28.28% 11.35% 1.80% 1.42% 1.71% 8.91% 3.88%
2010 6.59% 30.41% 11.73% 1.97% 1.41% 1.88% 8.01% 3.49%
2011 5.59% 35.19% 9.76% 2.12% 1.44% 1.95% 8.00% 4.04%
Hubei Hunan 
Guang-
dong Guangxi Hainan 
Chong-
qing Sichuan Guizhou 
2001 3.70% 2.15% 7.73% 0.27% 0.09% 3.50% 1.25% 0.15%
2002 2.91% 2.12% 9.18% 0.36% 0.07% 3.34% 1.42% 0.19%
2003 2.21% 1.19% 10.24% 0.49% 0.02% 3.60% 1.53% 0.27%
2004 1.51% 1.16% 17.45% 0.41% 0.01% 2.85% 1.30% 0.27%
2005 2.28% 1.37% 17.33% 0.43% 0.00% 2.43% 1.37% 0.23%
2006 2.08% 1.27% 14.68% 0.37% --- 2.16% 1.64% 0.20%
2007 1.86% 1.35% 15.48% 0.41% --- 1.97% 1.77% 0.21%
2008 1.53% 3.18% 12.64% 0.46% --- 1.99% 2.54% 0.13%
2009 1.43% 2.99% 9.76% 0.52% --- 1.82% 2.88% 0.18%
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2010 1.25% 3.64% 9.64% 0.62% --- 2.22% 1.44% 0.13%
2011 1.05% 4.27% 8.87% 0.53% 0.12% 1.83% 1.57% 0.11%
Yunnan Shaanxi Gansu Qinghai Ningxia Xinjiang
2001 0.74% 2.37% 0.24% --- 0.53% 0.02%
2002 0.78% 2.42% 0.25% --- 0.62% 0.01%
2003 0.62% 2.07% 0.37% 0.06% 0.48% 0.03%
2004 0.44% 2.54% 0.19% 0.07% 0.42% 0.04%
2005 0.36% 1.74% 0.14% 0.06% 0.31% 0.05%
2006 0.39% 2.04% 0.09% 0.04% 0.07% 0.04%
2007 0.32% 1.72% 0.08% 0.04% 0.20% 0.04%
2008 0.33% 0.99% 0.03% 0.04% 0.19% 0.02%
2009 0.29% 1.79% 0.07% 0.02% 0.20% 0.03%
2010 0.27% 1.50% 0.05% 0.02% 0.17% 0.03%
2011 0.17% 1.67% 0.03% 0.02% 0.15% 0.01%
Based on the data in Table 6-1 and Table 6-2, we used the criteria defined in Figure 6-2 
to evaluate the industrial professional level of each province, which is shown in Table 6-3. 
Table 6-3 Industry professional level of each province in China from 2001 to 2011. 
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Beijing A A A A A A A A A A A
Tianjin B B B B D D D D D D D
Hebei D D D D D D D D D D D
Shanxi D D D D D D D D D D D
Inner Mongolia D D … D … … … D D D D
Liaoning C C C C D D C C C C D
Jilin D D D D D D D D D D D
Heilongjiang D D D D D D D D D D D
Shanghai A A A A A A A A A A A
Jiangsu A A A A A A A A A A A
Zhejiang A A A A A A A A A A A
Anhui D D D D D D D D D D D
Fujian D D D D D D D D D D D
Jiangxi D D D D D D D D D D D
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Shandong C C C C C C C C C C C
Henan D D D D D D C C C C C
Hubei C D D D D D D D D D D
Hunan D D D D D D D D D C A
Guangdong C C C A A A A A C C C
Guangxi D D D D D D D D D D D
Hainan D D D D D … … … … … D
Chongqing A A A B B B B B D B D
Sichuan D D D D D D D D D D D
Guizhou D D D D D D D D D D D
Yunnan D D D D D D D D D D D
Shaanxi B B B B D D D D D D D
Gansu D D D D D D D D D D D
Qinghai … … D D D D D D D D D
Ningxia B B B B D D D D D D D
Xinjiang D D D D D D D D D D D
A=high LQ, high MS; B=high LQ, low MS; C=low LQ, high MS; D=low LQ, low MS. 
Area A (high LQ, high MS): From 2001 to 2011, there are four administrative divisions 
that stay in this area. They are two municipalities (Beijing and Shanghai) and two 
provinces (Jiangsu and Zhejiang). These four regions have the top medical device 
industrial professional level and competitive advantages over the rest of the country. 
Moreover, they accounted for about 55% of the medical device output market share in 
2011 according to Table 6-2.  
Area B (high LQ, low MS): There are four regions that stayed in area B. From 2005 to 
2011, the industrial professional level of Tianjin, Shaanxi and Ningxia moved to area D. 
Chongqing stayed in area A from 2001 to 2003 but dropped back to area B from 2004 to 
2008. These four regions are basically well developed with a good industrial professional 
level but their MS has not reached the countrys average level; they thus do not have a 
competitive advantage. However, compared to other industries in these four regions, the 
medical device industry has some competitive advantages in the local area, so the medical 
device industry in these four regions has the capacity to develop.  
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Area C (low LQ, high MS): Shandong province has been in this area for 11 years. 
Liaoning also occupies this area except for 2005, 2006 and 2011. Henan was in area D 
from 2001 to 2006; from 2007, Henan moved to area C. Provinces in area C have a 
national competitive advantage in their medical device industry, but low LQ means that 
the medical device industry does not have competitive advantage in their provinces. 
However, some strong industries exist in their provinces. 
Area D (low LQ, low MS): more than half the provinces (17) stayed in area D from 2001 
to 2011. The development of the medical device industry in these provinces was slow. 
The professional level of the medical device industry in these provinces does not have a 
competitive advantage and the industry output value was also lower than the country 
average level. 
Area C®A: Guangdong, as Chinas major economic province, plays a significant role in
the Chinese economy. Its medical device industrial professional level moved from area C 
to area A, which means Guangdongs medical device industry is leading the country. 
Based on the data, the medical device industry is on a rising trend, with a growing 
contribution to Guangdongs industrial output. From Table 6-2 we can see Guangdong 
accounts for about 12% of medical device output value market share in China. 
6.5 Discussion 
Using the geographic distribution of the Chinese medical device industry (Figure 6-1) 
together with the LQ and MS results indicates that the Chinese medical device industry 
is mainly concentrated in Bohai Economic Rim (Beijing, Shandong, Liaoning, etc.) in the 
North, and the Southeastern zone, which are two well-developed economic zones: 
Yangtze River Delta (Shanghai; Jiangsu and Zhejiang) in the East and Pearl River Delta26
(Guangdong) in the South. These economic zones and cities are located in the industry 
professional level matrix area A and area C. Medical device industries concentrated in 
these areas have a competitive advantage; they took about 77% market share in 2011. 
Beijing belongs to the Bohai Economic Rim 27 . Despite with the low competitive 
26 Pearl River Delta Economic Zone including Guangdong Province; Hong Kong and Macau.
27 The Bohai Economic Rim has traditionally been involved in heavy industries and manufacturing, which including 
Beijing; Tianjin; Hebei; Liaoning and Shandong which surrounds the Bohai Sea. 
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advantage in the local regions (low LQ), Liaoning and Shandong have high market share 
(area C) and high average output value in the medical device industry according to 
Appendix 8, which constitutes the leading regional medical device industry in China, the 
development trend will similar to Guangdongs. Except Chongqing, the majority of 
provinces are located in matrix area B and area D, which do not have competitive 
advantages and have a small medical device industry output value. 
The LQ of Beijing; Shanghai; Jiangsu and Zhejiang is not high, and shows a decreasing 
or fluctuating trend from 2001 to 2011. The medical device industrial professional level 
does not have a comparative advantage compared to other high-tech industries. Moreover, 
for one industry, the standard deviation of LQ (SDLQ) between regions indicates the 
difference in industrial professional level, which means the higher the SDLQ, the more 
concentrated and the higher professional level industrial region [203]. The SDLQ of the 
medical device industry was 0.96 in 2001. Compared with the SDLQ of other high-tech 
industries such as the pharmaceutical industry (1.22); aircraft and spacecraft (2.13) and 
electronic and telecommunication equipment industry (2.09) in 2001 [203], the medical 
device industry has a low concentration level, which means the medical device industry 
in China is fragmented, and only concentrated in particular regions such as the three 
economic zones.  
Potential investors are interested to know, which regions are best for investment in the 
Chinese medical device market. Based on the analysis above, three economic zones 
(Yangtze River Delta; Pearl River Delta and Bohai Economic Rim) have always enjoyed 
prosperous development of the medical device industry in China. The population of the 
three economic zones accounts for 25% of the total Chinese population; accounting for 
approximately 40% of GDP; foreign businesses account for 70% of investments and 
control 77% of total import and export value [204]; medical device industry output value 
and sales account for 75% of the total output value and sales.  
The three economic zones have something in common. (1) A strong industrial base to 
support medical device development, electronics and mechanical equipment 
manufacturing contributing to technical cooperation and product support; (2) Developed 
transportation systems are conducive to trade and technical exchanges domestically and 
internationally; (3) The most prestigious Chinese universities, colleges and education 
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institutions located in these areas, they provide potential human resources and 
knowledge-based professionals; (4) Strong medical research and clinical level due to a 
large number of hospitals being located in these areas; and (5) Strong financing channels 
including domestic and international capital. The three economic zones also have their 
own characteristics. Yangtze River Delta and Bohai Economic Rim are multi-province 
large areas, which historically have a good medical device manufacturing track record. 
The development of manufacturing and chemical industries has made these two areas 
leaders in the medical device industry. The Pearl River Delta Economic Zone is part of 
Guangdong Province, which previously had poor medical device manufacturing. 
However, the rapid speed of development of the medical device industry in this area has 
benefited from Chinas opening-up policy and introduced foreign capital, which has 
caused the medical device industry and electrical manufacturing to catch up. Moreover, 
Guangdong Province used the advantages of the opening-up policy to cooperate with 
Hong Kong and Macau, this has turned the Pearl River Delta into an internationally 
competitive area. Detailed information will be described in Chapter 7. 
Jiangsu, Zhejiang, Guangdong, Shandong, Shanghai, Beijing and Liaoning were in the 
top 7 of the average total medical device industry by output value from 2001 to 2011. 
Furthermore, the sales profits of these seven regions are 13,770; 5,730; 5,880; 4,160; 
4,600; 4,330 and 2,200 million yuan per annum respectively, which accounted for 74.87% 
of total medical device profits (54,320 million yuan) in 2010 [195]. Therefore, the three 
economic zones have comparative advantages due to their industrial scale and profits. 
These results are inseparable from the governments financial and support policy. In order 
to facilitate the continued development of high-tech industry, the Chinese central and 
local governments established the China National High-Tech Industrial Development 
Zone, which contains many areas of activity, such as: electronics and information 
technology; bioengineering and medical imaging; aerospace technology; nuclear 
application technology and energy-efficient technologies. By the end of 2014, there were 
114 National High-Tech Industrial Development Zones in China, with 23 of the high-tech 
industrial zones located in the Bohai Economic Rim; Yangtze River Delta and Pearl River 
Delta Economic Zone have 18 and 9, respectively [205]. The rapid economic growth and 
huge market potential of the Chinese medical device market is recognised by many 
international companies such as GE, Philips and Siemens, who have been expanding their 
business in China in recent years. For example, GE Medical Industrial Park (Beijing) is 
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one of the largest R&D bases in the world; Philips Healthcare established medical 
imaging bases in Suzhou (Jiangsu Province) [206]; Siemens Healthcare has two wholly 
owned subsidiaries in Shanghai and Shenzhen (Guangdong Province) [207]. 
This study has its limitations. The size of the sample is too small to perform statistical 
analysis. And, the data collected only run up to 2011. Moreover, the disadvantage of the 
LQ method is that it may not reflect the actual degree of specialization. For instance, 
Guangdong has a low LQ but is a promising market, while Ningxia has a high LQ but 
seems to be an underdeveloped region. The LQ method is not the only way to assess the 
industrial professional level but is probably the most frequently employed. Some methods 
like net present value (NPV) and real option [208] can also assess the market. But by 
combining the LQ and MS methods, the LQs error is reduced, making the findings of 
this study more reliable. Despite these limitations, the findings of this study provides 
some guidance for investors who want to do business in the Chinese medical device 
market.  
6.6 Conclusion 
The Chinese medical device market, like Chinas economy, is developing rapidly. It is 
clear that the medical device market in China has great investment potential. It is 
considered a promising market area in which companies, especially foreign companies, 
are already making investments. Moreover, the Chinese governments healthcare reforms, 
rising income and availability of insurance; improving medical infrastructure create a 
better investment environment. Furthermore, the new Chinese medical device regulations 
that came into force in 2014, made the Chinese medical device market more organised, 
which is beneficial for investors. 
This chapter illustrates the geographical distribution of the Chinese medical device 
industry, combined with the LQ assessment, to reveal the medical device industrys 
professional level and degree of concentration in each province, providing guidance for 
investors who are interested in medical device investment in China. The LQ and MS 
matrix reveals that the best investment regions in China are: Bohai Economic Rim, 
Yangtze River Delta and Pearl River Delta Economic Zones. The Chinese government 
has awarded favourable policy preferences to these regions in order to attract more 
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investment, hence, the investment environment has been relatively advantageous over 
other regions in China. Therefore, the three economic zones were chosen as the priority 
regions for the investors who want to invest in the Chinese medical device market.   
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Chapter 7 The Chinese Medical Device Market Competitive Analysis 
The Chinese medical device market does not have a strong competitive advantage 
compared with the US and EU market. However, there is no doubt that the Chinese 
medical device market is currently one of the most promising and fastest growing markets. 
This chapter will analyse the competitiveness of the market. 
7.1 The Chinese medical device market SWOT analysis 
The strengths, weaknesses, opportunities and threats (SWOT) analysis is an integrated 
tool to identify the internal and external factors that characterise the strategic position of 
the market [209].  
Table 7-1 The SWOT matrix of the Chinese medical device market. 
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Strengths (S) Weaknesses (W) 
1, Has more low-end technology 
products, which have low-cost 
advantages compared with foreign 
companies’ products 
2, With the rapid development, 
domestic companies have some 
technical strengths and research 
foundation 
3, Academic institutions 
1, Less R&D funding 
2, Less technical patents 
3, Low-level repetitive production and low 
quality products 
4, High-tech supporting technical level 
weaker than the developed countries 
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Opportunities (O) Threats (T) 
1, Huge market demand, growing and 
aging population 
2, The Chinese government’s policies 
to promote the market development 
3, The quality and standards tend to be 
consistent with the international 
standards 
4, The new medical device regulations 
improve the supervision and 
management 
5, Scientific progress 
1, Globalization 
2, The influx of foreign funds 
Source: author’s compilation and Shang [210] and Fang [211] 
Table 7-1 summarizes the SWOT of the Chinese medical device market. The competition 
of the low-end medical device market is fierce and the high-end medical device market 
is dominated by a few foreign companies. According to previous chapters analysis, 
China has a huge population especially the aging population, number of hospital visits, 
the number of hospitals and diseases, all these driving forces indicate that the market still 
has room to improve.  
Strengths: 
The Chinese medical device companies have a very small living space in the high-end 
medical device market, thus, they have focused on the middle and low-end of the market. 
In the middle and low-end medical device market, the Chinese products have competitive 
advantages on price compared with foreign companies. Moreover, the Chinese companies 
have the technology of low-end medical devices production, which are able to produce 
high quality products. More and more universities and academic institutions established 
medical device research centres and relevant courses, the number of medical 
professionals has increased in recent years. 
Weaknesses: 
The Chinese medical device companies have less R&D funding, this is also the important 
weakness of the Chinese medical device market. This results in less technical patents, 
low-level repetitive production and some low quality products. The Chinese middle and 
low-end medical device market is dominated by domestic companies, the majority of 
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which generally lack the expertise and experience compared to Western standards. There 
are only a few Chinese medical device companies are producing high-end medical 
devices and products. 
Opportunities: 
The Chinese medical device market is one of the fastest growing markets in the world. 
Huge market demand is driven by the growth of the aging population and improved life 
quality (rising incomes). Due to the changing diets and air pollution, the incidence of 
cancer and other chronic diseases keeps rising, this has made people willing to pay more 
on their health and created opportunities for pharmaceutical, medical device and hospital 
management that provides a wide range of healthcare products and services. Moreover, 
the Chinese central government invested in medical infrastructure in rural areas, updated 
many medical devices, which promote the medical device industry development. In 
addition, the new medical device regulations came into force in 2014, this strengthens the 
market supervision and management, resulting in many Chinese products that are 
encouraged to have high quality and are consistent with the international standards. The 
scientific progress will bring the latest medical devices to the market. Last but not least, 
the development of the market need funds, therefore the market becomes one of the most 
popular industries which can attract venture capital investment.   
Threats: 
After joining the World Trade Organization (WTO) and tariff reductions, more foreign 
products have entered into the Chinese market. The influx of foreign funds and products 
has increased, medical device market face fierce competition. The high-end medical 
device market is dominated by the foreign companies, while foreign companies have 
begun to get involved in the middle and low-end medical device market. Foreign 
companies rely on their technical superiority and brand effect, to further exploit and 
occupy the Chinese medical device market. Foreign companies began to produce cost-
effective middle and low-end medical devices, which are acceptable and affordable for 
the Tier-2 and Tier-1 hospitals and other grass-roots healthcare institutions. Therefore, 
the Chinese medical device companies are faced with serious threats, even to be acquired 
by foreign companies, their living space has been compressed. The Chinese medical 
device companies products should not only have price advantages, but also have high 
quality.  
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7.2 The Chinese medical device market regional competitiveness analysis 
In Chapter 6, the LQ and MS methods reveals that the best investment regions for medical 
devices in China are Bohai Economic Rim, Yangtze River Delta and Pearl River Delta 
Economic Zones. 
7.2.1 Bohai Economic Rim 
The Bohai Economic Rim includes two municipalities (Beijing and Tianjin) and three 
provinces (Liaoning, Hebei and Shandong). The total population has reached 230 million, 
which accounts for about 17% of the Chinese population, gross regional product reached 
11,966,352 million yuan, which accounts for about 25.3% of GDP in 2011. The Bohai 
Economic Rim has a geographical advantage, as it is located in the centre of Northeast 
Asia28 . This unique geographical advantages provide a favourable environment and 
conditions for the investors and foreign economic cooperation with many areas. The 
Bohai Economic Rim is the largest industrial-intensive area in China, it is the base of 
heavy industries and chemical industries, which has competitive advantages in resources 
and R&D. Moreover, the most prestigious universities, colleges and research institutes 
are located in this area, which provides scientific and technological human talent. The 
medical device industry, Chinese medicine and pharmaceuticals together constitute the 
bioengineering and new medical industries in this area.   
7.2.2 Yangtze River Delta 
The Yangtze River Delta includes one municipality (Shanghai) and two provinces 
(Jiangsu and Zhejiang). Total population reached 156 million, it accounts for about 17% 
of the Chinese population, gross regional product reached 10,062,481 million yuan, 
which accounts for about 21.3% of GDP in 2011. The Yangtze River Delta is not only 
the largest, fastest-growing economic area, but also the most promising economic area in 
China. This region has a strong industrial base, developed economy and convenient 
transportation, it is Chinas largest export base.  
28 Northeast Asia includes China, Japan, Korean Peninsula (Democratic Peoples Republic of Korea (DPRK) and 
Republic of Korea) Mongolia and the Russian Far East and Siberia. 
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As the regional leader, Shanghai plays an important roles in the medical device industry. 
Many medical device companies are located in Shanghai, because Shanghai is an 
attractive place for foreign investment and human talent. Zhangjiang Hi-Tech Park is one 
of Chinas first state-level high-tech zones, which includes the field of software, bio-
pharmaceutical and medical devices.  
7.2.3 Pearl River Delta Economic Zones 
The Pearl River Delta Economic Zones includes one province (Guangdong) and two 
special administrative regions (Hong Kong and Macau). The development of the Pearl 
River Delta Economic Zones is primarily thanks to Hong Kong, where it has been a major 
source of the investments. Total population (Guangdong province) reached 104 million, 
which accounts for about 8% of the Chinese population, gross regional product reached 
5,321,028 million yuan, accounting for about 11.3% of GDP in 2011. The Pearl River 
Delta Economic Zones is Chinas third-largest economic zone, the total economic output 
is only behind Yangtze River Delta and Bohai Economic Rim. 
The development of manufacturing industry and medical device industry in Guangdong 
is mature and very influential in China. Many high-tech companies are located in 
Shenzhen, which has become Chinas high-end medical device manufacturing base. The 
products cover almost all areas of clinical medicine, mainly concentrated in the high-end 
medical diagnostic imaging devices (such as CT, MRI and ultrasound), radiation therapy 
products (such as Gamma Knife), medical electronic products (such as various types of 
patient monitors) and interventional treatment products (such as catheters). 
7.2.4 The foreign medical device companies’ business activities 
Many famous foreign medical device companies are now doing business in China through 
mergers and acquisitions or joint ventures. In this part we only discuss the main medical 
imaging companies. 
GE Healthcare [212] started doing business in China since 1979, and established the first 
agency in China in 1986. Currently, GE Healthcare has established more business entities, 
including wholly owned and joint venture companies. For example, GE Healthcare is to 
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form a joint venture with Shinva Medical Instrument in Zibo (Shandong Province), which 
was the first Chinese medical device company (established in 1943). GE Medical 
Industrial Park (Beijing) is one of the largest R&D bases in the world. The partnership 
aims to be active in R&D and manufacturing/sales; the production of medical devices 
includes: CT, MRI and X-rays. GE Healthcare established a factory for ultrasound 
equipment and patient monitors production in Wuxi (Jiangsu Province). In addition, the 
production base of MRI in Tianjin is under construction.  
The market share of GE Healthcare has reached 50%-60% in the Chinese high-end 
medical device market, the medical devices are manufactured (especially CT) in China, 
not only to supply to the local market, but also to provide the worldwide demand. GE 
Healthcare China exports 70% of its devices but wants to increase its local sales. The 
revenues from GE Healthcare was one billion US dollars in China in 2008 with increasing 
sales performance.  
Siemens Healthcare [207] has two wholly owned subsidiaries in China, one called 
Siemens Shanghai Medical Equipment Ltd. (founded in 1992) in Shanghai, which is a 
R&D base and manufactures CT and X-ray systems; Siemens Healthcare and Shenzhen 
Mindit Instruments Co. Ltd. established a joint venture in the area of MRI, so the other 
one is Siemens Mindit Magnetic Resonance Ltd. (founded in 2002) in Shenzhen 
(Guangdong Province). The market share of Siemens Healthcare is second only to GE 
Healthcare in China. 
Compared with GE Healthcare and Siemens Healthcare, Philips Healthcares business 
activities in China were relatively late. In 2004, Philips Healthcare [206] set up a joint 
venture with Neusoft (Philips holding 51% of company share and Neusoft holding 49%) 
in Shenyang (Liaoning Province) for developing and manufacturing medical imaging 
systems (CT, MRI, ultrasound and X-rays) for the Chinese and international markets. 
Philips Healthcare acquired the Chinese patient monitoring company Shenzhen Goldway 
Industrial, Inc. in Shenzhen (Guangdong Province) in 2008. Philips Healthcare is the 
market leader in the global patient monitoring market, which was estimated to be worth 
approximately USD 3 billion [213]. Philips Healthcare established medical imaging bases 
for manufacturing CT, MRI and X-rays in Suzhou (Jiangsu Province) in 2009 and 
purchased Shanghai Apex Electronics in 2010 for ultrasound production.  
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The Hitachi Medical Corporation [214] established three Medical Systems Corporations 
in Suzhou (Jiangsu Province), Beijing and Guangzhou (Guangdong Province). In 2002, 
Hitachi set up a wholly owned subsidiary in Suzhou for manufacturing X-rays for smaller 
hospitals in China. Moreover, Hitachi invested more to this company to produce lower 
priced diagnostic imaging devices in 2009. In order to adapt and meet the rising market 
demand, Hitachi set up a new company in Beijing for developing medical imaging 
devices in 2006. In the same year, Hitachi set up a wholly owned subsidiary in Guangzhou 
for manufacturing ultrasound. Aloka, a Japanese manufacturer, is the first company, 
which transferred its ultrasound manufacturing operations to China in 1996. Since Hitachi 
acquired Aloka in 2011, Hitachi Alokas ultrasound devices became the chief 
representative of the Chinese ultrasound market. 
Toshiba Medical System (China) Corporation Ltd was established in Dalian (Liaoning 
Province) in 2002 and Beijing in 2007 for developing medical imaging devices such as 
CT, X-ray, MRI and ultrasound. Toshiba set up a R&D base in Dalian in 2013 to further 
optimize its innovative strength, to produce the medical products, which are fully adapted 
to the Chinese customers needs.  
7.2.5 The Chinese medical device companies’ business activities 
(1) Mindray Medical International Ltd. [215] is the largest Chinese medical device 
manufacturer, which was founded in 1991 in Shenzhen (Guangdong Province). Mindray 
offers a broad range of products including patient monitoring devices and ultrasound 
imaging system, a solid distribution network has been established around the world to 
market their products and services.   
(2) Yuwell medical equipment & supply Co., Ltd. [216] is a Chinese listed company 
founded in 1998 in Danyang (Jiangsu Province). Yuwell is the top brand in the Chinese 
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homecare medical device industry of 2015. The products including homecare products
such as: electronic blood pressure monitor, stethoscope, thermometer and wheelchair, etc.; 
oxygen supply equipment such as oxygen concentrator, oxygen regulator and oxygen 
generator and medical imaging device (X-ray). 
(3) China Resources Wandong Medical Equipment Co., Ltd. [217] is a state-owned 
company, which was established in 1955 in Beijing. Wandong is involved in developing, 
manufacturing and selling of X-ray and MRI devices, which is a leading supplier of 
medical imaging devices in China. With the fierce market competition, the market share 
of Wandong in the Chinese high-end medical device market is getting smaller, foreign 
companies are dominating the market. Therefore, Wandongs products are mainly 
focused on the low-end medical device market. 
(4) Neusoft Medical Systems Co., Ltd. [218] is a leading manufacturer of medical 
equipment and services, which is the largest healthcare information technology (IT) 
solutions and services provider, it was founded in 1998 in Shenyang (Liaoning Province). 
The products including major imaging devices such as CT, MRI, X-ray and ultrasound. 
Neusoft is the only one Chinese medical device company, which has access to the 
technology of CT, MRI, X-ray and ultrasound medical imaging devices. Their products 
have passed ISO 9001 quality management system standards and have FDA and CE mark 
approval. 
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(5) Lepu Medical Technology (Beijing) Co., Ltd. [219] is specialized in high-tech 
medical device manufacturing and selling, which was founded in 1999. Lepu focuses on 
cardiac therapy, with products including interventional cardiology, prosthetic heart valves, 
pacemaker and cardiac in vitro diagnosis products, etc., it is the largest heart technology 
manufacturer in China. 
(6) MicroPort Scientific Corporation [220] was established in Shanghai in 1998, it is a 
premier medical solutions provider in China. The products including cardiovascular 
devices such as coronary stent systems; endovascular devices and orthopaedic devices. 
Coronary stent products is the first Chinese made drug-eluting stent system, MicroPort is 
the domestic market leader in the area of coronary stents. 
7.3 The Chinese medical device industry core competitiveness analysis 
Medical devices are a comprehensive reflection of multi-disciplinary product 
development. High-margin products require high investment in R&D, market 
competition requires costly promotion, all this determines that medical devices rely on 
more investment funding. As a knowledge-intensive industry, human talent gradually 
become industrys competitive advantage. Therefore, medical device industry core 
competitiveness can be described as the competition of products, funding and human 
talent. 
(1) Products 
The technology innovation of medical device is the key to development. Firstly, medical 
devices tend towards portability and miniaturization. Secondly, medical devices tend 
towards digitizing, specialization and networking. For example, the scanning speed, 
scanning range and clarity of CT has many great breakthroughs in recent years; MRI is 
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more focused on joint, heart and nervous systems detection and diagnosis; telemedicine 
requires networking. 
Moreover, the treatment of Chinas top five diseases (cancers; cerebrovascular disease; 
cardiovascular disease; respiratory system disease and injury, poisoning & external 
causes) involved medical devices that will bring profitable growth in the future. 
(2) Funding 
Development of modern high-tech medical devices requires a lot of financial support. For 
example, in the fiscal year of 2011, Siemens Healthcare R&D spending was USD 1.56 
billion, out of USD 16.3 billion in overall company revenue for the year. GE spent USD 
4.6 billion for R&D for its different divisions, from this USD 1.3 billion went to GE 
Healthcare; Philips poured USD 967 million into R&D for its healthcare division [221]. 
Chinas R&D expenditures as a percentage of GDP will approach the US levels within 
10 years [222]. However, many Chinese medical device companies cannot guarantee 
enough money for R&D. Some high-tech medical devices like diagnostic imaging devices 
need a longer R&D period, which means they need more funding to support development. 
As we said in 7.1, low R&D funding is one of the weaknesses of the Chinese medical 
device industry, and this is the most important factor, which results in fewer technical 
patents; low-level repetitive production and low quality products. In the hugely 
uncertainty R&D stage, it is difficult for companies to obtain loans from banks. Venture 
capital investment can provide strong financial support to medical device R&D.  
(3) Human talent 
The competition for human resources is global, especially for critical human talent. China 
has many universities, colleges and academic institutions, especially the most prestigious 
universities, which are located in the Bohai Economic Rim, Yangtze River Delta and 
Pearl River Delta Economic Zones, they provide potential human resources and 
knowledge-based human talent. Many universities have established and added new 
courses on medical device research. In addition, many students study in the developed 
countries and bring the advanced knowledge and practical experience to China. They 
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contribute to the medical device industry, such as Shanghai MicroPort Scientific 
Corporations chairman/founder. 
Moreover, the Chinese National Engineering Research Centre established five research 
centres in Guangzhou (Guangdong Province), Chengdu (Sichuan Province), Beijing, 
Shenyang (Liaoning Province) and Shenzhen (Guangdong Province) for medical devices 
R&D. They have many achievements in medical device research and have created 
significant professional talent that can contribute to Chinas new companies. 
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Chapter 8 Conclusion and future work 
8.1 Conclusion and findings 
The purpose of the study described in this thesis was to understand the in vivo diagnostic 
devices market that is developing and to explore the Chinese medical device market 
investment potential. The findings presented in this chapter are based on the evidence 
produced in previous chapters.  
(1) Applicable foreign investment theories: 
 Related investment theories for developed countries including Hymers 
monopolistic advantages theory; Vernons product life cycle theory, 
Porter, Hill and Joness industry life cycle theories and Dunnings eclectic 
theory of international production. 
 Investment theories for developing countries including Wellss small scale 
technology theory; Lalls technical localization theory; Cantwell and 
Narulas industry upgrade theory and Dunnings investment development 
cycle theory.  
 Some theories for the medical device industry indicates that research in 
the medical device market has an upward trend. 
 Some related investment theories have been extracted from the foreign 
investment theory. Little research has focused on the medical device 
market before, with the development of the medical device industry, 
literature in this area may increase. Combination of investment theories 
and medical device market is one of the achievements in this research. 
(2) Analysis of the global medical device market: 
 Analysis of the global medical device market indicates that top 10 medical 
device manufacturers are mainly from the US and Europe. 
 In vivo diagnostics/medical imaging market is dominated by the key 
manufacturers (GE, Siemens and Philips). They have a strong position in 
CT, ultrasound, MRI and X-ray market. 
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(3) Analysis of the Chinese medical device market: 
 Official data show that export volume of medical devices and related 
products is higher than the import volume except for medical diagnosis 
and treatment, which means Chinas high-end medical device market is 
dependent upon imports. 
 Some research found that the main medical device market growth drivers 
are demographics, unmet clinical needs, disease profiles and other drivers 
like government investment and changed policies. Some of drivers can be 
examined by mathematical methods. Regression analysis shows that the 
number of hospital visits, aging population and the number of hospitals 
are the main drivers in the Chinese medical device market. 
 Disease is another driver of the market, especially common cancers. 
Medical imaging devices which can detect and diagnose common cancers, 
which means the demand for these kind of devices will increase. 
 The key medical device manufacturers business activities show that the 
Chinese medical device market has investment potential.   
(4) Medical device regulations: 
 Medical device regulations across the globe have significant variations. It 
is important for investors involved in bringing a medical device to market 
to have an understanding of the regulatory requirements. Analysis of the 
medical device regulations in the US and EU, demonstrates that the 
regulation of medical devices is an extremely complex process, because 
the regulatory authorities have to ensure that the medical devices are safe 
and effective. 
 As the established medical device regulations in the US and EU are 
relatively mature, they have a key influence in the world. The CFDA 
released the new medical device regulations in 2014, which is a milestone 
of the Chinese medical device regulations history.   
 The changes made in the new regulations show the Chinese governments 
efforts to upgrade and maintain an effective regulatory regime for the 
medical device market. The new medical device regulations covers 
various perspectives, such as medical device classification; registration; 
133 
supervision of production and distributions; adverse events and recalls; 
legal liabilities. Many changes cover premarket requirements and 
postmarket surveillance. 
 Few papers focus on the Chinese medical device regulations, because it is 
relatively new, which came into force in 2014. Therefore, this is another 
achievement of this research.  
(5) The Chinese medical device market investment guidance: 
 Previous research shows that the Chinese medical device market has 
investment potential. Therefore, the investment guidance is important for 
investors who want to enter the Chinese market. The LQ and MS matrix 
reveals that the best investment areas in China are Bohai Economic Rim, 
Yangtze River Delta and Pearl River Delta Economic Zones.  
 The LQ method is the first introduced to examine the medical device 
market. This is one of the achievements of this research.  
(6) Competitive analysis of the Chinese medical device market: 
 The SWOT analysis describes that the intense competition in the low-end 
medical device market and the high-end medical device market is 
dominated by a few foreign companies. 
 Regional competitive analysis is an extension of Chapter 6s results. The 
three economic zones were chosen as the priority areas for investors. 
These areas have something in common, but also have their own 
advantages. Regional competitive analysis provides information to 
investors for location choice in the three economic zones. 
The competition in the global medical device market is intense. Industry rivalry is high, 
and barriers to entry into the market for a young company are high, as market access is 
controlled by a few standard-setting large companies [4]. Large companies from the US, 
Europe and Japan accounted for more than 80% of the highly centralized market share. 
Global in vivo diagnostics is a specialty market and dominated by a few large companies.  
The medical device industry is one of the fastest growing industries in China. China has 
become the second largest medical device market in the world, which is only behind the 
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US market. However, the Chinese medical device market is occupied mainly by foreign 
companies (such as GE, Siemens and Philips) and high-end medical device market is 
dependent upon imports, which are mainly import from the US, EU and Japan. When a 
technological industrial firm in a developed country invests in a developing country (this 
country should gradually assimilate the economic structure), not only is the knowledge 
content of the investment important but it will also be directed towards a growth industry 
[223]. The US, EU and Japanese companies have been able to create an important 
presence in the newer Chinese medical devices industry; this is because these countries 
were much more advanced in this technology area than China. 
From the analysis in this research, there is no doubt that China is an immense market with 
many opportunities in the area of medical devices. The best opportunities for foreign 
investment are in high-tech, high-cost diagnostic devices in the following regions: Bohai 
Economic Rim, Yangtze River Delta and Pearl River Delta Economic Zones. The market 
growth drivers (demographics, number of hospital visits, number of hospitals, diseases, 
government investment and support policies) alongside the new medical device 
regulations (which came into force in 2014), made the Chinese medical device market 
more regulated and attractive for the foreign investment. 
In summary, this research explored the global medical device market especially for the in 
vivo diagnostics market, identified the key manufacturers in the global market as well as 
the Chinese market. Detailed analysis of the Chinese medical device market, allows 
researchers and investors to fully understand the market outlook, regulatory environment 
and optimum investment strategies. Further research and analysis is required in this area.   
8.2 Recommendations 
The Chinese medical device market is currently one of the most promising and fastest 
growing markets with market drivers such as 65+ population and number of hospital visits 
expanding demand. Chinas high-end medical device market is dominated by foreign 
companies, based on this market profile, here are some recommendations for the Chinese 
practitioners and policy makers. 
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The Chinese government healthcare reform made the Chinese medical device market 
develop rapidly. However, the government should pay more attention to scientific and 
technological innovation, give financial and policy support to companies innovation, 
encourage the Chinese companies R&D on medical devices. To build a national digital 
medical technology innovation platform, to support the Chinese medical device industry 
technological innovation and its sustainable development. Moreover, deepen the 
transnational cooperation with international companies. Increase the training and the 
introduction of human talent.   
Despite the new Chinese medical device regulations which draw on the experience of the 
international medical device regulations, which have improved many rules, some 
regulations and policies need continuous modification and improvement due to the 
changing market environments. For example, the medical device classification rules need 
further improvement; strengthening the supervision of the medical device market, 
especially for the high-risk devices.  
8.3 Future work 
The medical device market is one of the fastest growing industries in the world economy. 
More and more researchers and investors are getting involved in this area. Following the 
work in this thesis, there are some research gaps suggested that need to be further 
investigated:  
(1) Literature in medical device investment 
Literature in medical device investment will increase in the future. Literature may include 
foreign investment theories in high-tech areas and review of the medical device market. 
There are few academic resources (such as journal articles or books) that focus on the 
medical device market, literature on the medical device market are mainly collected from 
independent and consulting companies reports such as Frost & Sullivan and Espicom 
Business Intelligence and some online resources. Therefore, an increasing body of 
researchers will get into medical device market research in the future because the medical 
device market is an expanding market.
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(2) Update the relevant data 
With the rapid development of the medical device market, the relevant data in this thesis 
needs to be updated. In this thesis, some of the Chinese government data are hard to access. 
Data deficiency is a major problem faced by the research. However, the Chinese 
government is paying more attention on the construction of medical information 
repositories, the government reports and data on each area are improving.  
(3) Medical device regulations 
The regulatory information contained in this thesis is subject to frequent change. In order 
to adapt to the rapid development of science and technology, the existing regulatory 
frameworks for medical devices must be improved to safeguard public health and ensure 
the effectiveness of medical devices. Therefore, the updated and latest medical device 
regulations in the US, EU and China to ensure good medical device performance, safety, 
quality, must be continuously updated. Additional steps are needed to improve existing 
policies in the future.  
(4) New technological devices 
The demand for medical devices in China has remained high over the past few years, the 
growth trend is expected to continue. The key medical device manufacturers have been 
working to increase their market share in the mid-end device market in China. For 
example, as told in Chapter 7, Philips Healthcare set up a joint venture with local software 
leader Neusoft to capitalize on the demand for mid-end devices, to better meet the needs 
of Chinese market and other developing countries. 
Moreover, non-invasive or less invasive new technological devices such as electrical 
impedance tomography (EIT)29, which can be used in common cancers (lung, breast, 
cervix and brain) detection. In contrast to most other medical imaging techniques, EIT 
does not apply any kind of ionizing radiation. Even though EIT medical systems have not 
29 EIT is a non-invasive medical imaging technique in which an image of the conductivity or permittivity of part of the 
body is inferred from surface electrode measurements. (Available from: 
https://en.wikipedia.org/wiki/Electrical_impedance_tomography.) 
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been used widely until recently, many medical device manufacturers have been supplying 
commercial EIT systems (in lung and breast cancer detection) developed by university 
research groups [224]. Some non-invasive or less invasive new technological devices 
have investment potential and will occupy some market share in the future. Therefore, 
research in this area will continue expand.  
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Appendix 1 
Percentage points of the  distribution. 
Source: Computed by M. Longnecker using Splus 
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Appendix 2 
  Chinese population and its relevant data from 1980 to 2010. 
Year/Ages 
China total 65 
and above 
population 
(millions) 
China total 
population 
(millions) 
Percentages of 65 
and above 
population in 
China (%) 
China total 
population 
growth rate 
(annual %) 
1980 50.677 987.05 5.13 1.3 
1981 52.697 1,000.72 5.27 1.3 
1982 54.594 1,016.54 5.37 1.5 
1983 56.419 1,030.08 5.48 1.4 
1984 58.218 1,043.57 5.58 1.3 
1985 60.009 1,058.51 5.67 1.4 
1986 61.565 1,075.07 5.73 1.5 
1987 63.149 1,093.00 5.78 1.6 
1988 64.754 1,110.26 5.83 1.6 
1989 66.377 1,127.04 5.89 1.5 
1990 68.05 1,143.33 5.95 1.5 
1991 69.808 1,158.23 6.03 1.4 
1992 71.671 1,171.71 6.12 1.2 
1993 73.608 1,185.17 6.21 1.1 
1994 75.58 1,198.50 6.31 1.1 
1995 77.576 1,211.21 6.40 1.1 
1996 80.073 1,223.89 6.54 1 
1997 82.387 1,236.26 6.66 1 
1998 84.584 1,247.61 6.78 1 
1999 86.749 1,257.86 6.90 0.9 
2000 88.912 1,267.43 7.02 0.8 
2001 91.044 1,276.27 7.13 0.7 
2002 93.202 1,284.53 7.26 0.7 
2003 95.336 1,292.27 7.38 0.6 
2004 97.312 1,299.88 7.49 0.6 
2005 99.087 1,307.56 7.58 0.6 
2006 101.237 1,314.48 7.70 0.6 
2007 103.21 1,321.29 7.81 0.5 
2008 105.163 1,328.02 7.92 0.5 
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2009 107.325 1,334.50 8.04 0.5 
2010 109.845 1,340.91 8.19 0.5 
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Appendix 3 
The predicted Chinese population from 2011 to 2020. 
Year/Ages Total China 
population (millions) 
Total 65+ population 
(millions) 
2011 1,342.32 112.71 
2012 1,347.63 115.14 
2013 1,353.85 117.61 
2014 1,354.77 121.50 
2015 1,356.35 125.45 
2016 1,359.52 127.99 
2017 1,362.93 131.16 
2018 1,364.14 135.08 
2019 1,363.05 138.37 
2020 1,365.06 141.98 
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Appendix 4 
Neural networks. 
Neurons Neural Network Error (res) 
4 0.049233 
5 0.16097 
6 0.048822 
7 0.1729 
8 0.078508 
9 0.114535 
10 0.171799 
11 0.105598 
12 0.166333 
13 0.127967 
14 0.091731 
15 0.047639 
16 0.029528 
17 0.070366 
18 0.111514 
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Appendix 5 
Percentage of Total Deaths of Top 5 Main Diseases in Certain Region from 2003 to 
2011(City).                                            
Cause
% 
2003 2004 2005 2006 2008 2009 2011 
Cancers 
(Malignant 
Tumours)  
25.47 23.92 22.94 27.25 25.47 27.01 27.79 
Cerebrovascular 
Disease  
19.95 19.09 21.23 17.66 19.95 20.36 20.22 
Cardiovascular 
Diseases 
(Ischemic Heart 
Disease) 
14.43 18.80 17.89 17.10 14.63 20.77 21.30 
Diseases of the 
Respiratory 
System  
14.63 13.12 12.57 13.06 14.63 10.54 10.56 
Injury, Poisoning 
& External Causes 
6.16 5.89 8.25 6.10 6.16 5.59 5.47 
Source: China Health Statistics, [101, 112-114] 
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Appendix 6 
Percentage of Total Deaths of Top 5 Main Diseases in Certain Region from 2003 to 
2011(County).                                           
Cause 
                         % 
2003 2004 2005 2006 2008 2009 2011 
Cancers 
(Malignant 
Tumors)  
25.28 23.70 20.29 25.14 25.28 24.26 23.62 
Cerebrovascular 
Disease  
23.75 14.85 21.17 20.36 23.75 23.19 21.72 
Cardiovascular 
Diseases 
(Ischemic Heart 
Disease) 
12.03 12.54 11.77 13.87 12.03 17.21 19.37 
Diseases of the 
Respiratory 
System  
18.72 13.30 23.45 16.40 18.72 14.96 13.31 
Injury, Poisoning 
& External Causes 
5.69 6.63 8.47 8.90 5.69 8.25 8.85 
Source: China Health Statistics, [101, 112-114] 
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Appendix 7 
Total output value of the medical device industry for each province in China from 2001 
to 2011.                                                                                            (Unit: million yuan)    
Beijing Tianjin Hebei Shanxi 
Inner 
Mongolia Liaoning Jilin 
Heilong-
jiang 
2001 6047 1896 971 201 22 2671 482 842
2002 8665 2001 935 219 24 3202 516 586
2003 10573 2667 1427 415 --- 3683 777 431
2004 13010 3010 1770 530 10 4480 1290 840
2005 16468 3192 2319 1013 --- 5526 1031 1023
2006 20131 4184 3003 1155 --- 7431 1221 1255
2007 23014 4073 4039 1423 --- 10928 1596 1890
2008 21362 5414 3907 1068 41 13650 2686 1541
2009 25380 6209 6248 1380 280 18578 3757 1933
2010 27880 7830 8230 1830 480 22120 5480 2220
2011 29510 6870 9420 2250 340 22420 6380 2080
Shanghai Jiangsu 
Zhe-
jiang Anhui Fujian Jiangxi 
Shan-
dong Henan 
2001 8887 11888 9640 652 1281 453 3599 924
2002 10281 12361 10315 1186 1703 981 3967 980
2003 10352 14273 14315 1508 2467 963 5133 1018
2004 16320 19580 16270 1920 2680 1710 8150 3120
2005 17923 27863 26238 2482 3044 1947 14738 3570
2006 23569 42435 35956 3122 4057 2891 23518 7431
2007 28305 59261 44851 4364 5065 4527 29345 10505
2008 27739 89171 36779 2688 4524 5589 27610 11968
2009 29403 123423 49546 7873 6199 7478 38905 16945
2010 37040 170830 65870 11070 7900 10540 45010 19600
2011 38480 242270 67160 14570 9940 13430 55080 27820
Hubei Hunan 
Guang-
dong Guangxi Hainan 
Chong-
qing Sichuan Guizhou 
2001 2413 1404 5045 174 60 2286 816 97
2002 2205 1612 6970 272 52 2531 1079 144
156 
2003 2018 1085 9331 446 18 3282 1395 247
2004 2010 1540 23160 550 10 3780 1730 360
2005 4075 2453 30932 767 3 4343 2444 402
2006 5047 3077 35533 892 --- 5231 3976 481
2007 5805 4237 48435 1273 --- 6151 5546 668
2008 5138 10724 42586 1550 --- 6713 8547 447
2009 6255 13046 42574 2285 --- 7935 12549 793
2010 7010 20430 54130 3490 --- 12480 8090 730
2011 7200 29390 61060 3630 840 12620 10800 740
Yunnan Shaanxi Gansu Qinghai Ningxia Xinjiang Total 
2001 482 1550 154 --- 344 12 65295
2002 590 1835 192 --- 471 7 75885
2003 568 1887 340 58 440 27 91144
2004 590 3370 250 90 560 50 132740
2005 636 3114 257 100 549 83 178535
2006 949 4950 229 87 170 86 242066
2007 1015 5390 257 129 619 110 312821
2008 1101 3350 101 149 629 81 336851
2009 1263 7830 287 90 859 127 439431
2010 1490 8430 290 100 960 150 561730
2011 1190 11490 240 130 1000 100 688420
Source: China Statistics Yearbook on High Technology Industry, 2009-12 
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Appendix 8 
Average of total output value of medical device industry for each province in China from 
2001 to 2011 (listed in decreasing average value).                      (Unit: million yuan)                                                              
Jiangsu 73941
Zhejiang 34267
Guangdong 32705
Shandong 23187
Shanghai 22573
Beijing 18367
Liaoning 10426
Henan 9444
Hunan 8091
Chongqing 6123
Sichuan 5179
Shaanxi 4836
Anhui 4676
Jiangxi 4592
Hubei 4471
Fujian 4442
Tianjin 4304
Hebei 3843
Jilin 2292
Guangxi 1394
Heilongjiang 1331
Shanxi 1044
Yunnan 898
Ningxia 600
Guizhou 464
Gansu 236
Inner Mongolia 109
Hainan 89
Qinghai 85
Xinjiang 76
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Appendix 9 
Gross regional product of each province in China from 2001 to 2011.  
                                                                                                        (Unit: million yuan) 
Beijing Tianjin Hebei Shanxi 
Inner 
Mongolia Liaoning Jilin 
Heilong-
jiang 
2001 284565 184010 557778 177997 154579 503308 203248 356100
2002 433040 215076 601828 232480 194094 545822 234854 363720
2003 502377 257803 692129 285523 238838 600254 266208 405740
2004 606028 311097 847763 357137 304107 667200 312201 475060
2005 688631 369762 1009611 417952 389555 786085 362027 551150
2006 787028 435915 1166043 475254 479148 925115 427512 618890
2007 984681 525276 1360732 602445 642318 1116430 528469 710400
2008 1111500 671901 1601197 731540 849620 1366858 642610 831437
2009 1215303 752185 1723548 735831 974025 1521249 727875 858700
2010 1411358 922446 2039426 920086 1167200 1845727 866758 1036860
2011 1625193 1130728 2451576 1123755 1435988 2222670 1056883 1258200
Shanghai Jiangsu Zhejiang Anhui Fujian Jiangxi Shandong Henan
2001 495084 951191 674815 329013 425368 217568 943831 564011
2002 574103 1060685 800367 351972 446755 245048 1027550 603548
2003 669423 1244287 970502 392310 498367 280741 1207815 686770
2004 807283 1500360 1164870 475932 576335 345670 1502184 855379
2005 916410 1830566 1343785 537512 656893 405676 1851687 1058742
2006 1036637 2164508 1574251 614873 761455 467053 2207736 1249597
2007 1249401 2601848 1875373 736092 924853 580025 2577691 1501246
2008 1406986 3098198 2146269 885166 1082301 697105 3093328 1801853
2009 1504645 3445730 2299035 1006282 1223653 765518 3389665 1948046
2010 1716598 4142548 2772231 1235933 1473712 945126 3916992 2309236
2011 1919569 4911027 3231885 1530065 1756018 1170282 4536185 2693103
Hubei Hunan 
Guang-
dong Guangxi Hainan 
Chong-
qing Sichuan Guizhou 
2001 466228 398300 1064771 223119 54596 174977 442176 108490
2002 421282 415154 1350242 252373 62197 199001 472501 124343
2003 475745 465999 1584464 282111 69320 227282 533309 142634
159 
2004 563324 564194 1886462 343350 79890 269281 637963 167780
2005 652014 651134 2236654 407575 89457 306692 738511 197906
2006 758132 756889 2620447 482851 105285 349157 863781 228200
2007 933340 943960 3177701 582341 125417 467613 1056239 288411
2008 1132889 1155500 3679671 702100 150306 579366 1260123 356156
2009 1296110 1305969 3948256 775916 165421 653001 1415128 391268
2010 1596761 1603796 4601306 956985 206450 792558 1718548 460216
2011 1963226 1966956 5321028 1172087 252266 1001137 2102668 570184
Yunnan Shaanxi Gansu Qinghai Ningxia Xinjiang
2001 207471 184427 107251 30095 29838 148548
2002 231282 225339 123203 34065 37716 161265
2003 255602 258772 139983 39020 44536 188635
2004 308191 317558 168849 46610 53716 220909
2005 347289 377269 193398 54332 60626 260419
2006 400672 452374 227670 64158 71076 304526
2007 477252 575729 270240 79735 91911 352316
2008 569212 731458 316682 101862 120392 418321
2009 616975 816980 338756 108127 135331 427705
2010 722418 1012348 412075 135043 168965 543747
2011 889312 1251230 502037 167044 210221 661005
Source: National Bureau of Statistics of the Peoples Republic of China, 2012 
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Appendix 10 
 Gross domestic product of China from 2001 to 2011.                 (Unit: million yuan) 
2001 10965520
2002 12033270
2003 13582280
2004 15987830
2005 18493740
2006 21631440
2007 26581030
2008 31404540
2009 34090280
2010 40151280
2011 47288160
Source: National Bureau of Statistics of the Peoples Republic of China, 2012 
